

MONOACYLGLYCEROL LIPASE MODULATORS

FIELD OF THE INVENTION

The present invention is related to certain 3.1.0 and 4.1.0 azabicyclic chemical entities having MGL modulating properties, pharmaceutical compositions comprising these chemical entities, chemical processes for preparing these chemical entities and their use in the treatment of diseases, disorders or conditions associated with MGL receptor activity in subjects, in particular humans.

BACKGROUND OF THE INVENTION

Cannabis Sativa and analogs of Δ^9 -tetrahydrocannabinol have been used since the days of folk medicine for therapeutic purposes. The endocannabinoid system consists of two G-protein coupled receptors, cannabinoid receptor type 1 (CB1) (Matsuda *et al.*, *Nature*, 1990, 346, 561-4) and cannabinoid receptor type 2 (CB2) (Munro *et al.*, *Nature*, 1993, 365, 61-5). CB1 receptor is one of the most abundant G-protein coupled receptor expressed in the brain (Herkenham *et al.*, *Proc. Nat. Acad. Sci.*, 1990, 87 (5), 1932-1936). CB1 is also expressed peripherally in the liver, gastrointestinal tract, pancreas, adipose tissue, and skeletal muscles (Di Marzo *et al.*, *Curr Opin Lipidol*, 2007, 18, 129-140). CB2 is predominantly expressed in immune cells such as monocytes (Pacher *et al.*, *Amer J Physiol*, 2008, 294, H1133-H1134) and under certain conditions (inflammation) in the brain ((Benito *et al.*, *Brit J Pharmacol*, 2008, 153, 277-285) and in skeletal (Cavuto *et al.*, *Biochem Biophys Res Commun*, 2007, 364, 105-110) and cardiac muscles (Hajrasouliha *et al.*, *Eur J Pharmacol*, 2008, 579, 246-252).

In 1992, N-arachidonylethanolamine (AEA or anandamide) was found to be an endogenous ligand for cannabinoid receptors (Devane *et al.*, *Science*, 1992, 258, 1946-9). Subsequently, 2-arachidonoylglycerol (2-AG) was also identified as an additional endogenous ligand for the cannabinoid receptors (Mechoulam *et al.*, *Biochem Pharmacol*, 1995, 50, 83-90; Sugiura *et al.*, *Biochem Biophys Res Commun*, 1995, 215, 89-97). Concentrations of 2-AG were reported to be at least 100 times higher than those of anandamide in the rat brain (Buczynski and Parsons, *Brit J Pharmacol*, 2010, 160 (3), 423-42). Therefore 2-AG may play more essential physiological roles than anandamide in the brain endocannabinoid system (Sugiura *et al.*, *Prostaglandins Leukot Essent Fatty Acids*, 2002, Feb-Mar, 66(2-3):173-92). The endocannabinoid 2-AG is a full agonist for CB1 and CB2 receptors, while anandamide is a partial agonist for both receptors (Sugiura *et al.*, *Prog Lipid Res*, 2006, 45(5):405-46). Unlike

many classical neurotransmitters, endocannabinoids signal through a retrograde mechanism. They are synthesized on demand in postsynaptic neurons and then rapidly degraded following binding to presynaptic cannabinoid receptors (Ahn *et al.*, *Chem Rev.* 2008, 108(5):1687-707). Monoacylglycerol lipase (MGLL, also known as MAG lipase and MGL) is the serine hydrolase responsible for the degradation of 2-AG into arachidonic acid and glycerol in the central nervous system (Mechoulam *et al.*, *Biochem Pharmacol.* 1995, 50, 83-90; Sugiura *et al.*, *Biochem Biophys Res Commun.* 1995, 215, 89-97; Long *et al.*, *Nat Chem Biol.* 2009 Jan;5(1):37-44;), Schlosburg *et al.*, *Nat Neurosci.*, 2010, Sep;13(9):1113-9) and peripheral tissues (Long *et al.*, *Chem Biol.*, 2009 Jul 31;16(7):744-53). Anandamide is hydrolyzed by fatty acid amide hydrolase (FAAH) (Piomelli, *Nat Rev Neurosci.* 2003, 4, 873-884). MGL exists in both soluble and membrane bound forms (Dinh *et al.*, *Proc Natl Acad Sci U S A.*, 2002, Aug 6;99(16):10819-24). In the brain MGL is located in presynaptic neurons (Straiker *et al.*, *Mol Pharmacol.*, 2009, Dec;76(6):1220-7) and astrocytes (Walter *et al.*, *J Neurosci.*, 2004, Sep 15;24(37):8068-74) within regions associated with high CB1 receptor density. Compared to wild-type controls, genetic ablation of MGL expression produces 10-fold increase in brain 2-AG levels without affecting anandamide concentration (Schlosburg *et al.*, *Nat Neurosci.*, 2010, Sep;13(9):1113-9).

Thus, MGL modulation offers an interesting strategy for potentiating the cannabinoid system. The primary advantage of this approach is that only brain regions where endocannabinoids are actively produced will be modulated, potentially minimizing the side effects associated with exogenous CB1 agonists. Pharmacological inactivation of MGL by covalent inhibitors in animals increase 2-AG content in brain and peripheral tissues and has been found to produce antinociceptive, anxiolytic and anti-inflammatory effects that are dependent on CB1 and/or CB2 receptors (Long *et al.*, *Nat Chem Biol.*, 2009, Jan, 5(1):37-44; Ghosh *et al.*, *Life Sci.*, 2013, Mar 19, 92(8-9):498-505; Bedse *et al.*, *Biol Psychiatry.*, 2017, Oct 1, 82(7):488-499; Bernal-Chico *et al.*, *Glia.*, 2015, Jan, 63(1):163-76; Patel *et al.*, *Neurosci Biobehav Rev.*, 2017, May, 76(Pt A):56-66; Betse *et al.*, *Transl Psychiatry.*, 2018, Apr 26, 8(1):92). In addition to the role of MGL in terminating 2-AG signaling, MGL modulation, including MGL inhibition also promotes CB1/2-independent effects on neuroinflammation (Nomura *et al.*, *Science.*, 2011, Nov 11;334(6057):809-13). MGL modulation, including MGL inhibition leads to reduction in proinflammatory prostanoid signaling in animal models of traumatic brain injury (Katz *et al.*, *J Neurotrauma.*, 2015, Mar 1;32(5):297-306; Zhang *et al.*, *J Cereb Blood Flow Metab.*, 2015, Mar

31;35(4):443-453), neurodegeneration including Alzheimer's disease (Piro *et al.*, *Cell Rep.*, 2012, Jun 28, 1(6):617-23; Wenzel *et al.*, *Life Sci.*, 2018, Aug 15, 207:314-322; Chen *et al.*, *Cell Rep.*, 2012, Nov 29, 2(5):1329-39), Parkinson's disease (Nomura *et al.*, *Science*, 2011, Nov 11, 334(6057), 809-13; Pasquarelli *et al.*, *Neurochem Int.*, 2017, Nov, 110:14-24), amyotrophic lateral sclerosis (Pasquarelli *et al.*, *Neuropharmacology*, 2017, Sep 15, 124:157-169), multiple sclerosis (Hernandez-Torres *et al.*, *Angew Chem Int Ed Engl.*, 2014, Dec 8, 53(50):13765-70; Bernal-Chico *et al.*, *Glia.*, 2015, Jan, 63(1):163-76), Huntington's disease (Covey *et al.*, *Neuropsychopharmacology*, 2018, 43, 2056-2063), Tourette syndrome and status epilepticus (Terrone *et al.*, *Epilepsia.*, 2018, Jan, 59(1), 79-91; von Ruden *et al.*, *Neurobiol Dis.*, 2015, May;77:238-45).

Therefore, by potentiating the cannabinoid system and attenuating proinflammatory cascades, MGL modulation, including MGL inhibition offers a compelling therapeutic approach for the treatment of a vast array of complex diseases. Importantly, MGL modulation, including MGL inhibition in animals does not produces the full spectrum of neurobehavioral effects observed with Δ^9 -tetrahydrocannabinol and other CB1 agonists (Tuo *et al.*, *J Med Chem.*, 2017, Jan 12, 60(1), 4-46; Mulvihill *et al.*, *Life Sci.*, 2013, Mar 19, 92(8-9), 492-7).

Endocannabinoid hypoactivity is a risk factor for the treatment of depression, anxiety, and post-traumatic stress disorders. Millennia of human use of cannabis sativa, and a brief period in which humans were treated with the endocannabinoid antagonist, rimonabant, provide support for that hypothesis. 2-AG levels are decreased in individuals with major depression (Hill *et al.*, *Pharmacopsychiatry.*, 2008, Mar; 41(2): 48-53; Hill *et al.*, *Psychoneuroendocrinology.*, 2009, Sep; 34(8): 1257-1262.). Low circulating 2-AG levels predict rates of depression (Hauer *et al.*, *Rev Neurosci.*, 2012, 23(5-6):681-90). Reduced circulating 2-AG has been found in patient with post-traumatic stress disorder (PTSD) (Hill *et al.*, *Psychoneuroendocrinology*, 2013, 38 (12), 2952-2961). Healthy volunteers exposed to chronic stressors exhibited progressively diminished circulating 2-AG levels which correlated with the onset of reductions in measures of positive emotions (Yi *et al.*, *Progress in Neuro-Psychopharmacology and Biological Psychiatry*, 2016, 67 (3), 92-97). The CB1 receptor inverse agonist/antagonist Rimonabant has been withdrawn from the market due to the high incidence of severe depression and suicidal ideation (Christensen *et al.*, *The Lancet*, 2007, 370, 1706-1713). Therefore, MGL modulators are potentially useful for the treatment of mood disorders, anxiety, and PTSD.

Cannabinoid receptor agonists are clinically used to treat pain, spasticity, emesis and anorexia (Di Marzo, *et al.*, *Annu Rev Med.*, 2006, 57:553-74; Ligresti *et al.*, *Curr Opin Chem Biol.*, 2009, Jun;13(3):321-31). Therefore, MGL modulators, including MGL inhibitors are also potentially useful for these indications. MGL exerts CB1-dependant antinociceptive effects in
5 animal models of noxious chemical, inflammatory, thermal and neuropathic pain (Guindon *et al.*, *Br J Pharmacol.*, 2011, Aug;163(7):1464-78; Kinsey *et al.*, *J Pharmacol Exp Ther.*, 2009, Sep;330(3):902-10; Long *et al.*, *Nat Chem Biol.*, 2009, Jan;5(1):37-44). MGL blockade reduces mechanical and acetone induced cold allodynia in mice subjected to chronic constriction injury of the sciatic nerve (Kinsey *et al.*, *J Pharmacol Exp Ther.*, 2009, Sep;330(3):902-10). MGL
10 inhibition produces opiate-sparing events with diminished tolerance, constipation, and cannabimimetic side effects (Wilkerson *et al.*, *J Pharmacol Exp Ther.*, 2016, Apr;357(1):145-56). MGL blockade is protective in model of inflammatory bowel disease (Alhouayek *et al.*, *FASEB J.*, 2011, Aug;25(8):2711-21). MGL inhibition also reverse Paclitaxel-induced nociceptive behavior and proinflammatory markers in a mouse model of chemotherapy-induced
15 neuropathy (Curry *et al.*, *J Pharmacol Exp Ther.*, 2018, Jul;366(1):169-18). MGL inhibitors are also potentially useful for the treatment of chronic inflammatory condition of the urinary bladder like interstitial cystitis (Chinnadurai *et al.*, 2019, Oct; 131: 109321).

Inhibition of 2-AG hydrolysis exerts anti-proliferative activity and reduction in prostate cancer cell invasiveness (Nithipatikom *et al.*, *Cancer Res.*, 2004, Dec 15, 64(24):8826-
20 30; Nithipatikom *et al.*, *Biochem Biophys Res Commun.*, 2005, Jul 15,332(4):1028-33; Nithipatikom *et al.*, *Prostaglandins Other Lipid Mediat.*, 2011, Feb, 94(1-2):34-43). MGL is upregulated in aggressive human cancer cells and primary tumors where it has a unique role of providing lipolytic sources of free fatty acids for synthesis of oncogenic signaling lipids that promote cancer aggressiveness. Thus, beyond the physiological roles of MGL in mediated
25 endocannabinoid signaling, MGL in cancer plays a distinct role in modulating the fatty acid precursor pools for synthesis of protumorigenic signaling lipids in malignant human cancer cells.

MGL blockade shows anti-emetic and anti-nausea effects in a lithium chloride model of vomiting in shrews (Sticht *et al.*, *Br J Pharmacol.*, 2012, Apr, 165(8):2425-35).
MGL modulators, including MGL inhibitors may have utility in modulating drug dependence of
30 opiates. MGL blockade reduces the intensity of naloxone-precipitated morphine withdrawal

symptoms in mice. MGL blockade also attenuated spontaneous withdrawal signs in morphine-dependent mice (Ramesh *et al.*, *J Pharmacol Exp Ther.*, 2011, Oct, 339(1):173-85).

MGL modulators are also potentially useful for the treatment of eye conditions, including but not limited to, glaucoma and disease states arising from elevated intraocular pressure (Miller *et al.*, *Pharmaceuticals*, 2018, 11, 50).


SUMMARY OF THE INVENTION

Embodiments of the present invention relate to chemical entities, pharmaceutical compositions containing them, methods of making and purifying them, and methods for using them the treatment of diseases, disorders, and conditions associated with the MGL modulation.

An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with the MGL modulation using at least one chemical entity of the invention. An additional embodiment of the invention provides at least one chemical entity of the invention for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL modulation. An additional embodiment of the invention provides use of at least one chemical entity of the invention for the manufacture of a medicament for treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL modulation.


Additional embodiments, features, and advantages of the invention will be apparent from the following detailed description and through practice of the invention.

Embodiments of this invention are compounds of Formula (I),



wherein

X is CH₂ or O;



R¹ is H;

R^{2a} and R^{2b} are each independently H;

- 5 R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁-alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁-alkyl, C₁-alkyl substituted with OH, C₁-alkyl substituted with CO₂H, C₁-haloalkyl, OC₁-haloalkyl, C₃-cycloalkyl, O-phenyl, and C₃-cycloalkyl substituted with CH₃;

- 10 R^a and R^b are each independently selected from the group consisting of: H and halo; and R^c is H or CH₃;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.


DETAILED DESCRIPTION OF THE INVENTION

- 15 As used herein, the terms "including", "containing" and "comprising" are used in their open, non-limiting sense.

- Unless qualified specifically in particular instances of use, the term "alkyl" refers to a straight- or branched-chain alkyl group having from 1 to 8 carbon atoms in the chain. Examples of alkyl groups include methyl (Me), ethyl (Et), n-propyl, isopropyl, butyl, isobutyl, sec-butyl, tert-butyl (tBu), pentyl, isopentyl, tert-pentyl, hexyl, isohexyl, and groups that in light of the
 20 ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples. "C₁-alkyl" refers to straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain. "C₁-alkyl" refers to straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain.

- 25 The term "cycloalkyl" refers to a saturated or partially saturated, monocyclic, fused polycyclic, or spiro polycyclic carbocycle having from 3 to 12 ring atoms per carbocycle.


Illustrative examples of cycloalkyl groups include the following entities, in the form of properly bonded moieties:



- 5 The term “3.1.0 azabicycle” refers to a bicyclic bridged compounds that contain a nitrogen. Illustrative example of 3.1.0 azabicycle group include the following entities, in the form of properly bonded moieties:



The term “4.1.0 azabicycle” refers to a bicyclic bridged compounds that contain a nitrogen. Illustrative example of 4.1.0 azabicycle groups include the following entities, in the



- 10 form of properly bonded moieties:

The term “halogen” or “halo” represents chlorine, fluorine, bromine, or iodine.

- The term “haloalkyl” refers to a straight- or branched-chain alkyl group having from 1 to 6 carbon atoms in the chain optionally substituting hydrogens with halogens. The term “C₁₋₄ haloalkyl” as used here refers to a straight- or branched-chain alkyl group having from 1 to 4 carbon atoms in the chain, optionally substituting hydrogens with halogens. Examples of “haloalkyl” groups include trifluoromethyl (CF₃), difluoromethyl (CF₂H), monofluoromethyl (CH₂F), pentafluoroethyl (CF₂CF₃), tetrafluoroethyl (CHFCH₂CF₃), monofluoroethyl (CH₂CH₂F), trifluoroethyl (CH₂CF₃), tetrafluorotrifluoromethylethyl (CF(CF₃)₂), and groups that in light of the ordinary skill in the art and the teachings provided herein would be considered equivalent to any one of the foregoing examples.

The term “aryl” refers to a monocyclic, aromatic carbocycle (ring structure having ring atoms that are all carbon) having 6 atoms per ring (Carbon atoms in the aryl groups are sp² hybridized.)




The term “phenyl” represents the following moiety:



Those skilled in the art will recognize that the species of 3.1.0 azabicyclo, 4.1.0 azabicyclo, cycloalkyl or aryl groups listed or illustrated above are not exhaustive, and that additional species within the scope of these defined terms may also be selected.

The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.

The term “variable point of attachment” means that a group is allowed to be attached at more than one alternative position in a structure. The attachment will always replace a hydrogen atom on one of the ring atoms. In other words, all permutations of bonding are represented by the single diagram, as shown in the illustrations below.



Those skilled in the art will recognize that if more than one such substituent is present for a given ring, the bonding of each substituent is independent of all of the others. The groups listed or illustrated above are not exhaustive.

The term “substituted” means that the specified group or moiety bears one or more substituents. The term “unsubstituted” means that the specified group bears no substituents. The term “optionally substituted” means that the specified group is unsubstituted or substituted by one or more substituents. Where the term “substituted” is used to describe a structural system, the substitution is meant to occur at any valency-allowed position on the system.

Any formula given herein is intended to represent compounds having structures depicted by the structural formula as well as certain variations or forms. In particular, compounds of any formula given herein may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of the general formula, and mixtures thereof, are considered within the scope of such formula. The compounds of this invention may possess one or more asymmetric centers; such compounds can therefore be produced as individual (*R*)- or (*S*)-stereoisomers or as mixtures thereof. Thus, any formula given herein is intended to represent a racemate, one or more of its enantiomeric forms, one or more of its diastereomeric forms, and mixtures thereof. Additionally, any formula given herein is intended to refer also to any one of: hydrates, solvates, polymorphs and of such compounds, and mixtures thereof, even if such forms are not listed explicitly.

The term “*R*” at a stereocenter designates that the stereocenter is purely of the *R*-configuration as defined in the art; likewise, the term “*S*” means that the stereocenter is purely of the *S*-configuration. As used herein, the term “*RS*” refers to a stereocenter that exists as a mixture of the *R*- and *S*-configurations.

Compounds containing one stereocenter drawn without a stereo bond designation are a mixture of 2 enantiomers. Compounds containing 2 stereocenters both drawn without stereo bond designations are a mixture of 4 diastereomers. Compounds with 2 stereocenters both labeled “*RS*” and drawn with stereo bond designations are a 2-component mixture with relative stereochemistry as drawn. Unlabeled stereocenters drawn without stereo bond designations are a mixture of the *R*- and *S*-configurations. For unlabeled stereocenters drawn with stereo bond designations, the absolute stereochemistry is as depicted.

Reference to a compound herein stands for a reference to any one of: (a) the actually recited form of such compound, and (b) any of the forms of such compound in the medium in which the compound is being considered when named. For example, reference herein to a compound such as *R*-COOH, encompasses reference to any one of: for example, *R*-COOH(s), *R*-COOH(sol), and *R*-COO-(sol). In this example, *R*-COOH(s) refers to the solid compound, as it could be for example in a tablet or some other solid pharmaceutical composition or preparation; *R*-COOH(sol) refers to the undissociated form of the compound in a solvent; and *R*-COO-(sol) refers to the dissociated form of the compound in a solvent, such as the dissociated form of the compound in an aqueous environment, whether such dissociated form derives from *R*-COOH,

from a salt thereof, or from any other entity that yields R-COO⁻ upon dissociation in the medium being considered. In another example, an expression such as “exposing an entity to compound of formula R-COOH” refers to the exposure of such entity to the form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such exposure takes place. In still another
5 example, an expression such as “reacting an entity with a compound of formula R-COOH” refers to the reacting of (a) such entity in the chemically relevant form, or forms, of such entity that exists, or exist, in the medium in which such reacting takes place, with (b) the chemically relevant form, or forms, of the compound R-COOH that exists, or exist, in the medium in which such reacting takes place. In this regard, if such entity is for example in an aqueous environment,
10 it is understood that the compound R-COOH is in such same medium, and therefore the entity is being exposed to species such as R-COOH(aq) and/or R-COO⁻(aq), where the subscript “(aq)” stands for “aqueous” according to its conventional meaning in chemistry and biochemistry. A carboxylic acid functional group has been chosen in these nomenclature examples; this choice is not intended, however, as a limitation but it is merely an illustration. It is understood that
15 analogous examples can be provided in terms of other functional groups, including but not limited to hydroxyl, basic nitrogen members, such as those in amines, and any other group that interacts or transforms according to known manners in the medium that contains the compound. Such interactions and transformations include, but are not limited to, dissociation, association, tautomerism, solvolysis, including hydrolysis, solvation, including hydration, protonation, and
20 deprotonation. No further examples in this regard are provided herein because these interactions and transformations in a given medium are known by any one of ordinary skill in the art.

Any formula given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom
25 having a selected atomic mass or mass number in an enriched form. Examples of isotopes that can be incorporated into compounds of the invention in a form that exceeds natural abundances include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine, chlorine, and iodine, such as ²H (or chemical symbol D), ³H (or chemical symbol T), ¹¹C, ¹³C, ¹⁴C, ¹⁵N, ¹⁸O, ¹⁷O, ³¹P, ³²P, ³⁵S, ¹⁸F, ³⁶Cl, and ¹²⁵I, respectively. Such isotopically labelled compounds are
30 useful in metabolic studies (preferably with ¹⁴C), reaction kinetic studies (with, for example ²H or ³H), detection or imaging techniques [such as positron emission tomography (PET) or single-

photon emission computed tomography (SPECT)] including drug or substrate tissue distribution assays, or in radioactive treatment of patients. In particular, an ^{18}F or ^{11}C labeled compound may be particularly preferred for PET or SPECT studies. Further, substitution with heavier isotopes such as deuterium (i.e., ^2H , or D) may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements. Isotopically labeled compounds of this invention can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent.

When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for such variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.

The term C_{n-m} alkyl refers to an aliphatic chain, whether straight or branched, with a total number N of carbon members in the chain that satisfies $n \leq N \leq m$, with $m > n$.

When the same plurality of substituents is assigned to various groups, the specific individual substituent assignment to each of such groups is meant to be independently made with respect to the specific individual substituent assignments to the remaining groups. By way of illustration, but not as a limitation, if each of groups Q and R can be H or F, the choice of H or F for Q is made independently of the choice of H or F for R, so the choice of assignment for Q does not determine or condition the choice of assignment for R, or vice-versa, unless it is expressly indicated otherwise. Illustrative claim recitation in this regard would read as “each of Q and R is independently H or F”, or “each of Q and R is independently selected from the group consisting of H and F”.

Unless indicated otherwise, the description or naming of a particular compound in the specification and claims is intended to include both individual enantiomers and mixtures, racemic or otherwise, thereof. The methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art.

In another example, a zwitterionic compound would be encompassed herein by referring to a compound that is known to form a zwitterion, even if it is not explicitly named in its

zwitterionic form. Terms such as zwitterion, zwitterions, and their synonyms zwitterionic compound(s) are standard IUPAC-endorsed names that are well known and part of standard sets of defined scientific names. In this regard, the name zwitterion is assigned the name identification CHEBI:27369 by the Chemical Entities of Biological Interest (ChEBI) dictionary of molecular entities. As generally well known, a zwitterion or zwitterionic compound is a neutral compound that has formal unit charges of opposite sign. Sometimes these compounds are referred to by the term “inner salts”. Other sources refer to these compounds as “dipolar ions”, although the latter term is regarded by still other sources as a misnomer. As a specific example, aminoethanoic acid (the amino acid glycine) has the formula $\text{H}_2\text{NCH}_2\text{COOH}$, and it exists in some media (in this case in neutral media) in the form of the zwitterion $^+\text{H}_3\text{NCH}_2\text{COO}^-$. Zwitterions, zwitterionic compounds, inner salts and dipolar ions in the known and well-established meanings of these terms are within the scope of this invention, as would in any case be so appreciated by those of ordinary skill in the art. Because there is no need to name each and every embodiment that would be recognized by those of ordinary skill in the art, no structures of the zwitterionic compounds that are associated with the compounds of this invention are given explicitly herein. They are, however, part of the embodiments of this invention. No further examples in this regard are provided herein because the interactions and transformations in a given medium that lead to the various forms of a given compound are known by any one of ordinary skill in the art.

When referring to any formula given herein, the selection of a particular moiety from a list of possible species for a specified variable is not intended to define the same choice of the species for the variable appearing elsewhere. In other words, where a variable appears more than once, the choice of the species from a specified list is independent of the choice of the species for the same variable elsewhere in the formula, unless stated otherwise.

By way of a first example on substituent terminology, if substituent $\text{S}^1_{\text{example}}$ is one of S_1 and S_2 , and substituent $\text{S}^2_{\text{example}}$ is one of S_3 and S_4 , then these assignments refer to embodiments of this invention given according to the choices $\text{S}^1_{\text{example}}$ is S_1 and $\text{S}^2_{\text{example}}$ is S_3 ; $\text{S}^1_{\text{example}}$ is S_1 and $\text{S}^2_{\text{example}}$ is S_4 ; $\text{S}^1_{\text{example}}$ is S_2 and $\text{S}^2_{\text{example}}$ is S_3 ; $\text{S}^1_{\text{example}}$ is S_2 and $\text{S}^2_{\text{example}}$ is S_4 ; and equivalents of each one of such choices. The shorter terminology “ $\text{S}^1_{\text{example}}$ is one of S_1 and S_2 , and $\text{S}^2_{\text{example}}$ is one of S_3 and S_4 ” is accordingly used herein for the sake of brevity, but not by way of limitation.

The foregoing first example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.

Furthermore, when more than one assignment is given for any member or substituent, embodiments of this invention comprise the various groupings that can be made from the listed assignments, taken independently, and equivalents thereof. By way of a second example on substituent terminology, if it is herein described that substituent S_{example} is one of S_1 , S_2 , and S_3 , this listing refers to embodiments of this invention for which S_{example} is S_1 ; S_{example} is S_2 ; S_{example} is S_3 ; S_{example} is one of S_1 and S_2 ; S_{example} is one of S_1 and S_3 ; S_{example} is one of S_2 and S_3 ; S_{example} is one of S_1 , S_2 and S_3 ; and S_{example} is any equivalent of each one of these choices. The shorter terminology " S_{example} is one of S_1 , S_2 , and S_3 " is accordingly used herein for the sake of brevity, but not by way of limitation. The foregoing second example on substituent terminology, which is stated in generic terms, is meant to illustrate the various substituent assignments described herein.

The nomenclature " C_i-C_j " with $j > i$, when applied herein to a class of substituents, is meant to refer to embodiments of this invention for which each and every one of the number of carbon members, from i to j including i and j , is independently realized. By way of example, the term C_1-C_3 or C_{1-3} refers independently to embodiments that have one carbon member (C_1), embodiments that have two carbon members (C_2), and embodiments that have three carbon members (C_3).

A "pharmaceutically acceptable salt" is intended to mean a salt of an acid or base of a compound represented by Formula (I) that is non-toxic, biologically tolerable, or otherwise biologically suitable for administration to the subject. See, generally, S.M. Berge, *et al.*, "Pharmaceutical Salts", J. Pharm. Sci., 1977, 66:1-19, and *Handbook of Pharmaceutical Salts, Properties, Selection, and Use*, Stahl and Wermuth, Eds., Wiley-VCH and VHCA, Zurich, 2002. Preferred pharmaceutically acceptable salts are those that are pharmacologically effective and suitable for contact with the tissues of patients without undue toxicity, irritation, or allergic response.

A compound of Formula (I) may possess a sufficiently acidic group, a sufficiently basic group, or both types of functional groups, and accordingly react with a number of inorganic or organic bases, and inorganic and organic acids, to form a pharmaceutically acceptable salt.

Examples of pharmaceutically acceptable salts include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, phosphates, monohydrogen-phosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, propionates, decanoates, caprylates, acrylates, formates, isobutyrate, caproates, heptanoates, propiolates, oxalates, malonates, succinates, suberates, sebacates, fumarates, maleates, butyne-1,4-dioates, hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates, sulfonates, xylenesulfonates, phenylacetates, phenylpropionates, phenylbutyrate, citrates, lactates, γ -hydroxybutyrate, glycolates, tartrates, methane-sulfonates, propanesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates, and mandelates.

Compounds of Formula (I) may contain at least one nitrogen of basic character, so desired pharmaceutically acceptable salts may be prepared by any suitable method available in the art, for example, treatment of the free base with an inorganic acid, such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, nitric acid, boric acid, phosphoric acid, and the like, or with an organic acid, such as acetic acid, phenylacetic acid, propionic acid, stearic acid, lactic acid, ascorbic acid, maleic acid, hydroxymaleic acid, isethionic acid, succinic acid, valeric acid, fumaric acid, malonic acid, pyruvic acid, oxalic acid, glycolic acid, salicylic acid, oleic acid, palmitic acid, lauric acid, a pyranosidyl acid, such as glucuronic acid or galacturonic acid, an α -hydroxy acid, such as mandelic acid, citric acid, or tartaric acid, an amino acid, such as aspartic acid or glutamic acid, an aromatic acid, such as benzoic acid, 2-acetoxybenzoic acid, naphthoic acid, or cinnamic acid, a sulfonic acid, such as laurylsulfonic acid, p-toluenesulfonic acid, methanesulfonic acid, ethanesulfonic acid, any compatible mixture of acids such as those given as examples herein, and any other acid and mixture thereof that are regarded as equivalents.

Compounds of Formula (I) may contain a carboxylic acid moiety, a desired pharmaceutically acceptable salt may be prepared by any suitable method, for example, treatment of the free acid with an inorganic or organic base, such as an amine (primary, secondary or tertiary), an alkali metal hydroxide, alkaline earth metal hydroxide, any compatible mixture of bases such as those given as examples herein, and any other base and mixture thereof that are regarded as equivalents or acceptable substitutes in light of the ordinary level of skill in this technology. Illustrative examples of suitable salts include organic salts derived from amino acids, such as glycine and arginine, ammonia, carbonates, bicarbonates, primary, secondary, and

tertiary amines, and cyclic amines, such as benzylamines, pyrrolidines, piperidine, morpholine, piperazine, *N*-methyl-glucamine and tromethamine and inorganic salts derived from sodium, calcium, potassium, magnesium, manganese, iron, copper, zinc, aluminum, and lithium.

The compounds of the invention, including their pharmaceutically acceptable salts,
5 whether alone or in combination, (collectively, "active agent" or "active agents") of the present invention are useful as MGL-modulators in the methods of the invention. Such methods for modulating MGL comprise the use of a therapeutically effective amount of at least one chemical entity of the invention.

For each and every method of the invention, the invention provides a further embodiment
10 relating to a compound of the invention or a pharmaceutically acceptable salt thereof for use in that method. In some embodiments, the invention provides a compound of the invention or a pharmaceutically acceptable salt thereof for use in therapy.

For each and every method of the invention, the invention provides a further embodiment relating to the use of a compound of the invention or a pharmaceutically acceptable salt thereof
15 for the manufacture of a medicament for that method. In some embodiments, the invention provides use of a compound of the invention or a pharmaceutically acceptable salt thereof for the manufacture of a medicament.

In some embodiments, the MGL modulator is an inhibitor and is used in a subject diagnosed with or suffering from a disease, disorder, or condition associated with MGL receptor
20 activity, such as those described herein. Symptoms or disease states are intended to be included within the scope of "disease, disorders or conditions."

Accordingly, the invention relates to methods of using the active agents described herein to treat subjects diagnosed with or suffering from a disease, disorder, or condition associated with the MGL receptor activity. The term "treat" or "treating" as used herein is intended to refer
25 to administration of an active agent or composition of the invention to a subject for the purpose of effecting a therapeutic or prophylactic benefit through modulation of MGL receptor activity. Treating includes reversing, ameliorating, alleviating, inhibiting the progress of, lessening the severity of, or preventing a disease, disorder, or condition, or one or more symptoms of such disease, disorder or condition associated with the MGL modulation. The term "subject" refers to
30 a mammalian patient in need of such treatment, such as a human.

The term “composition” refers to a product that includes the specified ingredients in therapeutically effective amounts, as well as any product that results, directly, or indirectly, from combinations of the specified ingredients in the specified amounts.

The term “MGL inhibitor” is intended to encompass a compound that interacts with
5 MGL to substantially reduce or eliminate its catalytic activity, thereby increasing the concentrations of its substrate(s). The term “MGL-modulated” is used to refer to the condition of being affected by the modulation of the MGL enzyme including the condition of being affected by the inhibition of the MGL enzyme. The disclosure is directed to methods for treating, ameliorating and / or preventing diseases, conditions, or disorders associated with pain
10 (including inflammatory pain), and also psychiatric disorders, neurological disorders, cancers and eye conditions by the administration of therapeutically effective amounts of MGL modulators to subjects in need thereof.

The term “modulators” include both inhibitors and activators, where “inhibitors” refer to compounds that decrease, prevent, inactivate, desensitize, or down-regulate the MGL expression
15 or activity, and “activators” are compounds that increase, activate, facilitate, sensitize, or up-regulate MGL expression or activity.

As used herein, unless otherwise noted, the term “affect” or “affected” (when referring to a disease, condition or disorder that is affected by inhibition of MGL) includes a reduction in the frequency and / or severity of one or more symptoms or manifestations of said disease, condition
20 or disorder; and / or include the prevention of the development of one or more symptoms or manifestations of said disease, condition or disorder or the development of the disease, condition or disorder.

In treatment methods according to the invention, a therapeutically effective amount of at least one active agent according to the invention is administered to a subject suffering from or
25 diagnosed as having such a disease, disorder, or condition. A “therapeutically effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic or prophylactic benefit in subjects in need of such treatment for the designated disease, disorder, or condition. Effective amounts or doses of the active agents of the present invention may be ascertained by routine methods such as modeling, dose escalation studies or clinical trials, and by
30 taking into consideration routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the disease, disorder, or

condition, the subject's previous or ongoing therapy, the subject's health status and response to drugs, and the judgment of the treating physician. For a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units (e.g., BID, TID, QID or as required by modality).

5 Once improvement of the subject's disease, disorder, or condition has occurred, the dose may be adjusted for preventive or maintenance treatment. For example, the dosage or the frequency of administration, or both, may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained. Of course, if symptoms have been alleviated to an appropriate level, treatment may cease. Subjects may, however, require
10 intermittent treatment on a long-term basis upon any recurrence of symptoms.

 In addition, the compounds of the invention are envisaged for use alone, in combination with one or more of other compounds of this invention, or in combination with additional active ingredients in the treatment of the conditions discussed below. The additional active ingredients may be co-administered separately with at least one compound of the invention, with active
15 agents of the invention or included with such an agent in a pharmaceutical composition according to the invention. In an illustrative embodiment, additional active ingredients are those that are known or discovered to be effective in the treatment of conditions, disorders, or diseases associated with the MGL modulation, such as another MGL inhibitor or a compound active
20 against another target associated with the particular condition, disorder, or disease. The combination may serve to increase efficacy (e.g., by including in the combination a compound potentiating the potency or effectiveness of an agent according to the invention), decrease one or more side effects, or decrease the required dose of the active agent according to the invention.

 When referring to inhibiting the target, an "effective amount" means an amount sufficient to affect MGL modulation.

25 The active agents of the invention are envisaged for use, alone or in combination with one or more additional active ingredients, to formulate pharmaceutical compositions of the invention. A pharmaceutical composition of the invention comprises a therapeutically effective amount of at least one active agent in accordance with the invention.

 Pharmaceutically acceptable excipients commonly used in pharmaceutical compositions
30 are substances that are non-toxic, biologically tolerable, and otherwise biologically suitable for administration to a subject, such as an inert substance, added to a pharmacological composition

or otherwise used as a vehicle, carrier, or diluent to facilitate administration of an agent and that is compatible therewith. Examples of such excipients include calcium carbonate, calcium phosphate, various sugars and types of starch, cellulose derivatives, gelatin, vegetable oils, and polyethylene glycols.

- 5 Delivery forms of the pharmaceutical compositions containing one or more dosage units of the active agents may be prepared using pharmaceutically acceptable excipients and compounding techniques known or that become available to those of ordinary skill in the art. The compositions may be administered in the inventive methods by a suitable route of delivery, e.g., oral, parenteral, rectal, topical, or ocular routes, or by inhalation.
- 10 The preparation may be in the form of tablets, capsules, sachets, dragees, powders, granules, lozenges, powders for reconstitution, liquid preparations, or suppositories. The compositions may be formulated for any one of a plurality of administration routes, such as intravenous infusion, topical administration, or oral administration. Preferably, the compositions may be formulated for oral administration.
- 15 For oral administration, the active agents of the invention can be provided in the form of tablets or capsules, or as a solution, emulsion, or suspension. To prepare the oral compositions, the active agents may be formulated to yield a dosage of, e.g., for a 70-kg human, an illustrative range for a suitable dosage amount is from about 1 to 1000 mg/day in single or multiple dosage units.
- 20 Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents. Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
- 25 Exemplary liquid oral excipients include ethanol, glycerol, water, and the like. Starch, polyvinyl-pyrrolidone (PVP), sodium starch glycolate, microcrystalline cellulose, and alginic acid are exemplary disintegrating agents. Binding agents may include starch and gelatin. The lubricating agent, if present, may be magnesium stearate, stearic acid or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to
- 30 delay absorption in the gastrointestinal tract or may be coated with an enteric coating.

Capsules for oral administration include hard and soft gelatin or (hydroxypropyl)methyl cellulose capsules. To prepare hard gelatin capsules, active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent. Liquids for oral administration may be in the form of suspensions, solutions, emulsions or syrups or may be lyophilized or presented as a dry product
5 for reconstitution with water or other suitable vehicle before use. Such liquid compositions may optionally contain: pharmaceutically-acceptable excipients such as suspending agents (for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethyl cellulose, carboxymethylcellulose, aluminum stearate gel and the like); non-aqueous vehicles, e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water;
10 preservatives (for example, methyl or propyl p-hydroxybenzoate or sorbic acid); wetting agents such as lecithin; and, if desired, flavoring or coloring agents.

The active agents of this invention may also be administered by non-oral routes. For example, compositions may be formulated for rectal administration as a suppository, enema or foam. For parenteral use, including intravenous, intramuscular, intraperitoneal, or subcutaneous
15 routes, the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil. Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride. Such forms may be presented in unit-dose form such as ampules or disposable injection devices, in multi-dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that
20 can be used to prepare an injectable formulation. Illustrative infusion doses range from about 1 to 1000 $\mu\text{g/kg/minute}$ of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.

For topical administration, the agents may be mixed with a pharmaceutical carrier at a concentration of about 0.01% to about 20% of drug to vehicle, preferably 0.1% to 10%. Another
25 mode of administering the agents of the invention may utilize a patch formulation to affect transdermal delivery.

Active agents may alternatively be administered in methods of this invention by inhalation, via the nasal or oral routes, e.g., in a spray formulation also containing a suitable carrier.

30 In a further embodiment, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL

modulation, comprising administering to the subject in need of such treatment a therapeutically effective amount of the active agent.

In a further embodiment, the invention is directed to a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition associated with MGL

5 modulation, comprising administering to the subject in need of such treatment a therapeutically effective amount of a pharmaceutical composition of the invention.

The compounds of Formula (I) are useful in methods for treating, ameliorating and / or preventing a disease, a condition or a disorder that is affected by the inhibition of MGL. Such methods comprise administering to a subject, including an animal, a mammal, and a human in
10 need of such treatment, amelioration and / or prevention, a therapeutically effective amount of a compound of Formula (I), or an enantiomer, diastereomer, solvate or pharmaceutically acceptable salt thereof.

In particular, the compounds of Formula (I), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof, are useful for treating, ameliorating and /
15 or preventing diseases, conditions, or disorders causing pain, psychiatric disorders, neurological disorders, cancers and eyes conditions. More particularly, the compounds of Formula (I), or pharmaceutically acceptable salts, isotopes, N-oxides, solvates and stereoisomers thereof, are useful for treating, ameliorating and / or preventing inflammatory pain, major depressive disorder, treatment resistant depression, anxious depression or bipolar disorder by administering
20 to a subject in need thereof a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof as herein defined.

1) Pain

Examples of inflammatory pain include, but are not limited to, pain due to a disease,
25 condition, disorder, or a pain state including inflammatory bowel disease, visceral pain, migraine, post-operative pain, osteoarthritis, rheumatoid arthritis, back pain, lower back pain, joint pain, abdominal pain, chest pain, labor, musculoskeletal diseases, skin diseases, toothache, pyresis, burn, sunburn, snake bite, venomous snake bite, spider bite, insect sting, neurogenic bladder, interstitial cystitis, urinary tract infection, rhinitis, contact dermatitis/hypersensitivity,
30 itch, eczema, pharyngitis, mucositis, enteritis, irritable bowel syndrome, cholecystitis,

pancreatitis, postmastectomy pain syndrome, menstrual pain, endometriosis, pain due to physical trauma, headache, sinus headache, tension headache, or arachnoiditis.

One type of inflammatory pain is inflammatory hyperalgesia / hypersensitivity.

Examples of inflammatory hyperalgesia include a disease, condition, disorder, or pain state
5 including inflammation, osteoarthritis, rheumatoid arthritis, back pain, joint pain, abdominal pain, musculoskeletal diseases, skin diseases, post-operative pain, headaches, toothache, burn, sunburn, insect sting, neurogenic bladder, urinary incontinence, interstitial cystitis, urinary tract infection, cough, asthma, chronic obstructive pulmonary disease, rhinitis, contact dermatitis/hypersensitivity and/or dermal allergy, itch, eczema, pharyngitis, enteritis, irritable
10 bowel syndrome, inflammatory bowel diseases including Crohn's Disease, ulcerative colitis, benign prostatic hypertrophy, and nasal hypersensitivity.

In an embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing inflammatory visceral hyperalgesia in which an enhanced visceral irritability exists, comprising, consisting of, and/or consisting essentially of the step of administering to a
15 subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof. In a further embodiment, the present invention is directed to a method for treating inflammatory somatic hyperalgesia in which a hypersensitivity to thermal, mechanical and/or chemical stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective
20 amount of a compound of Formula (I) , or a pharmaceutically acceptable salt, isotope, N-oxide, solvate or stereoisomer thereof.

A further embodiment of the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic pain. Examples of a neuropathic pain include pain due to a disease, condition, disorder, or pain state including cancer, neurological disorders, spine
25 and peripheral nerve surgery, brain tumor, traumatic brain injury (TBI), spinal cord trauma, chronic pain syndrome, fibromyalgia, chronic fatigue syndrome, lupus, sarcoidosis, peripheral neuropathy, bilateral peripheral neuropathy, diabetic neuropathy, central pain, neuropathies associated with spinal cord injury, stroke, amyotrophic lateral sclerosis (ALS), Parkinson's disease, multiple sclerosis, sciatic neuritis, mandibular joint neuralgia, peripheral neuritis,
30 polyneuritis, stump pain, phantom limb pain, bony fractures, oral neuropathic pain, Charcot's pain, complex regional pain syndrome I and II (CRPS I/II), radiculopathy, Guillain-Barre

syndrome, meralgia paresthetica, burning-mouth syndrome, optic neuritis, postfebrile neuritis, migrating neuritis, segmental neuritis, Gombault's neuritis, neuronitis, cervicobrachial neuralgia, cranial neuralgia, geniculate neuralgia, glossopharyngeal neuralgia, migrainous neuralgia, idiopathic neuralgia, intercostals neuralgia, mammary neuralgia, Morton's neuralgia, nasociliary
5 neuralgia, occipital neuralgia, postherpetic neuralgia, causalgia, red neuralgia, Sluder's neuralgia, splenopalatine neuralgia, supraorbital neuralgia, trigeminal neuralgia, vulvodynia, vidian neuralgia or chemotherapy-induced neuropathy.

One type of neuropathic pain is neuropathic cold allodynia, which can be characterized by the presence of a neuropathy-associated allodynic state in which a hypersensitivity to cooling
10 stimuli exists. Examples of neuropathic cold allodynia include allodynia due to a disease, condition, disorder or pain state including neuropathic pain (neuralgia), pain arising from spine and peripheral nerve surgery or trauma, traumatic brain injury (TBI), trigeminal neuralgia, postherpetic neuralgia, causalgia, peripheral neuropathy, diabetic neuropathy, central pain, stroke, peripheral neuritis, polyneuritis, complex regional pain syndrome I and II (CRPS I/II) and
15 radiculopathy.

In a further embodiment, the present invention is directed to a method for treating, ameliorating and / or preventing neuropathic cold allodynia in which a hypersensitivity to a cooling stimuli exists, comprising administering to a subject in need of such treatment a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable
20 salt, isotope, N-oxide, solvate or stereoisomer thereof.

2) Psychiatric disorders

Examples of psychiatric disorders include, but are not limited to, anxieties such as, social anxiety, post-traumatic stress disorder, phobias, social phobia, special phobias, panic disorder, obsessive-compulsive disorder, acute stress disorder, separation anxiety disorder, and
25 generalized anxiety disorder, as well as depression such as, major depression, bipolar disorder, seasonal affective disorder, post-natal depression, manic depression, and bipolar depression, mood disorders and mood affective disorders that can be treated according to the present invention include, but are not limited to, bipolar disorder I depressed, hypomanic, manic and mixed form; bipolar disorder II; depressive disorders, such as single depressive episode or
30 recurrent major depressive disorder, minor depressive disorder, treatment-resistant depression, anxious depression, bipolar disorder, depressive disorder with postpartum onset, depressive

disorders with psychotic symptoms; persistent mood disorders, such as cyclothymia, dysthymia, euthymia; and premenstrual dysphoric disorder; psychoses.

3) Neurological disorders

Examples of neurological disorder include, but are not limited to, tremors, dyskinesias, dystonias, spasticity, Tourette's Syndrome; neuromyelitis optica, Parkinson's disease; Alzheimer's disease; senile dementia; Huntington's disease; Epilepsy/seizure disorders and sleep disorders.

4) Cancers:


Examples of cancers include, but are not limited to, benign skin tumors, prostate tumors, ovarian tumors and cerebral tumors (glioblastomas, medulloepitheliomas, medulloblastomas, neuroblastomas, tumors of embryonic origin, astrocytomas, astroblastomas, ependymomas, oligodendrogliomas, neuroepitheliomas, epiphyseal tumor, ependymblastomas, malignant meningiomas, sarcomatosis, malignant melanomas, schwannomas).

5) Eye conditions

Examples of eye conditions include, but are not limited to, ocular hypertension, glaucoma, degeneration, and apoptosis of retinal ganglion cells and neuroretinal cells.

Other embodiments of this invention provide for a method for modulating MGL receptor activity, including when such receptor is in a subject, comprising exposing MGL receptor to a therapeutically effective amount of at least one compound selected from compounds of the invention.



Embodiments of this invention are compounds of Formula (I),



wherein

X is CH₂ or O;

Y is selected from the group consisting of:

R¹ is H;

R^{2a} and R^{2b} are each independently H;

- 5 R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁-alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁-alkyl, C₁-alkyl substituted with OH, C₁-alkyl substituted with CO₂H, C₁-haloalkyl, OC₁-haloalkyl, C₃-cycloalkyl, O-phenyl, and C₃-cycloalkyl substituted with CH₃;


- 10 R^a and R^b are each independently selected from the group consisting of: H and halo; and R^c is H or CH₃;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.


An additional embodiment of the invention is a compound of Formula (I) wherein X is CH₂.

An additional embodiment of the invention is a compound of Formula (I) wherein X is O.


- 15 An additional embodiment of the invention is a compound of Formula (I) wherein Y is



An additional embodiment of the invention is a compound of Formula (I) wherein Y is



An additional embodiment of the invention is a compound of Formula (I) wherein Y is




5 An additional embodiment of the invention is a compound of Formula (I) wherein R^a and R^b are H.

An additional embodiment of the invention is a compound of Formula (I) wherein R^a and R^b are each independently H and Cl.


An additional embodiment of the invention is a compound of Formula (I) wherein R^a and R^b are F.

10 An additional embodiment of the invention is a compound of Formula (I) wherein R^3 is



15 An additional embodiment of the invention is a compound of Formula (I) wherein R^3 is phenyl, or phenyl substituted with one or two members each independently selected from the group consisting of: Cl, F, CH_3 , CH_2CH_3 , $\text{CH}(\text{CH}_3)_2$, $\text{C}(\text{CH}_3)_3$, $\text{CH}_2\text{CH}(\text{CH}_3)_2$, $\text{C}(\text{CH}_3)_2\text{CH}_2\text{OH}$, $\text{C}(\text{CH}_3)_2\text{CH}_2\text{CO}_2\text{H}$, CF_3 , OCF_3 , cyclopropyl, cyclopropyl substituted with CH_3 , and O-phenyl.

An additional embodiment of the invention is a compound of Formula (I) wherein R³ is



An additional embodiment of the invention is a compound of Formula (I) wherein R³ is
 3-tert-butylphenyl, 4-tert-butylphenyl, 4-methyl-3-trifluoromethylphenyl, or 3,4-
 5 dimethylphenyl.

A further embodiment of the current invention is a compound as shown below in Table 1.

Ex #	Compound Name
1	(rac)-(2s,4s)-2-(1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
2	(2s,4*R)-2-((1*S,5*R)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
3	(2s,4*S)-2-((1*R,5*S)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
4	(rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
5	(rac)-(2s,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
6	(rac)-(2s,4s)-2-(1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
7	(2s,4*S)-2-((1*R,5*S)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
8	(2s,4*R)-2-((1*S,5*R)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
9	(rac)-(2s,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
10	(2s,4*S)-2-((1*R,5*S)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
11	(2s,4*R)-2-((1*S,5*R)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
12	(rac)-(2r,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
13	(rac)-(2r,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
14	(2r,4*S)-2-((1*R,5*S)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
15	(2r,4*R)-2-((1*S,5*R)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
16	(rac)-(2s,4s)-2-(1-(3-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
17	(rac)-(2s,4s)-2-(1-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
18	(rac)-(2s,4s)-2-(1-(4-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
19	(rac)-(2s,4s)-2-(1-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
20	(rac)-(2s,4s)-2-(1-(o-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
21	(rac)-(2s,4s)-2-(1-(m-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
22	(rac)-(2s,4s)-2-(1-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
23	(rac)-(2s,4s)-2-(1-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
24	(rac)-(2s,4s)-2-(1-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
25	(rac)-(2s,4s)-2-(1-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
26	(rac)-(2s,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
27	(rac)-(2r,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
28	(rac)-(2s,4s)-2-(1-(4-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
29	(rac)-(2s,4s)-2-(1-(3-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
30	(rac)-(2s,4s)-2-(1-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
31	(rac)-(2s,4s)-2-(1-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
32	(rac)-(2s,4s)-2-(1-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
33	(rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
34	(rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
35	(rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
36	(rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
37	(rac)-(2s,4s)-2-(1-(3-Fluoro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
38	(2s,4S)-2-((1R,5S,6S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
39	(rac)-(2s,4s)-2-(6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
40	(2s,4S)-2-((1R,6S)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
41	(2s,4R)-2-((1S,6R)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
42	(rac)-(2s,4s)-2-(7,7-Difluoro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
43	(rac)-(2s,4s)-2-(6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
44	(2s,4*R)-2-((1*S,6*R)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
45	(2s,4*S)-2-((1*R,6*S)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
46	(rac)-(2s,4s)-2-(6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
47	(2s,4*R)-2-((1*S,6*R)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
48	(2s,4*S)-2-((1*R,6*S)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
49	(rac)-(2s,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
50	(2s,4*R)-2-((1*S,6*R)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
51	(2s,4*S)-2-((1*R,6*S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
52	(rac)-(2r,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
53	(rac)-(2s,4s)-2-(6-(o-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
54	(rac)-(2s,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
55	(rac)-(2r,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
56	(rac)-(2s,4s)-2-(6-(p-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
57	(rac)-(2s,4s)-2-(6-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
58	(rac)-(2s,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
59	(rac)-(2r,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
60	(rac)-(2s,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
61	(rac)-(2r,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
62	(rac)-(2s,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
63	(rac)-(2r,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
64	(rac)-(2s,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
65	(rac)-(2r,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
66	(rac)-(2s,4s)-2-(6-(4-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
67	(rac)-(2s,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
68	(rac)-(2r,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
69	(rac)-(2s,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
70	(rac)-(2r,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
71	(rac)-(2s,4s)-2-(6-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
72	(rac)-(2s,4s)-2-(6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
73	(rac)-(2s,4s)-2-(6-(3-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
74	(rac)-(2s,4s)-2-(6-(4-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
75	(rac)-(2s,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
76	(rac)-(2r,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
77	(rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
78	(2s,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
79	(2r,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
80	(2s,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
81	(2r,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
82	(2s,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
83	(2r,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
84	(2s,4S)-2-((1R,5S,6S)-6-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
85	(2s,4S)-2-((1R,5S,6S)-6-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
86	(2s,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
87	(2r,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
88	(2s,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
89	(2r,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
90	(2s,4S)-2-((1R,5S,6S)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
91	(2r,4S)-2-((1R,5S,6S)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
92	(2s,4S)-2-((1R,5S,6S)-6-(2,3-Dihydro-1H-inden-5-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and
93	(rac)-(2s,4*S)-2-((1*R,5*S,6*R)-6-(3-(tert-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
94	(rac)-(2s,4s)-2-(1-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
95	(2 <i>r</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i>)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
96	(2 <i>r</i> ,4 <i>*R</i>)-2-((1 <i>*S</i> ,5 <i>*R</i>)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
97	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(<i>o</i> -tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
98	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(<i>o</i> -Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
99	(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-6-(3-(<i>tert</i> -Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
100	(2 <i>s</i> ,4 <i>*R</i>)-2-((1 <i>*S</i> ,5 <i>*R</i> ,6 <i>*S</i>)-6-(3-(<i>tert</i> -Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
101	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Isobutylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
102	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-6-(3,4-Dimethylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
103	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-(<i>tert</i> -Butyl)phenyl-5-D)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
104	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-(1-Hydroxy-2-methylpropan-2-yl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
105	2-Methyl-2-(3-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-3-((2 <i>s</i> ,4 <i>S</i>)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoic acid;
106	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
107	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
108	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-6-(4-Cyclopropylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
109	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
110	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
111	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Ethyl-4-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
112	(<i>rac</i>)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(4-methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

Ex #	Compound Name
113	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(2-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
114	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
115	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
116	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>R</i>)-6-(6-(<i>tert</i> -Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
117	(2 <i>s</i> ,4* <i>R</i>)-2-((1* <i>S</i> ,6* <i>R</i>)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
118	(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,6* <i>S</i>)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
119	(2 <i>r</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,6* <i>S</i>)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
120	(2 <i>r</i> ,4* <i>R</i>)-2-((1* <i>S</i> ,6* <i>R</i>)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
121	(2 <i>r</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,6* <i>S</i>)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
122	(2 <i>r</i> ,4* <i>R</i>)-2-((1* <i>S</i> ,6* <i>R</i>)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
123	(<i>rac</i>)-(2 <i>s</i> ,4 <i>s</i>)-2-(7-Chloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and
124	(<i>rac</i>)-(2 <i>s</i> ,4 <i>s</i>)-2-(7,7-Dichloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

A further embodiment of the current invention is a compound selected from the group consisting of:

- 5 (*rac*)-(2*s*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and

(2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

5 A further embodiment of the current invention is a compound that is (*rac*)-(2*s*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

10 A further embodiment of the current invention is a compound that is (2*s*,4**R*)-2-((1**S*,5**R*)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.

15 A further embodiment of the current invention is a compound that is (2*s*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

20 A further embodiment of the current invention is a compound that is (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.


25 A further embodiment of the current invention is a compound that is (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof

30 A further embodiment of the current invention is a compound that is (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

A further embodiment of the current invention is a compound that is (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.

- 5 A further embodiment of the current invention is a compound that is (2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

- 10 An additional embodiment of the invention is a compound of Formula (I) having the Formula (IA):




wherein

X is CH₂ or O; and

- 15 R³ is selected from the group consisting of: phenyl; phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆haloalkyl, OC₁₋₆haloalkyl, C₃₋₆cycloalkyl, O-phenyl, and C₃₋₆cycloalkyl substituted with CH₃.

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IB):



20


wherein

X is CH₂ or O;

- R³ is selected from the group consisting of: 2,3-dihydro-1*H*-indene; pyridyl substituted with C₁₋₆alkyl; phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH, C₁₋₆alkyl substituted with CO₂H, C₁₋₆haloalkyl, OC₁₋₆haloalkyl and cyclopropyl; and
- 25

R^c is H or CH_3 .

An additional embodiment of the invention is a compound of Formula (I) having the Formula (IC):



5

wherein

X is CH_2 or O;

R^3 is selected from the group consisting of: phenyl; phenyl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} haloalkyl,


10 OC_{1-6} haloalkyl, C_{3-6} cycloalkyl, and C_{3-6} cycloalkyl substituted with CH_3 ; and

R^a and R^b are each independently selected from the group consisting of: H, Cl and F.

An additional embodiment of the invention is a pharmaceutical composition comprising:

(A) a therapeutically effective amount of at least one compound selected from



15 compounds of Formula (I)



wherein

X is CH_2 or O;

Y is selected from the group consisting of:



20

R^1 is H;

R^{2a} and R^{2b} are each independently H;

R^3 is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁-

- 5 6alkyl; phenyl; and phenyl substituted with one or two members each independently
 selected from the group consisting of: halo, C₁-6alkyl, C₁-6alkyl substituted with OH, C₁-
 6alkyl substituted with CO₂H, C₁-6haloalkyl, OC₁-6haloalkyl, C₃-6cycloalkyl, O-phenyl, and
 C₃-6cycloalkyl substituted with CH₃;

R^a and R^b are each independently selected from the group consisting of: H and halo; and


- 10 R^c is H or CH₃;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
 compounds of Formula (I);

and (B) at least one pharmaceutically acceptable excipient.


An additional embodiment of the invention is a pharmaceutical composition comprising a
 therapeutically effective amount of at least one compound in Table 1, as well as and
 pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds
 of Table 1, pharmaceutically acceptable prodrugs of compounds of Table 1, and
 pharmaceutically active metabolites of Table 1; and at least one pharmaceutically acceptable
 excipient.

- 15 An additional embodiment of the invention is a method of treating a subject suffering
 from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity,
 comprising administering to a subject in need of such treatment a therapeutically effective
 amount of at least one compound selected from compounds of Formula (I):



wherein

X is CH₂ or O;



R^1 is H;

R^{2a} and R^{2b} are each independently H;

- 5 R^3 is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C_{1-6} alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkyl substituted with OH, C_{1-6} alkyl substituted with CO_2H , C_{1-6} haloalkyl, OC_{1-6} haloalkyl, C_{3-6} cycloalkyl, O-phenyl, and C_{3-6} cycloalkyl substituted with CH_3 ;
- 10 R^a and R^b are each independently selected from the group consisting of: H and halo; and R^c is H or CH_3 ;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, to a subject in need thereof.

An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IA), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IA), pharmaceutically acceptable prodrugs of compounds of Formula (IA), and pharmaceutically active metabolites of Formula (IA); and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IB), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IB), pharmaceutically acceptable prodrugs of compounds of Formula (IB), and pharmaceutically active metabolites of Formula (IB); and at least one pharmaceutically acceptable excipient.

An additional embodiment of the invention is a pharmaceutical composition comprising a therapeutically effective amount of at least one compound of Formula (IC), as well as pharmaceutically acceptable salts, N-oxides or solvates of compounds of Formula (IC),

pharmaceutically acceptable prodrugs of compounds of Formula (IC), and pharmaceutically active metabolites of Formula (IC); and at least one pharmaceutically acceptable excipient.

Also within the scope of the invention are enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)). Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), and pharmaceutically active metabolites of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)).

Also within the scope of the invention are isotopic variations of compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), such as, e.g., deuterated compounds of Formula (I).

Also within the scope of the invention are the pharmaceutically acceptable salts, N-oxides or solvates of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)). Also within the scope of the invention are the pharmaceutically acceptable prodrugs of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), and pharmaceutically active metabolites of the isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)).

An additional embodiment of the invention is a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound selected from compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), enantiomers and diastereomers of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), isotopic variations of the compounds of Formula (I) (as well as Formulas (IA), (IB), and (IC)), and pharmaceutically acceptable salts of all of the foregoing.

Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples that follow. Artisans will recognize that, to obtain the various compounds herein, starting materials may be suitably selected so that the ultimately desired substituents will be carried through the reaction scheme with or without protection as appropriate to yield the desired product. Alternatively, it may be necessary or desirable to employ, in the place of the ultimately desired substituent, a suitable group that may be carried through the reaction scheme and

- replaced as appropriate with the desired substituent. Unless otherwise specified, the variables are as defined above in reference to Formula (I). Reactions may be performed between the melting point and the reflux temperature of the solvent, and preferably between 0 °C and the reflux temperature of the solvent. Reactions may be heated employing conventional heating or
- 5 microwave heating. Reactions may also be conducted in sealed pressure vessels above the normal reflux temperature of the solvent.

Abbreviations and acronyms used herein include the following:

Table 2:

Term	Acronym
Bis(triphenylphosphine)palladium(II) dichloride	PdCl ₂ (PPh ₃) ₂
Microliter	μL or uL
Acetonitrile	ACN, MeCN
Aqueous	aq
Atmosphere	atm
<i>tert</i> -Butyloxycarbonyl	BOC or Boc
Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate	BOP
Broad	br
Mesylate[(di(1-adamantyl)- <i>n</i> -butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II)	CatacXium [®] A Pd G3
Diatomaceous Earth	Celite [®]
1,8-Diazabicyclo[5.4.0]undec-7-ene	DBU
<i>N,N'</i> -Dicyclohexylcarbodiimide	DCC
Dichloromethane	DCM
Diisobutylaluminum hydride	DIBAL-H
Diisopropyl ether	DIPE
<i>N</i> -Ethyl-diisopropylamine	DIPEA
4-Dimethylaminopyridine	DMAP
1,2-Dimethoxyethane	DME
Dimethylformamide	DMF
Dimethylsulfoxide	DMSO
1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide	EDC, EDAC or EDCI
Electrospray ionization	ESI
Diethyl ether	Ether, Et ₂ O
Ethyl Acetate	EtOAc, or EA
Ethanol	EtOH

Term	Acronym
Normal-phase silica gel chromatography	FCC
Grams	g
Hours	h, hr, hrs
1-[Bis(dimethylamino)methylene]-1 <i>H</i> -1,2,3-triazolo[4,5- <i>b</i>]pyridinium 3-oxide hexafluorophosphate	HATU
<i>N,N,N',N'</i> -Tetramethyl- <i>O</i> -(1 <i>H</i> -benzotriazol-1-yl)uronium hexafluorophosphate	HBTU
Hydroxybenzotriazole	HOBt
High-pressure liquid chromatography	HPLC
Hertz	Hz
Isopropyl alcohol	<i>i</i> PrOH, IPA
Potassium <i>tert</i> -butoxide	KO <i>t</i> Bu
Lithium aluminum hydride	LAH
Liquid chromatography and mass spectrometry	LCMS
Molar	M
Mass to charge ratio	m/z
Methanol	MeOH
Milligrams	mg
Minute	min
Milliliter	mL
Millimoles	mmol
Mass spectrometry	MS
Normal	N
Sodium acetate	NaOAc
N-Bromosuccinimide	NBS
Nuclear magnetic resonance	NMR
Palladium on carbon	Pd/C
Bis(dibenzylideneacetone)palladium	Pd(dba) ₂
Bis(diphenylphosphino)ferrocene]dichloropalladium(II)	Pd(dppf)Cl ₂
Tetrakis(triphenylphosphine)palladium	Pd(PPh ₃) ₄
Parts per million	ppm
Protecting Group	PG
Precipitate	ppt
Polytetrafluoroethylene	PTFE
Bromotripyrrolidinophosphonium hexafluorophosphate	PyBroP [®]
Reverse Phase	RP


Term	Acronym
Retention time	R _t
Room temperature	rt
Saturated	sat
Supercritical Fluid Chromatography	SFC
2-Dicyclohexylphosphino-2',6'-dimethoxybiphenyl	SPhos
Temperature	T
2,4,6-Tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide	T3P [®]
Triethylamine	TEA
Trifluoroacetic acid	TFA
Trifluoroacetic anhydride	TFAA
Tetrahydrofuran	THF
Thin layer chromatography	TLC
<i>N,N,N',N'</i> -Tetramethylethylenediamine	TMEDA
Volume in milliliters of solvent per gram of substrate	V, or volumes

PREPARATIVE EXAMPLES

Exemplary compounds useful in methods of the invention will now be described by reference to the illustrative synthetic schemes for their general preparation below and the specific examples to follow.

5


SCHEME 1



According to SCHEME 1, a compound of formula (V), where R^a is C₁₋₄alkyl, is treated with hydroxylamine; using an additive such as sodium acetate (NaOAc), and the like; in a suitable solvent such as ethanol (EtOH), and the like; to provide a compound of formula (VI).


- 10 A compound of formula (VII) is prepared from a compound of formula (VI) using an oxidant such as hydrogen peroxide, urea-hydrogen peroxide, and the like; in the presence of an activator such as trifluoroacetic anhydride (TFAA), and the like; in the presence of a base such as dibasic sodium phosphate, and the like; in a solvent such as acetonitrile (ACN), and the like.

SCHEME 2




- According to SCHEME 2, compounds of formula (VIIIa) and (VIIIb) are prepared by reacting a compound of formula (VII), where R^a is C_{1-4} alkyl, with formaldehyde in the presence of a base such as triethylamine (TEA), and the like; in a solvent such as ACN, and the like.
- 5 A compound of formula (IX) is prepared by hydrogenolysis of a compound of formula (VIIIb) under an atmosphere of hydrogen gas (H_2) in the presence of a catalyst such as palladium on carbon (Pd/C), and the like; in a solvent such as ethyl acetate (EtOAc), EtOH, and the like.
- A compound of formula (X) is prepared by the reaction of a compound of formula (IX) with triphosgene in the presence of a base such as TEA, and the like; in a solvent such as
- 10 tetrahydrofuran (THF), and the like. A compound of formula (XI) is prepared by the acidic deprotection of a compound of formula (X) using an acid such as trifluoroacetic acid (TFA), HCl in dioxane, and the like.

SCHEME 3



According to SCHEME 3, compounds of formula (XIIa) and formula (XIIb) are prepared by a Michael-type reaction between a compound of formula (VII), where R^a is ethyl; and methyl acrylate; in the presence of a base such as 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU), and the like; in a solvent such as ACN, and the like. Reductive ring closure of a compound of formula (XIIa) using a reducing agent such as sodium borohydride (NaBH₄), and the like; an additive such as nickel(II) chloride hexahydrate, and the like; in a suitable solvent such as methanol (MeOH), and the like; provides a compound of formula (XIII), where X is CH₂.


SCHEME 4



According to SCHEME 4, a compound of formula (XIV) may be prepared by reacting a compound of formula (VII), where R^a is C₁₋₄alkyl; with acetaldehyde in the presence of a base such as TEA, and the like; in a solvent such as ACN, and the like, at temperatures ranging from 0 °C to room temperature, for a period of 18 h. A compound of formula (XIV) may be subjected


to hydrogenolysis; employing conditions previously described, to provide compounds of formula (XVa) and (XVb).

SCHEME 5




According to SCHEME 5, a compound of formula (XVa), where R^a is C₁₋₄alkyl, may be subjected to ring closure conditions with triphosgene, employing conditions previously described, to provide a compound of formula (XVI). A compound of formula (XVI) may be subjected to acidic deprotection conditions previously described to provide a compound of formula (XVII), where X is O.

SCHEME 6




According to SCHEME 6, a commercially available or synthetically accessible compound of formula (XVIII), is reacted in a Simmons–Smith type reaction to provide a compound of formula (XIX). For example, compound of formula (XVIII), where PG is BOC, and *n* is independently 1 or 2, is reacted with diethylzinc; diiodomethane; and TFA; in a suitable solvent such as dichloromethane (DCM), and the like; at temperatures ranging from -40 °C to -15 °C. The BOC protecting group is cleaved under these conditions. Boc protection is achieved employing di-*tert*-butyl dicarbonate; a suitable base such as TEA, and the like; and 4-dimethylaminopyridine (DMAP); in a suitable solvent such as THF, DCM, and the like; to provide a compound of formula (XIX). A compound of formula (XIX) is treated with potassium bifluoride (KHF₂) in a suitable solvent such as MeOH, and the like; at temperatures ranging from rt to the reflux temperature of the solvent; to provide a compound of formula (XX).

SCHEME 7




According to SCHEME 7, a compound of formula (XX), where n is independently 1 or 2, and PG is BOC, is reacted with a variably substituted bromobenzene of formula (XXI), where R³ is a suitably substituted aryl group; a catalyst such as mesylate[(di(1-adamantyl)-*n*-butylphosphine)-2-(2'-amino-1,1'-biphenyl)]palladium(II) (CatacXium[®] A Pd G3), and the like; a base such as cesium carbonate (Cs₂CO₃), and the like; in a mixture of solvents such as toluene/water, and the like; at a temperature range of 80 °C to 100 °C; for a period of 18 h; to provide a compound of formula (XXII). Cleavage of the protecting group on a compound of formula (XXII) is achieved according to procedures known to one skilled in the art. For example, acidic conditions such as TFA/DCM, HCl/Dioxane, and the like, provides a compound of formula (XXIII).

SCHEME 8




According to SCHEME 8, *tert*-butyl 3-methyl-2,5-dihydro-1H-pyrrole-1-carboxylate is deprotected employing conditions previously described to provide 3-methyl-2,5-dihydro-1H-pyrrole. 3-Methyl-2,5-dihydro-1H-pyrrole undergoes reductive amination with benzaldehyde using a reducing agent such as sodium triacetoxyborohydride, sodium cyanoborohydride, and the like; in a suitable solvent such as DCM, and the like; to afford 1-benzyl-3-methyl-2,5-dihydro-1H-pyrrole.

SCHEME 9



According to SCHEME 9, a compound of formula (XXIV), where R^3 is suitably substituted aryl group, is condensed with 4-methylbenzenesulfonhydrazide; in a suitable solvent such as THF, MeOH, and the like; at room temperature for a period of 1-16 h to provide a compound of formula (XXV). A compound of formula (XXV) is treated with a base such as sodium hydride (NaH), sodium hydroxide, and the like; with or without an additive such as benzyltriethylammonium chloride; in a solvent such as THF, toluene, and the like; at temperatures ranging from room temperature to 80 °C; for a period of 1-2 h; and the resulting aryldiazo intermediate is reacted under the Charette modification of Simmons-Smith cyclopropanation conditions with a compound of formula (XXVI), where R^c is H or CH_3 ; with a suitable catalyst such as zinc diiodide, and the like; in a solvent such as DCM, and the like; at room temperature; over 1-16 h; to provide a compound of formula (XXVII). A compound of formula (XXVIII) is prepared by hydrogenolysis of a compound of formula (XXVII) under an atmosphere of H_2 ; in the presence of a catalyst such as Pd/C, and the like; in a suitable solvent such as EtOAc, EtOH, MeOH, THF, and the like. Alternatively, a compound of formula (XXVIII) is prepared by deprotecting a compound of formula (XXVII) using an acylating agent such as 1-chloroethylcarbonochloridate; a base such as TEA, and the like; in a solvent such as DCM, and the like; followed by stirring in a solvent such as MeOH and the like; at a temperature of 80 °C.

SCHEME 10




20

According to SCHEME 10, a compound of formula (XXIV), where R^3 is suitably substituted aryl group, is condensed with hydrazine monohydrate; at room temperature for a

period of 30 min; to provide a compound of formula (XXIX). A compound of formula (XXIX) is treated with manganese(IV) oxide; in a suitable solvent such as 1,4-dioxane, and the like; at room temperature; for a period of 2 h; and the resulting intermediate is reacted with *N*-benzylmaleimide at a temperature of 100 °C for a period of 16 h to provide a compound of formula (XXXI). Under conditions known to one skilled in the art, a compound of formula (XXXI) is reduced with a reducing agent such as NaBH₄, LiAlH₄, LiBH₄, diisobutylaluminum hydride (DIBAL-H), and the like; in a suitable solvent such as THF, MeOH, EtOH, and the like; at temperatures ranging from -78 to 0 °C; for a period of 30 min to 16 h; to provide a compound of formula (XXVII), where R^c is H. A compound of formula (XXVII) is subjected to hydrogenolysis employing conditions previously described to provide a compound of formula (XXVIII).

SCHEME 11




According to SCHEME 11, pinacol(dichloromethyl)boronate is reacted with sodium iodide (NaI); in a suitable solvent such as acetone, and the like; at a temperature of 55 °C over a period of 72 h to provide pinacol(diiodomethyl)boronate. Either pinacol(diiodomethyl)boronate or pinacol(dichloromethyl)boronate is reacted with a pre-stirred mixture of chromium(II) chloride; *N,N,N',N'*-tetramethylethylenediamine (TMEDA); in a suitable solvent such as THF, and the like; before adding *tert*-butyl 2,5 dihydro-1*H*-pyrrole-1-carboxylate and heating to 50 °C for 20 h to provide *tert*-butyl (1*R*,5*S*,6*s*)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. *tert*-Butyl (1*R*,5*S*,6*s*)-6-(4,4,5,5-tetramethyl-1,3,2-

dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate is reacted under Suzuki coupling conditions with a suitably substituted aryl halide of formula (XXXII), where R^3 is a suitably substituted aryl group and X is either iodo or bromo; a palladium catalyst such as bis(triphenylphosphine)palladium(II) dichloride, CataCXium A Pd G3, and the like; a suitable

5 base such a potassium phosphate, Cs_2CO_3 , and the like; in a suitable solvent such as dioxane, water, EtOH, or a mixture thereof; to provide a compound of formula (XXXIV). A compound of formula (XXXIV) is submitted to deprotection conditions as previously described to a compound of formula (XXVIII), where R^c is H.

SCHEME 12




10 According to SCHEME 12, a compound of Formula (I), where R^1 is hydrogen and X is CH_2 or O, is prepared by conventional amide bond forming techniques such as coupling reactions which are well known to those skilled in the art (such as HATU (1-[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxide hexafluorophosphate), BOP (benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate), or conversion of the acid to an acid chloride). For example, reaction of a

15 compound of formula (XXVIII), where R^c is H or CH_3 , and R^3 is as defined in claim 1; or a compound of formula (XXIII), where n is each independently 1 or 2; is reacted with a synthetically accessible suitably substituted carboxylic acid of formula (XXXV) (which includes

20 a compound of formula (XI)), where the acid is activated with an appropriate activating reagent, for example a carbodiimide, such as *N,N'*-dicyclohexylcarbodiimide (DCC) or 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC, EDAC or EDCI) optionally in the presence of hydroxybenzotriazole (HOBt) and/or a catalyst such as 4-dimethylaminopyridine (DMAP); a


halotrisaminophosphonium salt such as (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate (BOP), or bromotripyrrolidinophosphonium hexafluorophosphate (PyBroP[®]); a suitable pyridinium salt such as 2-chloro-1-methyl pyridinium chloride; or another suitable coupling agent such as *N,N,N',N'*-tetramethyl-*O*-(1*H*-benzotriazol-1-yl)uronium
 5 hexafluorophosphate (HBTU), 1-[bis(dimethylamino)methylene]-1*H*-1,2,3-triazolo[4,5-*b*]pyridinium 3-oxid hexafluorophosphate (HATU), 2,4,6-tripropyl-1,3,5,2,4,6-trioxatriphosphorinane-2,4,6-trioxide (T3P[®]) and the like. Coupling reactions are conducted in a suitable solvent such as DCM, THF, DMF and the like, optionally in the presence of a tertiary amine such as *N*-methylmorpholine, *N*-ethyldiisopropylamine (DIPEA), or triethylamine (TEA),
 10 at a temperature ranging from 0 °C to rt, to provide a compound of Formula (I).

A compound of Formula (I) where R³ is phenyl substituted with C(CH₃)₂CO₂CH₃ is reacted under hydrolysis conditions known to one skilled in the art, for example, utilizing a base such as LiOH•H₂O, and the like; in a suitable solvent such as water, 1,4-dioxane, and the like; at room temperature for up to 16 hours to provide a compound of Formula (I) where R³ is
 15 phenyl substituted with C(CH₃)₂CO₂H.



A compound of Formula (I), where Y is substituted with I and tert-butyl, is reacted in an H-Cube[®] under continuous-flow deuteration conditions utilizing D₂O as the source for deuterium gas; a suitable catalyst such as Pd/C and the like; in a suitable solvent such as CD₃OD, tetrahydrofuran-*d*₈, or a mixture thereof; to provide
 20 (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-butyl)phenyl-5-*D*)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.

SCHEME 13




According to SCHEME 13, a suitably substituted, commercially available aryl bromide
 25 of formula (XXXVI), where R³ is phenyl substituted with one or two members each independently selected from F or C₁₋₄alkyl; is reacted with a base, such as *n*-BuLi, and the like; a

formyl source such as DMF and the like; in a solvent such as THF, and the like; for a period of 3 hours at a temperature of -70 °C to provide a compound of formula (XXIV).


- A compound of formula (XXIV), where R³ is phenyl substituted with one or two members each independently selected from Br or C₁₋₄alkyl; is reacted in a metal-mediated cross coupling reaction to provide a compound of formula (XXIV), where R³ is phenyl substituted with one or two members each independently selected from C₃₋₆cycloalkyl or C₁₋₄alkyl. For example, a compound of formula (XXIV), where R³ is substituted with Br and CH₃; is reacted with a commercially available suitably substituted boronic acid such as cyclopropylboronic acid; in the presence of a palladium catalyst such as Pd(OAc)₂,
 10 *bis*(triphenylphosphine)palladium(II)chloride (PdCl₂(PPh₃)₂), [1,1'-*bis*(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl₂(dppf)), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh₃)₄), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl][2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (RuPhos-Pd-G3), and the like; a phosphine ligand such as PPh₃; base such as potassium
 15 phosphate, Na₂CO₃, Cs₂CO₃, and the like; in a suitable solvent such as ACN, water, 1,4-dioxane, toluene, or a mixture thereof; at a temperature ranging from 70 °C – 120 °C; for a period ranging from 2 h to 48 h, using conventional or microwave heating, to provide a compound of formula (XXIV), where R³ is phenyl substituted with cyclopropyl and CH₃.

SCHEME 14



- According to SCHEME 14, 1-iodo-3-methyl-benzene is treated with *tert*-butyl chloride and aluminum chloride; for a period of 1 h; at temperatures ranging from 0 °C to rt; to provide 1-*tert*-butyl-3-iodo-5-methylbenzene. 1-*tert*-Butyl-3-iodo-5-methylbenzene is treated with (PhCO₂)₂; and NBS; in a suitable solvent such as carbon tetrachloride; at reflux temperature; for
 25 a period of 16 hours; to provide 1-(bromomethyl)-3-*tert*-butyl-5-iodobenzene. 1-(Bromomethyl)-3-*tert*-butyl-5-iodobenzene is oxidized under Kornblum conditions; in a suitable solvent such as DMSO, and the like; at temperatures ranging from rt to 100 °C; to provide a compound of formula (XXIV) where R³ is phenyl substituted with iodo and *tert*-butyl.

SCHEME 15




According to SCHEME 15, (1*R*,5*S*,6*s*)-3-benzyl-6-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane is reacted with ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane; ZnF₂; a suitable catalyst such as Pd₂(dba)₃, and the like; and a ligand such as P(*t*-Bu)₃, and the like; at a temperature of 90 °C over 6 hours to provide a compound of formula (XXVII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CO₂CH₃. A compound of formula (XXVIII), where R₃ is phenyl substituted with C(CH₃)₂CO₂CH₃ is prepared from a compound of formula (XXVII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CO₂CH₃ employing hydrogenolysis conditions known to one skilled in the art or as previously described.

A compound of formula (XXVIII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CH₂OH, is prepared in two steps from a compound of formula (XXVII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CO₂CH₃. In a first step, a compound of formula (XXVII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CO₂CH₃ is reduced employing conditions known to one skilled in the art. For example, a compound of formula (XXVII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CO₂CH₃ is reduced with a suitable reducing agent such as NaBH₄, LiAlH₄, LiBH₄, diisobutylaluminum hydride (DIBAL-H), and the like; in a suitable solvent such as tetrahydrofuran (THF), methanol (MeOH), ethanol (EtOH), and the like; at temperatures ranging from -78 to 0 °C; for a period of 30 min to 16 h. Subsequent hydrogenolysis, employing conditions as previously described, to provides a compound of formula (XXVIII), where R^c is H and R³ is phenyl substituted with C(CH₃)₂CH₂OH.

- Alternately, (*racemic*)-(1**R*,5**S*,6**R*)-3-benzyl-6-(4-bromo-3-(trifluoromethoxy)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane is reacted in a metal-mediated cross coupling reaction with a commercially available suitably substituted borane, such as 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane; in the presence of a palladium catalyst such as Pd(OAc)₂,
- 5 *bis*(triphenylphosphine)palladium(II)chloride (PdCl₂(PPh₃)₂), [1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (PdCl₂(dppf)), tetrakis(triphenylphosphine)palladium(0) (Pd(PPh₃)₄), 2-dicyclohexylphosphino-2',6'-diisopropoxy-1,1'-biphenyl[2-(2'-amino-1,1'-biphenyl)]palladium(II) methanesulfonate (RuPhos-Pd-G3), and the like; a phosphine ligand such as PPh₃; base such as
- 10 potassium phosphate, Na₂CO₃, Cs₂CO₃, and the like; in a suitable solvent such as ACN, water, 1,4-dioxane, toluene, or a mixture thereof; at a temperature ranging from 70 °C – 120 °C; for a period ranging from 2 h to 48 h, using conventional or microwave heating, to provide a compound of formula (XXVII), where R³ is phenyl substituted with OCF₃ and CH₃. A compound of formula (XXVII), where R³ is phenyl substituted with OCF₃ and CH₃, is reacted
- 15 under hydrogenolysis conditions as previously described, to provide a compound of formula (XXVIII), where R^c is H.

SCHEME 16



- According to SCHEME 16, a compound of formula (XXIX), where R³ is as described in
- 20 claim 1, is treated with *tert*-butyl 2,5-dioxo-2,5-dihydro-1*H*-pyrrole-1-carboxylate, employing conditions previously described in SCHEME 10, to provide a compound of formula (XXXIV). A compound of formula (XXVIII), is prepared in two steps from a compound of formula (XXXIV). In a first step, deprotection of the *tert*-butyl carbamate protecting group is achieved employing conditions known to one skilled in the art, or as previously described. Subsequent
- 25 reduction of is achieved employing conditions known to one skilled in the art, for example, reduction with a suitable reducing agent such as NaBH₄, LiAlH₄, LiBH₄, diisobutylaluminum hydride (DIBAL-H), and the like; with an additive such as BF₃•OEt₂; in a suitable solvent such

as THF, MeOH, EtOH, and the like; at temperatures ranging from 0 to 50 °C; for a period of 30 min to 16 h; to provide a compound of formula (XXVIII), where R⁶ is H.

Compounds of Formula (I) may be converted to their corresponding salts using methods known to one of ordinary skill in the art. For example, an amine of Formula (I) is treated with
5 trifluoroacetic acid, HCl, or citric acid in a solvent such as Et₂O, CH₂Cl₂, THF, MeOH, chloroform, or isopropanol to provide the corresponding salt form. Alternately, trifluoroacetic acid or formic acid salts are obtained as a result of reverse phase HPLC purification conditions. Crystalline forms of pharmaceutically acceptable salts of compounds of Formula (I) may be obtained in crystalline form by recrystallization from polar solvents (including mixtures of polar
10 solvents and aqueous mixtures of polar solvents) or from non-polar solvents (including mixtures of non-polar solvents).

Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and
15 mixtures thereof are encompassed within the scope of the present invention.

Compounds prepared according to the schemes described above may be obtained as single forms, such as single enantiomers, by form-specific synthesis, or by resolution. Compounds prepared according to the schemes above may alternately be obtained as mixtures of various forms, such as racemic (1:1) or non-racemic (not 1:1) mixtures. Where racemic and non-
20 racemic mixtures of enantiomers are obtained, single enantiomers may be isolated using conventional separation methods known to one of ordinary skill in the art, such as chiral chromatography, recrystallization, diastereomeric salt formation, derivatization into diastereomeric adducts, biotransformation, or enzymatic transformation. Where regioisomeric or diastereomeric mixtures are obtained, as applicable, single isomers may be separated using
25 conventional methods such as chromatography or crystallization.

The following specific examples are provided to further illustrate the invention and various preferred embodiments.

EXAMPLES

In obtaining the compounds described in the examples below and the corresponding analytical data, the following experimental and analytical protocols were followed unless otherwise indicated.

- 5 Unless otherwise stated, reaction mixtures were magnetically stirred at room temperature (rt) under a nitrogen atmosphere. Where solutions were “dried,” they were generally dried over a drying agent such as Na₂SO₄ or MgSO₄. Where mixtures, solutions, and extracts were “concentrated”, they were typically concentrated on a rotary evaporator under reduced pressure. Reactions under microwave irradiation conditions were carried out in a Biotage Initiator or CEM
10 (Microwave Reactor) Discover instrument.

For the reactions conducted under continuous flow conditions, “flowed through a LTF-VS mixer” refers to the use of a Chemyx Fusion 100 Touch Syringe Pump that is in line via 1/16” PTFE tubing to a LTF-VS mixer (Little Things Factory GmbH (<http://www.ltf-gmbh.com>), unless otherwise indicated.

- 15 Normal-phase silica gel chromatography (FCC) was performed on silica gel (SiO₂) using prepacked cartridges.

Preparative reverse-phase high performance liquid chromatography (RP HPLC) was performed on either:

- METHOD A. An Agilent HPLC with an Xterra Prep RP18 column (5 μM, 30 x 100 or 50
20 x 150mm) or an XBridge C18 OBD column (5 μM, 30 x 100 or 50 x 150mm), and a mobile phase of 5% ACN in 20mM NH₄OH was held for 2 min, then a gradient of 5-99% ACN over 15 min, then held at 99% ACN for 5 min, with a flow rate of 40 or 80 mL/min.

or

- METHOD B. A Shimadzu LC-8A Series HPLC with an Inertsil ODS-3 column (3 μm,
25 30 x 100mm, T = 45 °C), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was held for 1 min, then a gradient of 5-99% ACN over 6 min, then held at 99% ACN for 3 min, with a flow rate of 80 mL/min.

or

- METHOD C. A Shimadzu LC-8A Series HPLC with an XBridge C18 OBD column (5
30 μm, 50 x 100mm), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was held for 1 min,

then a gradient of 5-99% ACN over 14 min, then held at 99% ACN for 10 min, with a flow rate of 80 mL/min.

or

METHOD D. A Gilson HPLC with an XBridge C18 column (5 μ m, 100 x 50mm), mobile
5 phase of 5-99% ACN in 20 mM NH₄OH over 10 min and then hold at 99 ACN for 2 min, at a
flow rate of 80 mL/min.

or

METHOD E. An ACCQ Prep HPLC with an XBridge C18 OBD column (5 μ M, 50 x
100), mobile phase of 5% ACN in H₂O (both with 0.05% TFA) was held for 1 min, then a
10 gradient of 5-95% ACN over 12 min, then held at 95% ACN for 2 min, with a flow rate of 80
mL/min.

Preparative supercritical fluid high performance liquid chromatography (SFC) was
performed on either on a Jasco preparative SFC system, an APS 1010 system from Berger
instruments, or a SFC-PICLAB-PREP 200 (PIC SOLUTION, Avignon, France). The separations
15 were conducted at 100 to 150 bar with a flow rate ranging from 40 to 60 mL/min. The column
was heated to 35 to 40 °C.

SFC Method: SFC-Lux Cellulose-1, Column Phenomenex Lux Cellulose-1 150 x 4.6
mm, 5 μ m, Isocratic mode: 40% Methanol + 0.1% Diethylamine and 60 % CO₂)


Mass spectra (MS) were obtained on an Agilent series 1100 MSD using electrospray
20 ionization (ESI) in positive mode unless otherwise indicated. Calculated (calcd.) mass
corresponds to the exact mass.

Nuclear magnetic resonance (NMR) spectra were obtained on Bruker model DRX
spectrometers. Definitions for multiplicity are as follows: s = singlet, d = doublet, t= triplet, q =
quartet, p = pentet, hept = heptet, dd = doublet of doublets, dt = doublet of triplets, dq = double
25 of quartets, dp = doublet of pentets, td = triplet of doublets, tt = triplet of triplets, ddd = doublet
of doublet of doublets, m = multiplet, br = broad. It will be understood that for compounds
comprising an exchangeable proton, said proton may or may not be visible on an NMR spectrum
depending on the choice of solvent used for running the NMR spectrum and the concentration of
the compound in the solution.

30 Chemical names were generated using ChemDraw Ultra 17.1 (CambridgeSoft Corp.,
Cambridge, MA) or OEMetaChem V1.4.0.4 (Open Eye).


Compounds designated as *R or *S are enantiopure compounds where the absolute configuration was not determined.

Intermediate 1: *tert*-Butyl 3-nitrocyclobutanecarboxylate.




- 5
- Step A: *tert*-Butyl 3-hydroxyiminocyclobutanecarboxylate. To a solution of *tert*-butyl 3-oxocyclobutane-1-carboxylate (100 g, 588 mmol) in ethanol (EtOH) (1.8 L) was added sodium acetate (NaOAc) (192 g, 2340 mmol) and hydroxylamine hydrochloride (81 g, 1166 mmol). The reaction mixture was stirred at reflux for 4 h then filtered through a pad of Celite[®] and the pad
- 10 was washed with EtOH. The combined filtrates were evaporated and the residue was taken up in ethyl acetate (EtOAc) and washed with water and brine. The organic layer was dried over magnesium sulfate, filtered, and concentrated to give the title compound (108 g, 584 mmol, 99%) as a white solid. MS (ESI): mass calcd. for C₉H₁₅NO₃ 185.1; m/z found, 186.2 [M+H]⁺.
- Step B: *tert*-Butyl 3-nitrocyclobutanecarboxylate. To a suspension of urea hydrogen peroxide
- 15 (164 g, 1.74 mol) in acetonitrile (MeCN) (1 L) was added a solution of trifluoroacetic anhydride (TFAA) (245 mL, 1.75 mol) in MeCN (500 mL) dropwise over 1 h at -10 °C. The reaction mixture was stirred at room temperature for 1 h. The solution was added to a solution of *tert*-butyl 3-hydroxyiminocyclobutanecarboxylate (108 g, 0.584 mol) and sodium phosphate dibasic (911 g, 6.42 mol) in MeCN (1 L) dropwise over 30 min at 80 °C. The reaction mixture was
- 20 stirred at 80 °C for 30 min then filtered through a pad of Celite[®] and the pad was washed with MeCN. The combined filtrates were diluted with EtOAc. The mixture was washed with water and brine. The organic layer was dried over magnesium sulfate, filtered and evaporated. The residue was purified by flash column chromatography (FCC) on silica (0-20% EtOAc in heptane) to give the title compound (89.6 g, 445 mmol, 76%) as a yellow oil as a 1.3:1 mixture
- 25 of *cis/trans* isomers. Compound does not ionize with ESI⁺ LCMS.

Intermediate 2: Ethyl 3-nitrocyclobutanecarboxylate.



The title compound was prepared in a manner analogous to Intermediate 1 using ethyl 3-oxocyclobutane-1-carboxylate instead of *tert*-butyl 3-oxocyclobutane-1-carboxylate in Step A. Compound does not ionize with ESI⁺ LCMS. ¹H NMR (300 MHz, Chloroform-d) δ 5.02 – 4.70 (m, 1H), 4.20 (q, *J* = 7.2 Hz, 2H), 3.04 – 2.71 (m, 5H), 1.29 (t, *J* = 7.0 Hz, 3H).

Intermediate 3: (2*s*,4*s*)-6-Oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid.



Step A: *tert*-Butyl (1*s*,3*s*)-3-(hydroxymethyl)-3-nitrocyclobutane-1-carboxylate. To a solution of *tert*-butyl 3-nitrocyclobutanecarboxylate (Intermediate 1, 89.6 g, 445 mmol) in MeCN (1 L) was added formaldehyde (37 wt% in water, 73 mL, 971 mmol). To the reaction mixture was added triethylamine (TEA) (62 mL, 444 mmol) dropwise at 0 °C and the reaction was stirred at room temperature for 2 h. The reaction mixture was evaporated and the residue was purified by FCC on silica (0-25% EtOAc in heptane) to give the title compound (38.25 g, 165 mmol, 37%) as a white powder. MS (ESI): mass calcd. for C₁₀H₁₇NO₅ 231.2; *m/z* found, 254.1 [M+Na]⁺. *trans*-*tert*-Butyl 3-(hydroxymethyl)-3-nitro-cyclobutanecarboxylate was formed, but not isolated.


Step B: *tert*-Butyl (1*s*,3*s*)-3-amino-3-(hydroxymethyl)cyclobutane-1-carboxylate. To a solution of *tert*-butyl (1*s*,3*s*)-3-(hydroxymethyl)-3-nitro-cyclobutanecarboxylate (38.2 g, 165 mmol) in EtOAc (600 mL) was added 10% palladium on carbon (Pd/C) (1.9 g). The reaction mixture was stirred at 50 °C for 1 h under hydrogen (H₂) (10 bar). The reaction mixture was filtered through a pad of Celite[®]. To the filtrate was added 10% Pd/C (1.9 g). The reaction mixture was stirred at 50 °C for 2 h under H₂ (10 bar). The reaction mixture was filtered through a pad of Celite[®] and the Celite[®] was washed with EtOAc. The combined filtrates were evaporated and the residue was triturated with diethyl ether (Et₂O) to give the title compound (18.6 g, 92.4 mmol, 55%) as a white powder. MS (ESI): mass calcd. for C₁₀H₁₉NO₃ 201.1; *m/z* found, 202.2 [M+H]⁺. ¹H NMR

(300 MHz, DMSO- d_6) δ 5.26 – 3.98 (m, 1H), 3.74 – 2.94 (m, 4H), 2.70 – 2.57 (m, 1H), 2.20 – 2.07 (m, 2H), 1.97 – 1.82 (m, 2H), 1.39 (s, 9H).

Step C: *tert*-Butyl (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylate. To a solution of *tert*-butyl (1*s*,3*s*)-3-amino-3-(hydroxymethyl)cyclobutane-1-carboxylate (18.6 g, 92.4 mmol) in tetrahydrofuran (THF) (300 mL) was added TEA (26 mL, 186 mmol). To the mixture was added a solution of triphosgene (9.6 g, 32.4 mmol) in THF (200 mL) dropwise at -10 °C and stirred at room temperature for 1 h. The reaction mixture poured into saturated sodium bicarbonate (600 mL) and the mixture was extracted with EtOAc. The combined organic layers were dried over magnesium sulfate, filtered, and evaporated. The residue was triturated with Et₂O to give the title compound (17.7 g, 77.9 mmol, 84%) as a white powder. MS (ESI): mass calcd. for C₁₁H₁₇NO₄ 227.1; *m/z* found, 228.2 [M+H]⁺.

Step D: (2*s*,4*s*)-6-Oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid. To trifluoroacetic acid (TFA) (180 mL, 235 mmol) was added *tert*-butyl (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylate (17.7 g, 77.9 mmol) in portions at 0 °C. The reaction mixture was stirred at room temperature for 1 h. The reaction mixture was evaporated and the residue was triturated with Et₂O to afford the title compound (12.9 g, 75.4 mmol, 96%) as a white powder. MS (ESI): mass calcd. for C₇H₉NO₃ 171.0; *m/z* found, 172.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO- d_6) δ 12.26 (br s, 1H), 8.08 (s, 1H), 4.34 (s, 2H), 2.79 – 2.66 (m, 1H), 2.43 – 2.29 (m, 4H).

Intermediate 4: (2*r*,4*s*)-6-Oxo-5-azaspiro[3.4]octane-2-carboxylic acid




Step A: Ethyl (1*r*,3*s*)-3-(3-methoxy-3-oxopropyl)-3-nitrocyclobutane-1-carboxylate. To a solution of ethyl 3-nitrocyclobutanecarboxylate (Intermediate 2, 16.6 g, 95.6 mmol) in MeCN (145 mL) was added methyl acrylate (10.3 mL, 114 mmol). To the reaction mixture was added 1,8-diazabicyclo[5.4.0]undec-7-ene (7.1 mL, 47.6 mmol) dropwise at 0 °C and the reaction mixture was stirred at 0 °C for 1 h. The reaction mixture was diluted with saturated ammonium chloride and EtOAc and the layers were separated. The organic layer was dried over magnesium sulfate, filtered and evaporated. The residue was purified by FCC on silica (0-15% EtOAc in

heptane) to give the title compound (13.6 g, 52.7 mmol, 55%) as a colorless liquid. MS (ESI): mass calcd. for $C_{11}H_{17}NO_6$ 259.1; m/z found, 282.1 $[M+Na]^+$. 1H NMR (300 MHz, Chloroform- d) δ 4.17 (q, $J = 7.1$ Hz, 2H), 3.70 (s, 3H), 3.12 – 2.79 (m, 3H), 2.69 – 2.49 (m, 2H), 2.48 – 2.21 (m, 4H), 1.27 (t, $J = 7.1$ Hz, 3H).

- 5 Step B: (2*r*,4*s*)-6-Oxo-5-azaspiro[3.4]octane-2-carboxylic acid. To a solution of ethyl (1*r*,3*s*)-3-(3-methoxy-3-oxopropyl)-3-nitrocyclobutane-1-carboxylate (13.6 g, 52.5 mmol) in methanol (MeOH) (133 mL) was added nickel(II) chloride hexahydrate (12.5 g, 52.6 mmol). To the reaction mixture was added sodium borohydride ($NaBH_4$) (10 g, 264 mmol) in small portions at $-10^\circ C$ and the reaction mixture was stirred at $0^\circ C$ for 1 h. To the reaction mixture was added
- 10 aqueous potassium carbonate (47 mL, 141 mmol, 3 M) dropwise at $0^\circ C$ (pH 10) and the reaction mixture was stirred at $0^\circ C$ for 1 h. The reaction mixture was filtered through a pad of Celite[®] and the pad was washed with EtOH. The combined filtrates were evaporated. The residue was purified by FCC on silica eluting with chloroform:methanol:acetic acid (100:0:0 $\rightarrow$ 9:1:1) to give the title compound (4.8 g, 28.2 mmol, 53%) as an off-white powder. MS (ESI): mass calcd.
- 15 for $C_8H_{11}NO_3$ 169.1; m/z found, 170.1 $[M+H]^+$. 1H NMR (300 MHz, DMSO- d_6) δ 7.97 (br s, 1H), 4.01 – 2.94 (m, 1H), 2.82 – 2.65 (m, 1H), 2.36 – 2.01 (m, 8H).

Intermediate 5: Potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate.




- Step A: *tert*-Butyl 1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. In a flask under N_2 was placed anhydrous DCM (62 mL) followed by diethylzinc (68 mL, 1 M in hexanes, 68 mmol). The mixture was cooled to $-40^\circ C$ and a solution of diiodomethane (11 mL, 135 mmol) in DCM (26 mL) was slowly added by addition funnel over
- 25 30 min. The reaction was then allowed to stir at $-40^\circ C$ for 1 h. At $-40^\circ C$, a solution of TFA (5.2 mL, 68 mmol) in DCM (26 mL) was slowly added over 20 min by addition funnel. The reaction was warmed to $-15^\circ C$ and stirred for 1 h. A solution of *tert*-butyl 3-(4,4,5,5-

tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1*H*-pyrrole-1-carboxylate (2.5 g, 8.5 mmol) in DCM (26 mL) was slowly added by addition funnel to the reaction mixture. The reaction was allowed to warm overnight with stirring. Over the course of the reaction, the BOC group is cleaved and must be reinstalled. After stirring overnight, the crude reaction mixture is partially concentrated to one quarter volume. THF (38 mL) is added followed by di-*tert*-butyl dicarbonate (9.2 g, 42 mmol), TEA (11.8 mL, 85 mmol), and DMAP (0.25 g, 2.1 mmol). The reaction was stirred at room temperature for 3 h under N₂, after which it was diluted with EtOAc and washed with sat. NaHCO₃. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure to afford the crude product as red-brown oil. The crude product was purified by FCC on silica (0-10% EtOAc in heptane). The desired fractions were collected and concentrated under vacuum to yield a pale yellow solid (1.0 g, 38% yield). MS (ESI): mass calcd. for C₁₆H₂₈BNO₄ 309.2; m/z found, 254.0 [M+2H-tBu]⁺. ¹H NMR (300 MHz, CDCl₃) δ 3.67 – 3.27 (m, 4H), 1.66 – 1.55 (m, 1H), 1.41 (s, 9H), 1.22 (s, 12H), 0.95 (dd, *J* = 7.2, 4.1 Hz, 1H), 0.44 – 0.35 (m, 1H).


Step B: Potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate. *tert*-Butyl 1-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (1 g, 3.2 mmol) was dissolved in MeOH (20 mL), treated with KHF₂ (1.8 g, 22.6 mmol) and stirred at 65 °C for 16 h. The reaction mixture was cooled to room temperature and concentrated under reduced pressure. The resulting residue was triturated with 20% Et₂O in heptane (13 mL) for 10 min. The precipitate was collected by filtration and rinsed with Et₂O. The precipitate was dissolved in hot ACN (100 mL) and filtered to remove KHF₂. The filtrate was collected and concentrated under reduced pressure to afford the title compound as a white solid (830 mg, 88% yield). MS (ESI): mass calcd. for C₁₀H₁₆BF₃KNO₂ 289.1; m/z found, 172.1 [M-tBu-KF]⁺. ¹H NMR (300 MHz, DMSO-*d*₆) δ 3.30 (s, 1H), 3.19 – 3.05 (m, 3H), 1.35 (s, 9H), 0.94 (s, 1H), 0.39 – 0.29 (m, 1H), -0.41 (s, 1H).

Intermediate 6: Potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate.




- The title compound was prepared in a manner analogous to Intermediate 5 using *tert*-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate instead of *tert*-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1*H*-pyrrole-1-carboxylate in Step A. MS (ESI): mass calcd. for C₁₁H₁₈BF₃KNO₂ 303.1; m/z found, 186.0 [M-tBu-KF]⁺. ¹H NMR (300 MHz, DMSO-*d*₆) δ 3.51 – 3.36 (m, 2H), 3.11 – 3.02 (m, 1H), 2.89 (s, 1H), 1.81 – 1.69 (m, 1H), 1.36 (s, 9H), 1.31 – 1.21 (m, 1H), 0.63 – 0.53 (m, 1H), 0.26 – 0.16 (m, 1H), -0.29 (s, 1H).

10 Intermediate 7: Potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-1-yl)trifluoroborate.



- The title compound was prepared in a manner analogous to Intermediate 5 using *tert*-butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,6-dihydropyridine-1(2*H*)-carboxylate instead of *tert*-butyl 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2,5-dihydro-1*H*-pyrrole-1-carboxylate in Step A. MS (ESI): mass calcd. for C₁₁H₁₈BF₃KNO₂ 303.1; m/z found, 186.0 [M-tBu-KF]⁺. ¹H NMR (300 MHz, DMSO-*d*₆) δ 3.66 – 3.38 (m, 2H), 3.19 (s, 1H), 2.72 (s, 1H), 1.76 – 1.51 (m, 2H), 1.39 – 1.36 (m, 9H), 0.60 (s, 1H), 0.23 – 0.14 (m, 1H), -0.35 (s, 1H).


20 Intermediate 8: 4-Bromo-1-methyl-2-(trifluoromethoxy)benzene.



4-Bromo-2-(trifluoromethoxy)iodobenzene (321 μL, 1.9 mmol) added to a solution of tetrakis(triphenylphosphine)palladium (220 mg, 0.19 mmol) in anhydrous THF (90 mL) under N₂. Dimethylzinc solution (1M in hexane, 2.86 mL) was added dropwise. The mixture was


stirred at 50 °C for 3 h. The reaction mixture was partially concentrated under vacuum (product is volatile) and filtered through silica gel eluting with pentane. The result was partially concentrated to yield the title compound (486 mg, crude). This was used without further purification in subsequent steps. MS (ESI): mass calcd. for C₈H₆BrF₃O 254.0; m/z found, 253.9 [M]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.39 – 7.30 (m, 2H), 7.13 (d, *J* = 8.1 Hz, 1H), 2.27 (s, 3H).

Intermediate 9: 1-Benzyl-3-methyl-2,5-dihydro-1H-pyrrole.



To a solution of *tert*-butyl 3-methyl-2,5-dihydro-1H-pyrrole-1-carboxylate (250 mg, 1.36 mmol) in DCM (4 mL) was added TFA (1 mL), and the reaction stirred at room temperature for 40 min. The mixture was concentrated *in vacuo*, the residue re-dissolved in DCM (2.6 mL), and benzaldehyde (0.14 mL, 1.36 mmol) added. After stirring at room temperature for 1 h, sodium triacetoxyborohydride (578 mg, 2.73 mmol) was added portion-wise and the reaction allowed to stir overnight. The mixture was carefully quenched with sat. aq. NaHCO₃ and the aqueous phase extracted with DCM. The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and the filtrate concentrated under reduced pressure. The crude residue was purified by FCC on silica (0–10% of a 2M NH₃/MeOH solution in DCM) to afford the title compound as a brown oil (104 mg, 44%). MS (ESI): mass calcd. for C₁₂H₁₅N, 173.1; m/z found, 174.1 [M+H]⁺. ¹H NMR (600 MHz, Chloroform-d) δ 7.37 – 7.34 (m, 2H), 7.33 – 7.30 (m, 2H), 7.25 (d, *J* = 10.2 Hz, 1H), 5.39 – 5.36 (m, *J* = 1.8 Hz, 1H), 3.80 (s, 2H), 3.48 – 3.44 (m, 2H), 3.37 – 3.34 (m, 2H), 1.73 – 1.69 (m, 3H).

Intermediate 10: 3-Isobutylbenzaldehyde.




n-BuLi (2.2 mL, 2.5 M in hexane, 5.5 mmol) was added dropwise to a -70 °C solution of 1-bromo-3-isobutylbenzene (1.0 g, 4.7 mmol) in anhydrous THF (15 mL). The resultant mixture was stirred at -70 °C for 1 hour before being treated with DMF (0.36 mL, 4.7 mmol). The mixture was stirred at -70 °C for 2 hours before being quenched with water and extracted with

ethyl acetate. The combined organic extracts were dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give the title compound (800 mg, crude), as a colorless oil. ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 9.99 (s, 1H), 7.77 - 7.67 (m, 2H), 7.54 - 7.49 (m, 2H), 2.55 (d, $J = 7.3$ Hz, 2H), 1.92 - 1.80 (m, 1H), 0.86 (d, $J = 6.5$ Hz, 6H).

5


Intermediate 11: 3-Ethyl-4-fluorobenzaldehyde.



The title compound was prepared in a manner analogous to Intermediate 10 using 4-bromo-2-ethyl-1-fluorobenzene instead of 1-bromo-3-isobutylbenzene. ^1H NMR (400 MHz, CDCl_3) δ 9.84 - 9.79 (m, 1H), 7.68 - 7.64 (m, 1H), 7.63 - 7.58 (m, 1H), 7.07 - 7.00 (m, 1H), 2.62 (q, $J = 7.5$ Hz, 2H), 1.15 (t, $J = 7.6$ Hz, 3H).

10


Intermediate 12: 4-Cyclopropyl-2-methylbenzaldehyde.



4-Bromo-2-methylbenzaldehyde (1.5 g, 7.54 mmol) was taken up in 1,4-dioxane (15 mL) and water (6 mL) under a nitrogen atmosphere. To this was added cyclopropylboronic acid (1.6 g, 18.8 mmol), Cs_2CO_3 (5.4 g, 16.6 mmol), and $\text{Pd}(\text{dppf})\text{Cl}_2$ (0.92 g, 1.13 mmol). The mixture was stirred at 90 °C for 16 h before cooling to rt. The mixture was filtered through Celite[®] then diluted with diethylether and washed with water and brine. The organic phase was dried over MgSO_4 , filtered, and concentrated under reduced pressure. The crude product was purified by FCC (0-40% DCM in pentane) to provide the title compound as a colorless oil (1.2 g, 96% yield). ^1H NMR (300 MHz, CDCl_3) δ 10.18 (s, 1H), 7.68 (d, $J = 8.0$ Hz, 1H), 7.00 (d, $J = 7.9$ Hz, 1H), 6.92 (s, 1H), 2.63 (s, 3H), 2.00 - 1.82 (m, 1H), 1.05 (dd, $J = 7.2, 5.4$ Hz, 2H), 0.89 - 0.67 (m, 2H).

20
25

Intermediate 13: 3-tert-Butyl-5-iodobenzaldehyde.




Step A: 1-*tert*-Butyl-3-iodo-5-methylbenzene. *tert*-Butyl chloride (178 g, 1.93 mol) and 1-iodo-3-methyl-benzene (280 g, 1.28 mol) were placed under N₂ and cooled to 0 °C. To this was added aluminum chloride (514 g, 3.85 mol) and the resulting solution was allowed to warm to rt and stirred for 1 h. The reaction was diluted with DCM and purified by FCC (0-2% EtOAc in ether) to provide the title compound as a colorless oil (202 g, 57% yield).

Step B: 1-(Bromomethyl)-3-*tert*-butyl-5-iodobenzene. 1-*tert*-Butyl-3-iodo-5-methylbenzene (202 g, 737 mmol), CCl₄ (3.0 L), and (PhCO₂)₂ (8.9 g, 36.8 mmol) were combined under N₂ and heated to reflux. To this was added NBS (262 g, 1.47 mol) and the resulting solution was heated at reflux overnight. The reaction mixture was cooled to room temperature, diluted with H₂O, and extracted with DCM. The combined organic layers were washed with sat. aq. NaHCO₃, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by FCC (0-2% EtOAc in ether) to provide the title compound as a yellow oil (220 g, 85% yield).


Step C: 3-*tert*-Butyl-5-iodobenzaldehyde. 1-(Bromomethyl)-3-*tert*-butyl-5-iodobenzene (220 g, 625 mmol) was taken up in DMSO (2.2 L) under N₂ and stirred for 4 h at 100 °C. The reaction mixture was cooled to room temperature, quenched with water, and extracted with ethyl acetate. The combined organic layers were washed with brine, dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The crude residue was purified by FCC (0-2% EtOAc in ether) to provide the title compound as a white solid (100 g, 56% yield). MS (ESI): mass calcd. for C₁₁H₁₃IO, 288.0; m/z found, 288.1 [M]⁺.

Example 1: (*rac*)-(2*s*,4*s*)-2-(1-(*p*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




1-(*p*-Tolyl)-3-azabicyclo[3.1.0]hexane (20 mg, 0.115 mmol) and (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 20 mg, 0.115 mmol) were taken up in DMF (0.6 mL). DIPEA (60 μ L, 0.346 mmol) and HATU (50 mg, 0.127 mmol) were added and the reaction was stirred at rt for 16 h. The reaction mixture was filtered through a PTFE filter with MeOH and purified via reverse phase HPLC (5-95% ACN in 20 mM NH₄OH in water) to afford the title compound (30 mg, 80% yield). MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; *m/z* found, 327.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.10 (qd, *J* = 8.2, 3.5 Hz, 4H), 6.54 (d, *J* = 22.4 Hz, 1H), 4.36 (d, *J* = 4.2 Hz, 2H), 4.23 – 3.93 (m, 1H), 3.86 – 3.54 (m, 3H), 2.92 – 2.81 (m, 1H), 2.71 – 2.62 (m, 2H), 2.52 – 2.36 (m, 2H), 2.32 (d, *J* = 4.9 Hz, 3H), 1.95 – 1.79 (m, 1H), 1.18 – 1.07 (m, 1H), 0.73 (dt, *J* = 9.6, 4.7 Hz, 1H).

Example 2: (2*s*,4**R*)-2-((1**S*,5**R*)-1-(*p*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 1 (Stationary phase: Lux Cellulose 4, 5 μ m 250 x 21 mm, Mobile phase: 50% MeOH, 50% CO₂). MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; *m/z* found, 327.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-*d*) δ 7.15 – 7.10 (m, 2H), 7.12 – 7.05 (m, 2H), 6.27 (d, *J* = 20.1 Hz, 1H), 4.35 (d, *J* = 5.3 Hz, 2H), 4.23 – 3.93 (m, 1H), 3.85 – 3.55 (m, 3H), 2.93 – 2.83 (m, 1H), 2.69 – 2.59 (m, 2H), 2.54 – 2.41 (m, 2H), 2.33 (d, *J* = 4.9 Hz, 3H), 1.92 – 1.83 (m, 1H), 1.16 – 1.09 (m, 1H), 0.73 (dt, *J* = 11.9, 4.7 Hz, 1H).

Example 3: (2*s*,4*s*)-2-((1**R*,5**S*)-1-(*p*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- 5 The title compound was prepared by chiral supercritical fluid chromatography of Example 1 (Stationary phase: Lux Cellulose 4, 5 μ m 250 x 21 mm, Mobile phase: 50% MeOH, 50% CO₂). MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; m/z found, 327.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.13 (dd, *J* = 8.0, 4.2 Hz, 2H), 7.12 – 7.05 (m, 2H), 6.12 (d, *J* = 15.9 Hz, 1H), 4.35 (d, *J* = 5.4 Hz, 2H), 4.23 – 3.93 (m, 1H), 3.84 – 3.56 (m, 3H), 2.93 – 2.83 (m, 1H), 2.67 – 2.58 (m, 2H), 2.54 – 2.41 (m, 2H), 2.33 (d, *J* = 4.2 Hz, 3H), 1.92 – 1.83 (m, 1H), 1.13 (q, *J* = 5.8 Hz, 1H), 0.74 (dt, *J* = 11.6, 4.7 Hz, 1H).
- 10

Example 4: (rac)-(2*s*,4*s*)-2-(1-Phenyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 15 The title compound was prepared in a manner analogous to Example 1 using 1-phenyl-3-azabicyclo[3.1.0]hexane hydrochloride instead of 1-(*p*-tolyl)-3-azabicyclo[3.1.0]hexane. MS (ESI): mass calcd. for C₁₈H₂₀N₂O₃, 312.1; m/z found, 313.0 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.40 – 7.08 (m, 5H), 4.48 (m, 2H), 4.17 – 3.96 (m, 1H), 3.93 – 3.78 (m, 2H), 3.61 – 3.53 (m, 1H), 3.02 (m, 1H), 2.61 – 2.40 (m, 4H), 2.04 – 1.93 (m, 1H), 1.17 – 1.10 (m, 1H), 0.75 (m, 1H).
- 20

Example 5: (rac)-(2*s*,4*s*)-2-(1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



Step A: *tert*-Butyl 1-(4-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. In a vial
 5 was combined potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5, 210 mg, 0.73 mmol), CataCXium® A Pd G3 (30 mg, 0.036 mmol), 1-bromo-4-(*tert*-butyl)benzene (250 μ L, 1.4 mmol), Cs₂CO₃ (709.9 mg, 2.2 mmol), toluene (14 mL) and water (1.4 mL). The resulting mixture was degassed by bubbling N₂ through the solution for 10 min. The reaction was then heated to 90 °C for 18 h. Water was added and the mixture was
 10 extracted with EtOAc. The organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by FCC on silica (0-10% EtOAc in heptane). The desired fractions were collected and concentrated under vacuum to yield a yellow oil (190 mg, 83% yield). MS (ESI): mass calcd. for C₂₀H₂₉NO₂, 315.2; m/z found, 260.0 [M+2H-tBu]⁺. ¹H NMR (300 MHz, CDCl₃) δ 7.33 (d, *J* = 8.2 Hz, 2H), 7.11 (t, *J* = 7.7 Hz, 2H),
 15 4.04 – 3.80 (m, 1H), 3.77 – 3.44 (m, 3H), 1.82 – 1.74 (m, 1H), 1.46 (s, 9H), 1.31 (s, 9H), 1.12 – 1.04 (m, 1H), 0.86 – 0.79 (m, 1H).


Step B: 1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane. TFA (0.55 mL, 7.2 mmol) was added to a solution of *tert*-butyl 1-(4-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (190 mg, 0.6 mmol) in DCM (5 mL) at 0 °C. The reaction mixture was stirred at rt
 20 for 1 h. The reaction mixture was concentrated under vacuum. DCM was added and washed with saturated solution of Na₂CO₃. The organic layers were combined, dried over MgSO₄, filtered, and concentrated under vacuum to yield a yellow oil. The product was used as such in the next step without further purification (129 mg, 0.6 mmol, yield 99%, crude). MS (ESI): mass calcd. for C₁₅H₂₁N, 215.2; m/z found, 216.1 [M+H]⁺.

25 Step C: (rac)-(2*s*,4*s*)-2-(1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. HBTU (297 mg, 0.8 mmol) and DIPEA (0.262 mL, 1.5 mmol) were

added to a solution of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 123 mg, 0.722 mmol) in anhydrous DMF (4 mL). The mixture was stirred for 10 min at room temperature, then a solution of 1-(4-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane (129 mg, 0.6 mmol) in DMF (1 mL) was added, and the reaction mixture was stirred at room temperature for
 5 additional 16 h. Saturated NaHCO₃ was added and the mixture was extracted with EtOAc. The organic layers were dried over MgSO₄, filtered and concentrated under reduced pressure. The crude product was purified by FCC on silica (0-30% (DCM/MeOH 20:1) in DCM). The desired fractions were collected and concentrated under vacuum. The resulting solid was triturated with pentane, diisopropyl ether (DIPE), and filtered to yield a beige solid (121.2 mg, 52% yield). MS
 10 (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.34 (dd, *J* = 8.5, 2.0 Hz, 2H), 7.12 (dd, *J* = 8.3, 5.0 Hz, 2H), 6.16 (d, *J* = 6.6 Hz, 1H), 4.36 (d, *J* = 4.5 Hz, 2H), 4.23 – 3.93 (m, 1H), 3.85 – 3.56 (m, 3H), 2.94 – 2.83 (m, 1H), 2.68 – 2.58 (m, 2H), 2.56 – 2.42 (m, 2H), 1.96 – 1.83 (m, 1H), 1.31 (d, *J* = 1.5 Hz, 9H), 1.19 – 1.13 (m, 1H), 0.78 – 0.69 (m, 1H).


15

Example 6: (rac)-(2*s*,4*s*)-2-(1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-isopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.21 (m, 1H), 7.11 (t, *J* = 7.9 Hz, 1H), 7.06 – 6.95 (m, 2H), 6.18 (d, *J* = 26.5 Hz, 1H), 4.36 (d, *J* = 3.3 Hz, 2H), 4.25 – 3.94 (m, 1H), 3.87 – 3.57 (m, 3H), 2.95 – 2.81 (m, 2H), 2.70 – 2.59 (m, 2H), 2.57 – 2.40 (m, 2H), 1.98 – 1.87 (m, 1H), 1.25 (dd, *J* = 6.9, 2.7 Hz, 6H), 1.20 – 1.14 (m, 1H), 0.81 –
 20 0.72 (m, 1H).
 25

Example 7: (2*S*,4*S*)-2-((1*R*,5*S*)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 6
 5 (Stationary phase: Whelk O1 SS, 5µm 250 x 21 mm, Mobile phase: 20% MeOH with 0.2% TEA, 80% CO₂). MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.23 (dd, *J* = 7.6, 6.5 Hz, 1H), 7.14 – 7.06 (m, 1H), 7.05 – 6.95 (m, 2H), 6.54 (d, *J* = 45.5 Hz, 1H), 4.36 (d, *J* = 4.1 Hz, 2H), 4.25 – 3.94 (m, 1H), 3.86 – 3.56 (m, 3H), 2.95 – 2.82 (m, 2H), 2.71 – 2.61 (m, 2H), 2.52 – 2.40 (m, 2H), 1.98 – 1.86 (m,
 10 1H), 1.24 (dd, *J* = 6.9, 4.2 Hz, 6H), 1.16 (dt, *J* = 8.5, 4.4 Hz, 1H), 0.76 (dt, *J* = 16.0, 4.8 Hz, 1H).


Example 8: (2*S*,4*R*)-2-((1*S*,5*R*)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



15 The title compound was prepared by chiral supercritical fluid chromatography of Example 6 (Stationary phase: Whelk O1 SS, 5µm 250 x 21 mm, Mobile phase: 20% MeOH with 0.2% TEA, 80% CO₂). MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.23 (dd, *J* = 7.6, 6.4 Hz, 1H), 7.13 – 7.07 (m, 1H), 7.05 – 6.95 (m, 2H), 6.51 (d, *J* = 45.8 Hz, 1H), 4.36 (d, *J* = 4.1 Hz, 2H), 4.25 – 3.94 (m, 1H), 3.87 –
 20 6.95 (m, 2H), 6.51 (d, *J* = 45.8 Hz, 1H), 4.36 (d, *J* = 4.1 Hz, 2H), 4.25 – 3.94 (m, 1H), 3.87 –


3.57 (m, 3H), 2.93 – 2.82 (m, 2H), 2.71 – 2.61 (m, 2H), 2.52 – 2.41 (m, 2H), 1.97 – 1.84 (m, 1H), 1.24 (dd, $J = 6.8, 4.1$ Hz, 6H), 1.18 – 1.13 (m, 1H), 0.76 (dt, $J = 15.9, 4.8$ Hz, 1H).

Example 9: (rac)-(2*s*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-isopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{21}H_{26}N_2O_3$, 354.2; m/z found, 355.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.21 – 7.16 (m, 2H), 7.14 – 7.09 (m, 2H), 6.13 (d, $J = 11.4$ Hz, 1H), 4.35 (d, $J = 4.4$ Hz, 2H), 4.24 – 3.92 (m, 1H), 3.86 – 3.55 (m, 3H), 2.94 – 2.83 (m, 2H), 2.68 – 2.60 (m, 2H), 2.54 – 2.41 (m, 2H), 1.96 – 1.83 (m, 1H), 1.24 (dd, $J = 6.9, 1.5$ Hz, 6H), 1.19 – 1.12 (m, 1H), 0.77 – 0.69 (m, 1H).


Example 10: (2*s*,4**S*)-2-((1**R*,5**S*)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 9 (Stationary phase: Whelk O1 SS, 5 μ m 250 x 21 mm, Mobile phase: 15% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 85% CO_2). MS (ESI): mass calcd. for $C_{21}H_{26}N_2O_3$, 354.2; m/z found, 355.3 $[M+H]^+$. 1H NMR (400 MHz, Chloroform- d) δ 7.21 – 7.15 (m, 2H), 7.15 – 7.08 (m, 2H), 6.36 (d, $J = 13.1$ Hz, 1H), 4.36 (d, $J = 4.6$ Hz, 2H), 4.24 – 3.92 (m, 1H), 3.85 – 3.56 (m,


3H), 2.95 - 2.82 (m, 2H), 2.69 - 2.59 (m, 2H), 2.53 - 2.40 (m, 2H), 1.94 - 1.84 (m, 1H), 1.23 (dd, $J = 6.9, 2.0$ Hz, 6H), 1.15 (dq, $J = 8.7, 4.3$ Hz, 1H), 0.74 (dt, $J = 10.8, 4.8$ Hz, 1H).

Example 11: (2*s*,4*R*)-2-((1*S*,5*R*)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 9 (Stationary phase: Whelk O1 SS, 5 μ m 250 x 21 mm, Mobile phase: 15% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 85% CO₂). MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.18 (dd, $J = 8.3, 3.1$ Hz, 2H), 7.15 - 7.08 (m, 2H), 6.54 (d, $J = 15.8$ Hz, 1H), 4.36 (d, $J = 4.6$ Hz, 2H), 4.24 - 3.92 (m, 1H), 3.85 - 3.55 (m, 3H), 2.95 - 2.82 (m, 2H), 2.71 - 2.60 (m, 2H), 2.53 - 2.40 (m, 2H), 1.94 - 1.84 (m, 1H), 1.23 (dd, $J = 6.9, 2.5$ Hz, 6H), 1.15 (dt, $J = 9.2, 5.1$ Hz, 1H), 0.74 (dt, $J = 11.0, 4.7$ Hz, 1H).

Example 12: (rac)-(2*r*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-isopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for

$C_{22}H_{28}N_2O_2$, 352.2; m/z found, 353.1 $[M+H]^+$. 1H NMR (400 MHz, $DMSO-d_6$) δ 7.95 (s, 1H), 7.24 – 7.08 (m, 4H), 4.05 – 3.56 (m, 3H), 3.47 – 3.37 (m, 1H), 3.01 – 2.79 (m, 2H), 2.34 – 2.06 (m, 8H), 2.01 – 1.86 (m, 1H), 1.17 (dd, $J = 6.9, 1.1$ Hz, 6H), 1.06 – 0.99 (m, 1H), 0.66 (t, $J = 4.1$ Hz, 1H).

5


Example 13: (rac)-(2*r*,4*s*)-2-(1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for $C_{23}H_{30}N_2O_2$, 366.2; m/z found, 367.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.34 (dd, $J = 8.3, 2.6$ Hz, 2H), 7.16 – 7.09 (m, 2H), 6.11 (s, 1H), 4.25 – 3.89 (m, 1H), 3.88 – 3.46 (m, 3H), 2.98 – 2.84 (m, 1H), 2.60 – 2.47 (m, 2H), 2.44 – 2.32 (m, 4H), 2.30 – 2.18 (m, 2H), 1.95 – 1.82 (m, 1H), 1.31 (s, 9H), 1.18 – 1.09 (m, 1H), 0.77 – 0.69 (m, 1H).

15


Example 14: (2*r*,4**S*)-2-((1**R*,5**S*)-1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 13 (Stationary phase: Whelk O1 SS, 5 μ m 250 x 21 mm, Mobile phase: 15% MeOH:isopropanol


(1:1) with 0.2% isopropylamine, 85% CO₂). MS (ESI): mass calcd. for C₂₃H₃₀N₂O₂, 366.2; m/z found, 367.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.34 (dd, *J* = 8.2, 3.5 Hz, 2H), 7.12 (t, *J* = 8.8 Hz, 2H), 6.17 (s, 1H), 4.25 – 3.89 (m, 1H), 3.88 – 3.46 (m, 3H), 2.90 (t, *J* = 7.7 Hz, 1H), 2.60 – 2.45 (m, 2H), 2.37 (d, *J* = 10.3 Hz, 4H), 2.21 (q, *J* = 7.1 Hz, 2H), 1.94 – 1.81 (m, 1H), 1.31 (d, *J* = 1.9 Hz, 9H), 1.14 (dt, *J* = 9.1, 5.0 Hz, 1H), 0.74 (dt, *J* = 9.8, 4.6 Hz, 1H).

Example 15: (2*r*,4**R*)-2-((1**S*,5**R*)-1-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 13 (Stationary phase: Whelk O1 SS, 5μm 250 x 21 mm, Mobile phase: 15% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 85% CO₂). MS (ESI): mass calcd. for C₂₃H₃₀N₂O₂, 366.2; m/z found, 367.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.34 (dd, *J* = 8.3, 3.6 Hz, 2H), 7.12 (t, *J* = 8.7 Hz, 2H), 6.28 – 6.17 (m, 1H), 4.25 – 3.89 (m, 1H), 3.88 – 3.50 (m, 3H), 2.89 (tt, *J* = 8.9, 4.4 Hz, 1H), 2.52 (td, *J* = 11.1, 10.6, 6.3 Hz, 2H), 2.37 (d, *J* = 10.3 Hz, 4H), 2.27 – 2.14 (m, 2H), 1.94 – 1.81 (m, 1H), 1.31 (d, *J* = 2.1 Hz, 9H), 1.14 (p, *J* = 4.9 Hz, 1H), 0.74 (dt, *J* = 10.0, 4.8 Hz, 1H).

Example 16: (rac)-(2*s*,4*s*)-2-(1-(3-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-cyclopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₁H₂₄N₂O₃, 352.2; m/z found, 353.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.23 – 7.17 (m, 1H), 6.99 – 6.94 (m, 1H), 6.94 – 6.89 (m, 2H), 5.96 (d, *J* = 10.5 Hz, 1H), 4.36 (d, *J* = 3.3 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.84 – 3.55 (m, 3H), 2.94 – 2.83 (m, 1H), 2.71 – 2.56 (m, 2H), 2.55 – 2.42 (m, 2H), 1.96 – 1.84 (m, 2H), 1.18 – 1.15 (m, 1H), 1.00 – 0.92 (m, 2H), 0.78 – 0.72 (m, 1H), 0.71 – 0.65 (m, 2H).

Example 17: (*rac*)-(2*s*,4*s*)-2-(1-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-(*tert*-butyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.31 – 7.27 (m, 1H), 7.26 – 7.23 (m, 1H), 7.21 – 7.18 (m, 1H), 7.04 – 6.95 (m, 1H), 5.93 (d, *J* = 15.7 Hz, 1H), 4.36 (d, *J* = 4.3 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.88 – 3.58 (m, 3H), 2.96 – 2.83 (m, 1H), 2.69 – 2.57 (m, 2H), 2.57 – 2.42 (m, 2H), 2.00 – 1.86 (m, 1H), 1.32 (d, *J* = 2.3 Hz, 9H), 1.20 – 1.14 (m, 1H), 0.80 – 0.72 (m, 1H).

Example 18: (*rac*)-(2*s*,4*s*)-2-(1-(4-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-cyclopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{21}H_{24}N_2O_3$, 352.2; m/z found, 353.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.11 – 7.05 (m, 2H), 7.05 – 7.01 (m, 2H), 5.89 (br s, 1H), 4.35 (d, $J = 4.5$ Hz, 2H), 4.25 – 3.89 (m, 1H), 3.84 – 3.55 (m, 3H), 2.95 – 2.82 (m, 1H), 2.67 – 2.56 (m, 2H), 2.55 – 2.42 (m, 2H), 1.93 – 1.81 (m, 2H), 1.16 – 1.13 (m, 1H), 1.01 – 0.91 (m, 2H), 0.77 – 0.70 (m, 1H), 0.70 – 0.62 (m, 2H).

Example 19: (rac)-(2*s*,4*s*)-2-(1-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_2O_4$, 396.1; m/z found, 397.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.35 (td, $J = 8.0, 3.2$ Hz, 1H), 7.15 – 7.07 (m, 2H), 7.00 (d, $J = 13.0$ Hz, 1H), 5.95 (d, $J = 7.4$ Hz, 1H), 4.36 (d, $J = 1.6$ Hz, 2H), 4.25 – 3.92 (m, 1H), 3.89 – 3.56 (m, 3H), 2.96 – 2.82 (m, 1H), 2.69 – 2.57 (m, 2H), 2.57 – 2.43 (m, 2H), 2.01 – 1.90 (m, 1H), 1.19 (t, $J = 7.1$ Hz, 1H), 0.88 – 0.80 (m, 1H).

Example 20: (rac)-(2*s*,4*s*)-2-(1-(*o*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-2-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{22}N_2O_3$, 326.2; m/z found, 327.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.24 (s, 1H), 7.21 – 7.12 (m, 3H), 5.89 (d, $J = 11.2$ Hz, 1H), 4.34 (d, $J = 17.2$ Hz, 2H), 4.15 – 3.94 (m, 1H), 3.87 – 3.63 (m, 2H), 3.50 – 3.31 (m, 1H), 2.96 – 2.77 (m, 1H), 2.71 – 2.42 (m, 4H), 2.39 (d, $J = 2.4$ Hz, 3H), 1.87 – 1.79 (m, 1H), 1.20 – 1.06 (m, 1H), 0.75 (q, $J = 4.8$ Hz, 1H).

Example 21: (rac)-(2s,4s)-2-(1-(*m*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{22}N_2O_3$, 326.2; m/z found, 327.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.21 (td, $J = 7.5$, 3.0 Hz, 1H), 7.05 (t, $J = 7.0$ Hz, 1H), 7.01 – 6.95 (m, 2H), 5.95 (d, $J = 7.6$ Hz, 1H), 4.36 (d, $J = 3.0$ Hz, 2H), 4.25 – 3.89 (m, 1H), 3.86 – 3.55 (m, 3H), 2.95 – 2.84 (m, 1H), 2.68 – 2.57 (m, 2H), 2.57 – 2.43 (m, 2H), 2.34 (d, $J = 2.4$ Hz, 3H), 1.99 – 1.86 (m, 1H), 1.19 – 1.11 (m, 1H), 0.80 – 0.70 (m, 1H).

Example 22: (rac)-(2s,4s)-2-(1-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_2O_4$, 396.1; m/z found, 397.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.24 – 7.14 (m, 4H), 6.09 (d, $J = 8.1$ Hz, 1H), 4.36 (d, $J = 4.9$ Hz, 2H), 4.25 – 3.89 (m, 1H), 3.85 – 3.55 (m, 3H), 2.95 – 2.82 (m, 1H), 2.70 – 2.58 (m, 2H), 2.57 – 2.43 (m, 2H), 2.00 – 1.84 (m, 1H), 1.19 – 1.15 (m, 1H), 0.84 – 0.78 (m, 1H).

Example 23: (rac)-(2s,4s)-2-(1-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_2O_3$, 380.1; m/z found, 381.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.56 – 7.30 (m, 4H), 6.16 (d, $J = 5.4$ Hz, 1H), 4.36 (d, $J = 1.9$ Hz, 2H), 4.25 – 3.93 (m, 1H), 3.90 – 3.57 (m, 3H), 2.97 – 2.84 (m, 1H), 2.72 – 2.60 (m, 2H), 2.57 – 2.43 (m, 2H), 2.04 – 1.93 (m, 1H), 1.24 – 1.18 (m, 1H), 0.89 – 0.82 (m, 1H).

Example 24: (rac)-(2s,4s)-2-(1-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{19}H_{19}F_3N_2O_3$, 380.1; m/z found, 381.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.57 (dd, $J = 8.2, 3.3$ Hz, 2H), 7.32 – 7.26 (m, 2H), 6.21 (d, $J = 15.1$ Hz, 1H), 4.36 (d, $J = 2.7$ Hz, 2H), 4.28 – 3.95 (m, 1H), 3.91 – 3.57 (m, 3H), 2.98 – 2.83 (m, 1H), 2.74 – 2.57 (m, 2H), 2.55 – 2.41 (m, 2H), 2.08 – 1.94 (m, 1H), 1.25 – 1.15 (m, 1H), 0.92 – 0.82 (m, 1H).

Example 25: (rac)-(2*s*,4*s*)-2-(1-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using 5-bromo-2-methylbenzotrifluoride instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{20}H_{21}F_3N_2O_3$, 394.1; m/z found, 395.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.40 (d, $J = 16.8$ Hz, 1H), 7.26 – 7.21 (m, 2H), 5.98 (d, $J = 8.8$ Hz, 1H), 4.36 (d, $J = 2.7$ Hz, 2H), 4.25 – 3.92 (m, 1H), 3.89 – 3.54 (m, 3H), 2.93 – 2.84 (m, 1H), 2.68 – 2.58 (m, 2H), 2.56 – 2.41 (m, 5H), 1.99 – 1.87 (m, 1H), 1.16 (dd, $J = 8.1, 5.3$ Hz, 1H), 0.83 – 0.76 (m, 1H).

Example 26: (rac)-(2*s*,4*s*)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI):

mass calcd. for $C_{22}H_{26}N_2O_3$, 366.2; m/z found, 367.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ

- 5 7.21 (dd, $J = 8.4, 2.1$ Hz, 2H), 7.13 – 7.06 (m, 2H), 6.02 (d, $J = 7.9$ Hz, 1H), 4.35 (d, $J = 4.5$ Hz, 2H), 4.25 – 3.89 (m, 1H), 3.85 – 3.54 (m, 3H), 2.94 – 2.81 (m, 1H), 2.69 – 2.57 (m, 2H), 2.55 – 2.41 (m, 2H), 1.93 – 1.82 (m, 1H), 1.39 (s, 3H), 1.18 – 1.13 (m, 1H), 0.83 (t, $J = 5.1$ Hz, 2H), 0.78 – 0.70 (m, 3H).


- 10 Example 27: (*rac*)-(2*r*,4*s*)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using


- 15 (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for $C_{23}H_{28}N_2O_2$, 364.2; m/z found, 365.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.23 – 7.17 (m, 2H), 7.13 – 7.07 (m, 2H), 6.13 (s, 1H), 4.25 – 3.89 (m, 1H), 3.85 – 3.52 (m, 3H), 2.95 – 2.83 (m, 1H), 2.58 – 2.45 (m, 2H), 2.45 – 2.31 (m, 4H), 2.26 – 2.15 (m, 2H), 1.92 – 1.81 (m, 1H), 1.39 (d, 20 $J = 1.6$ Hz, 3H), 1.18 – 1.07 (m, 1H), 0.83 (t, $J = 5.1$ Hz, 2H), 0.78 – 0.67 (m, 3H).

Example 28: (rac)-(2*s*,4*s*)-2-(1-(4-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 4-bromodiphenyl ether instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₄H₂₄N₂O₄, 404.2; m/z found, 405.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.36 – 7.30 (m, 2H), 7.19 – 7.07 (m, 3H), 7.02 – 6.93 (m, 4H), 5.99 (s, 1H), 4.35 (d, *J* = 5.1 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.86 – 3.56 (m, 3H), 2.92 – 2.83 (m, 1H), 2.69 – 2.58 (m, 2H), 2.56 – 2.41 (m, 2H), 1.93 – 1.83 (m, 1H), 1.19 – 1.14 (m, 1H), 0.79 – 0.71 (m, 1H).

Example 29: (rac)-(2*s*,4*s*)-2-(1-(3-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 3-bromodiphenyl ether instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₄H₂₄N₂O₄, 404.2; m/z found, 405.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.38 – 7.31 (m, 2H), 7.30 – 7.24 (m, 1H), 7.15 – 7.08 (m, 1H), 6.99 (d, *J* = 8.5 Hz, 2H), 6.91 (dd, *J* = 11.4, 7.9 Hz, 1H), 6.87 – 6.81 (m, 2H), 5.96 (d, *J* = 17.2 Hz, 1H), 4.35 (d, *J* = 1.0 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.88 – 3.54 (m, 3H), 2.94 – 2.80 (m, 1H), 2.69 – 2.57 (m, 2H), 2.55 – 2.41 (m, 2H), 1.98 – 1.82 (m, 1H), 1.19 – 1.14 (m, 1H), 0.78 (dd, *J* = 10.8, 5.1 Hz, 1H).

Example 30: (rac)-(2*s*,4*s*)-2-(1-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one




The title compound was prepared in a manner analogous to Example 5 using 4-bromo-2-chlorotoluene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₁₉H₂₁ClN₂O₃, 360.1; m/z found, 361.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.12 (m, 2H), 7.04 – 6.92 (m, 1H), 5.85 (s, 1H), 4.35 (d, *J* = 1.5 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.82 – 3.54 (m, 3H), 2.95 – 2.80 (m, 1H), 2.68 – 2.56 (m, 2H), 2.55 – 2.44 (m, 2H), 2.34 (d, *J* = 2.2 Hz, 3H), 1.95 – 1.85 (m, 1H), 1.17 – 1.13 (m, 1H), 0.81 – 0.70 (m, 1H).

Example 31: (rac)-(2*s*,4*s*)-2-(1-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₆N₂O₃, 366.2; m/z found, 367.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.20 (m, 1H), 7.16 – 7.10 (m, 1H), 7.09 – 7.06 (m, 1H), 7.02 – 6.93 (m, 1H), 6.07 (d, *J* = 27.9 Hz, 1H), 4.36 (d, *J* = 3.0 Hz, 2H), 4.25 – 3.89 (m, 1H), 3.88 – 3.56 (m, 3H), 2.98 – 2.80 (m, 1H), 2.69 – 2.59 (m, 2H), 2.56 – 2.42 (m, 2H), 1.97 – 1.86 (m, 1H), 1.39 (d, *J* = 2.8 Hz, 3H), 1.19 – 1.13 (m, 1H), 0.87 – 0.82 (m, 2H), 0.80 – 0.71 (m, 3H).

Example 32: (rac)-(2*s*,4*s*)-2-(1-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-cyclopropyl-2-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₆N₂O₃, 366.2; m/z found, 367.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.09 (m, 1H), 6.94 – 6.78 (m, 2H), 6.17 (d, *J* = 40.5 Hz, 1H), 4.42 – 4.29 (m, 2H), 4.13 – 3.92 (m, 1H), 3.87 – 3.58 (m, 2H), 3.47 – 3.28 (m, 1H), 2.92 – 2.75 (m, 1H), 2.69 – 2.57 (m, 2H), 2.55 – 2.36 (m, 2H), 2.34 (d, *J* = 2.8 Hz, 3H), 1.90 – 1.73 (m, 2H), 1.08 (ddd, *J* = 17.8, 7.8, 5.1 Hz, 1H), 0.99 – 0.88 (m, 2H), 0.74 – 0.59 (m, 3H).

Example 33: (rac)-(2*s*,4*s*)-2-(1-(2-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-2-methyl-4-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.1; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.46 – 7.32 (m, 3H), 6.06 (d, *J* = 22.0 Hz, 1H), 4.39 – 4.26 (m, 2H), 4.18 – 3.97 (m, 1H), 3.86 – 3.61 (m, 2H), 3.49 – 3.30 (m, 1H), 2.94 – 2.76 (m, 1H), 2.69 – 2.57 (m, 2H), 2.55 – 2.38 (m, 5H), 1.91 – 1.82 (m, 1H), 1.19 – 1.07 (m, 1H), 0.85 – 0.79 (m, 1H).

Example 34: (rac)-(2*s*,4*s*)-2-(1-(2-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 5 The title compound was prepared in a manner analogous to Example 5 using 1-bromo-2-methyl-4-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₄, 410.1; m/z found, 411.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.27 (dd, *J* = 11.6, 8.3 Hz, 1H), 7.04 – 6.95 (m, 2H), 5.96 (d, *J* = 15.4 Hz, 1H), 4.34 (d, *J* = 16.7 Hz, 2H), 4.16 – 3.95 (m, 1H), 3.86 – 3.60 (m, 2H), 3.48 – 3.29 (m, 1H), 2.97 – 2.75 (m, 1H), 2.69
10 – 2.41 (m, 4H), 2.40 (d, *J* = 1.9 Hz, 3H), 1.87 – 1.78 (m, 1H), 1.17 – 1.05 (m, 1H), 0.81 – 0.75 (m, 1H).


Example 35: (rac)-(2*s*,4*s*)-2-(1-(3-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 15 The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-methyl-4-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₄, 410.1; m/z found, 411.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.18 – 7.09 (m, 1H), 7.06 (s, 1H), 7.01 (td, *J* = 8.6, 1.9 Hz, 1H), 6.25 (d, *J* = 5.1 Hz, 1H), 4.36


(d, $J = 4.4$ Hz, 2H), 4.25 – 3.89 (m, 1H), 3.85 – 3.57 (m, 3H), 2.96 – 2.81 (m, 1H), 2.71 – 2.60 (m, 2H), 2.55 – 2.41 (m, 2H), 2.30 (d, $J = 2.6$ Hz, 3H), 1.97 – 1.86 (m, 1H), 1.17 – 1.11 (m, 1H), 0.81 – 0.74 (m, 1H).

- 5 Example 36: (rac)-(2*s*,4*s*)-2-(1-(3-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-methyl-4-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass
 10 calcd. for $C_{20}H_{21}F_3N_2O_3$, 394.1; m/z found, 395.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.54 (dd, $J = 8.5, 3.0$ Hz, 1H), 7.08 – 7.01 (m, 2H), 5.98 (s, 1H), 4.36 (d, $J = 1.7$ Hz, 2H), 4.25 – 3.95 (m, 1H), 3.91 – 3.56 (m, 3H), 2.95 – 2.84 (m, 1H), 2.68 – 2.57 (m, 2H), 2.57 – 2.48 (m, 2H), 2.47 (s, 3H), 2.04 – 1.92 (m, 1H), 1.18 (t, $J = 6.7$ Hz, 1H), 0.87 – 0.79 (m, 1H).


- 15 Example 37: (rac)-(2*s*,4*s*)-2-(1-(3-Fluoro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- The title compound was prepared in a manner analogous to Example 5 using 1-bromo-3-fluoro-4-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for
 20 $C_{19}H_{21}FN_2O_3$, 344.2; m/z found, 345.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.11 (td, $J = 8.0, 2.5$ Hz, 1H), 6.89 – 6.77 (m, 2H), 6.09 (d, $J = 9.1$ Hz, 1H), 4.36 (d, $J = 1.9$ Hz, 2H), 4.25 – 3.89

(m, 1H), 3.84 – 3.53 (m, 3H), 2.95 – 2.80 (m, 1H), 2.69 – 2.57 (m, 2H), 2.55 – 2.41 (m, 2H), 2.26 – 2.22 (m, 3H), 1.94 – 1.84 (m, 1H), 1.17 – 1.08 (m, 1H), 0.82 – 0.70 (m, 1H).

Example 38: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



Step A: 2-(Diiodomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane. In an oven-dried pressure vial under N₂, pinacol(dichloromethyl)boronate (0.4 mL, 2.08 mmol) was taken up in acetone (4.4 mL). To this was added NaI (721 mg, 4.78 mmol) and the reaction was heated to 55 °C for 72 h. The reaction was cooled to rt, filtered through Celite[®] with acetone, and concentrated under reduced pressure. The residue was taken up in DCM and excess iodine was quenched with sodium thiosulfate and magnesium sulfate by shaking the flask until the orange color disappeared. The slurry was filtered through Celite[®] with DCM, concentrated under reduced pressure, and used without further purification in subsequent steps. Compound does not ionize with ESI⁺ LCMS.

Step B: *tert*-butyl (1*R*,5*S*,6*S*)-6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. In an oven-dried flask under N₂, chromium(II) chloride (1.0 g, 8.14 mmol) was taken up in THF (13.5 mL). TMEDA (1.22 mL, 8.14 mmol) was added and this was stirred at rt for 25 min. 2-(Diiodomethyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (801 mg, 2.03 mmol) was added and this was stirred at rt for 30 min. Finally, *tert*-butyl 2,5 dihydro-1*H*-pyrrole-1-carboxylate (237 mg, 1.36 mmol) was added and this was stirred at 50 °C for 20 h. The reaction was quenched with water and extracted with EtOAc. The combined organic layers were washed with brine, dried over sodium sulfate, filtered, and concentrated under reduced pressure. The crude material was purified by FCC on silica (0-15-50% EtOAc in hexane) to afford the title compound (62 mg, 15% yield). MS (ESI): mass calcd. for C₁₆H₂₈BNO₄, 309.2; m/z found, 254.2 [M+2H-tBu]⁺.

Step C: *tert*-Butyl (1*R*,5*S*,6*S*)-6-(3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. In an oven-dried pressure vial under N₂ was combined

bis(dibenzylideneacetone)palladium (Pd(dba)₂) (1.9 mg, 0.003 mmol), 2-dicyclohexylphosphino-2',6'-dimethoxybiphenyl (SPhos) (2.7 mg, 0.006 mmol), potassium *tert*-butoxide (KO^tBu) (29 mg, 0.259 mmol), 1-iodo-3-(trifluoromethoxy)benzene (31 µL, 0.194 mmol), *tert*-butanol (0.26 mL), and 1,2-dimethoxyethane (DME) (0.78 mL). To this was added *tert*-butyl (1*R*,5*S*,6*S*)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (20 mg, 0.065 mmol) and this was heated to 80 °C for 20 h. The reaction was quenched with water and extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure. Purification via reverse phase HPLC (5-95% ACN in 20 mM NH₄OH in water) afforded the title compound (6 mg, 27% yield). MS (ESI): mass calcd. for C₁₇H₂₀F₃NO₃, 343.1; m/z found, 288.1 [M+2H-tBu]⁺.

Step D: (1*R*,5*S*,6*S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane hydrochloride.


To *tert*-butyl (1*R*,5*S*,6*S*)-6-(3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (6 mg, 0.017 mmol) in MeOH (0.1 mL) was added HCl in 1,4-dioxane (4 M, 0.1 mL). This was heated to 45 °C for 1 hour before concentrating under reduced pressure. The title compound was used without further purification in the next step. MS (ESI): mass calcd. for C₁₂H₁₃ClF₃NO 279.1; m/z found, 244.1 [M-Cl]⁺.

Step E: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. (1*R*,5*S*,6*S*)-6-(3-(trifluoromethoxy)phenyl)-3-

azabicyclo[3.1.0]hexane hydrochloride was taken up in DMF (0.2 mL) and to this was added (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 3.1 mg, 0.018 mmol), DIPEA (9.2 µL, 0.052 mmol), and HATU (7.5 mg, 0.019 mmol). The reaction mixture was stirred at room temperature for 2 hours. The reaction mixture was filtered through a PTFE filter with MeOH and purified via reverse phase HPLC (5-95% ACN in 20 mM NH₄OH in water) to afford the title compound (6 mg, 87% yield). MS (ESI): mass calcd. for C₁₉H₁₉F₃N₂O₄, 396.1; m/z found, 397.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.29 (d, *J* = 8.0 Hz, 1H), 7.06 - 7.01 (m, 1H), 6.95 (dt, *J* = 7.7, 1.3 Hz, 1H), 6.85 (dt, *J* = 2.5, 1.2 Hz, 1H), 6.22 (s, 1H), 4.36 (s, 2H), 4.00 (d, *J* = 12.3 Hz, 1H), 3.72 - 3.63 (m, 2H), 3.57 (dd, *J* = 12.3, 3.4 Hz, 1H),

2.88 (tt, $J = 8.5, 7.0$ Hz, 1H), 2.71 – 2.59 (m, 2H), 2.54 – 2.44 (m, 2H), 1.97 – 1.86 (m, 2H), 1.67 (d, $J = 3.5$ Hz, 1H).


Example 39: (rac)-(2*s*,4*s*)-2-(6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 1 using 6-phenyl-3-azabicyclo[4.1.0]heptane hydrochloride instead of 1-(*p*-tolyl)-3-azabicyclo[3.1.0]hexane. MS (ESI): mass calcd. for $C_{19}H_{22}N_2O_3$, 326.2; m/z found, 327.1 $[M+H]^+$. 1H NMR (400 MHz,

Chloroform- d) δ 7.34 - 7.16 (m, 5H), 6.28 (d, $J = 12.9$ Hz, 1H), 4.38 (d, $J = 8.8$ Hz, 2H), 4.03 - 3.63 (m, 2H), 3.56 - 3.42 (m, 1H), 3.41 - 3.18 (m, 1H), 2.98 (dp, $J = 18.7, 8.1$ Hz, 1H), 2.75 - 2.62 (m, 2H), 2.55 - 2.40 (m, 2H), 2.24 - 2.03 (m, 2H), 1.56 - 1.37 (m, 1H), 1.09 - 1.01 (m, 1H), 0.79 (q, $J = 5.0$ Hz, 1H).

Example 40: (2*s*,4*S*)-2-((1*R*,6*S*)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 39 (Stationary phase: Chiralpak AD, $5\mu m$ 250 x 21 mm, Mobile phase: 40% MeOH:isopropanol

(1:1) with 0.2% isopropylamine, 60% CO_2). MS (ESI): mass calcd. for $C_{19}H_{22}N_2O_3$, 326.2; m/z found, 327.2 $[M+H]^+$. 1H NMR (500 MHz, Chloroform- d) δ 7.34 - 7.16 (m, 5H), 6.42 (d, $J = 14.0$ Hz, 1H), 4.38 (d, $J = 10.8$ Hz, 2H), 4.03 - 3.58 (m, 2H), 3.50 (dp, $J = 19.0, 6.9$ Hz, 1H), 3.41 - 3.18 (m, 1H), 2.98 (dp, $J = 24.2, 8.2$ Hz, 1H), 2.70 (qd, $J = 10.4, 5.3$ Hz, 2H), 2.47 (td, $J =$


12.5, 8.2 Hz, 2H), 2.22 - 2.02 (m, 2H), 1.56 - 1.37 (m, 1H), 1.05 (dt, $J = 9.1, 4.8$ Hz, 1H), 0.79 (q, $J = 5.4$ Hz, 1H).

Example 41: (2*S*,4*R*)-2-((1*S*,6*R*)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 39 (Stationary phase: Chiralpak AD, 5 μ m 250 x 21 mm, Mobile phase: 40% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 60% CO₂). MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; m/z found, 327.2 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.29 (t, $J = 7.6$ Hz, 2H), 7.25 - 7.16 (m, 3H), 6.55 (d, $J = 11.8$ Hz, 1H), 4.38 (d, $J = 10.7$ Hz, 2H), 4.03 - 3.60 (m, 2H), 3.50 (dp, $J = 19.0, 6.9$ Hz, 1H), 3.41 - 3.18 (m, 1H), 2.97 (dp, $J = 24.4, 8.2$ Hz, 1H), 2.70 (qd, $J = 10.4, 5.3$ Hz, 2H), 2.47 (td, $J = 12.5, 8.2$ Hz, 2H), 2.22 - 2.02 (m, 2H), 1.53 - 1.38 (m, 1H), 1.09 - 1.01 (m, 1H), 0.78 (q, $J = 5.4$ Hz, 1H).

Example 42: (rac)-(2*S*,4*S*)-2-(7,7-Difluoro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 1 using 7,7-difluoro-6-phenyl-3-azabicyclo[4.1.0]heptane hydrochloride instead of 1-(*p*-tolyl)-3-azabicyclo[3.1.0]hexane. MS (ESI): mass calcd. for C₁₉H₂₀F₂N₂O₃, 362.1; m/z found, 363.2 [M+H]⁺. ¹H NMR (500 MHz, CD₃OD) δ 7.42 - 7.24 (m, 5H), 4.51 (d, $J = 0.7$ Hz, 1H), 4.48 - 4.42 (m, 1H), 4.05 - 3.76 (m, 2H), 3.73 - 3.50 (m, 1H), 3.30 - 3.01 (m, 2H), 2.64 - 2.37 (m, 4H), 2.34 - 2.12 (m, 2H), 2.01 - 1.85 (m, 1H).

Example 43: (rac)-(2*s*,4*s*)-2-(6-(*m*-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- 5 The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 3-bromotoluene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ
- 10 7.19 (t, *J* = 7.6 Hz, 1H), 7.07 – 6.99 (m, 3H), 5.75 (d, *J* = 20.8 Hz, 1H), 4.37 (d, *J* = 8.8 Hz, 2H), 4.02 – 3.86 (m, 1H), 3.74 (ddd, *J* = 15.3, 13.1, 3.3 Hz, 1H), 3.56 – 3.41 (m, 1H), 3.39 – 3.17 (m, 1H), 3.07 – 2.92 (m, 1H), 2.71 – 2.59 (m, 2H), 2.54 – 2.44 (m, 2H), 2.33 (s, 3H), 2.22 – 2.01 (m, 2H), 1.52 – 1.37 (m, 1H), 1.08 – 1.02 (m, 1H), 0.79 – 0.72 (m, 1H).

- 15 Example 44: (2*s*,4**R*)-2-((1**S*,6**R*)-6-(*m*-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- The title compound was prepared by chiral supercritical fluid chromatography of Example 43 (Stationary phase: Chiralpak AD, 5μm 250 x 21 mm, Mobile phase: 40% MeOH with 0.2% TEA, 60% CO₂). MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.1 [M+H]⁺. ¹H
- 20 NMR (400 MHz, Chloroform-d) δ 7.18 (t, *J* = 7.5 Hz, 1H), 7.07 – 6.98 (m, 3H), 6.20 (d, *J* = 13.5 Hz, 1H), 4.38 (d, *J* = 8.6 Hz, 2H), 4.02 – 3.40 (m, 3H), 3.40 – 3.17 (m, 1H), 3.12 – 2.89 (m, 1H), 2.74 – 2.61 (m, 2H), 2.54 – 2.41 (m, 2H), 2.33 (s, 3H), 2.21 – 2.06 (m, 2H), 1.52 – 1.36 (m, 1H), 1.04 (dt, *J* = 9.0, 4.7 Hz, 1H), 0.76 (td, *J* = 5.3, 2.9 Hz, 1H).

Example 45: (2*s*,4*s*)-2-((1*R*,6*s*)-6-(*m*-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 5 The title compound was prepared by chiral supercritical fluid chromatography of Example 43 (Stationary phase: Chiralpak AD, 5 μ m 250 x 21 mm, Mobile phase: 40% MeOH with 0.2% TEA, 60% CO₂). MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.18 (dd, *J* = 8.0, 7.1 Hz, 1H), 7.06 – 6.97 (m, 3H), 6.25 – 6.11 (m, 1H), 4.38 (d, *J* = 8.6 Hz, 2H), 4.02 – 3.39 (m, 3H), 3.39 – 3.18 (m, 1H), 3.05 – 2.89 (m, 1H), 2.72 – 2.61 (m, 2H), 2.53 – 2.41 (m, 2H), 2.33 (s, 3H), 2.22 – 2.05 (m, 2H), 1.52 – 1.34 (m, 1H), 1.04 (dt, *J* = 9.1, 4.7 Hz, 1H), 0.76 (td, *J* = 5.3, 2.9 Hz, 1H).


Example 46: (rac)-(2*s*,4*s*)-2-(6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 15 The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-fluoro-4-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in
- 20 Step A. MS (ESI): mass calcd. for C₂₀H₂₃FN₂O₃, 358.2; m/z found, 359.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.09 (t, *J* = 8.0 Hz, 1H), 6.92 – 6.77 (m, 2H), 6.00 (d, *J* = 18.1 Hz, 1H), 4.37 (d, *J* = 7.9 Hz, 2H), 3.99 – 3.86 (m, 1H), 3.73 (ddd, *J* = 15.3, 13.2, 3.3 Hz, 1H), 3.56 – 3.41 (m, 1H), 3.39 – 3.18 (m, 1H), 3.06 – 2.90 (m, 1H), 2.72 – 2.59 (m, 2H), 2.53 – 2.41 (m, 2H),


2.23 (d, $J = 1.6$ Hz, 3H), 2.18 – 2.01 (m, 2H), 1.51 – 1.33 (m, 1H), 1.06 – 0.97 (m, 1H), 0.81 – 0.71 (m, 1H).

Example 47: (2*S*,4*R*)-2-((1*S*,6*R*)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 46 (Stationary phase: Chiralcel OD-H 5 μ m 250 x 20 mm, Mobile phase: 15% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 85% CO₂). MS (ESI): mass calcd. for C₂₀H₂₃FN₂O₃, 358.2; m/z found, 359.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.08 (td, $J = 8.0, 0.9$ Hz, 1H), 6.91 – 6.82 (m, 2H), 6.37 (d, $J = 13.7$ Hz, 1H), 4.37 (d, $J = 7.8$ Hz, 2H), 3.98 – 3.61 (m, 2H), 3.55 – 3.39 (m, 1H), 3.39 – 3.17 (m, 1H), 3.03 – 2.89 (m, 1H), 2.73 – 2.61 (m, 2H), 2.53 – 2.41 (m, 2H), 2.22 (d, $J = 1.8$ Hz, 3H), 2.19 – 2.00 (m, 2H), 1.51 – 1.33 (m, 1H), 1.02 (dt, $J = 9.1, 5.2$ Hz, 1H), 0.78 (q, $J = 5.2$ Hz, 1H).


Example 48: (2*S*,4*S*)-2-((1*R*,6*S*)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 46 (Stationary phase: Chiralcel OD-H 5 μ m 250 x 20 mm, Mobile phase: 15% MeOH:isopropanol (1:1) with 0.2% isopropylamine, 85% CO₂). MS (ESI): mass calcd. for C₂₀H₂₃FN₂O₃, 358.2; m/z found, 359.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.09 (td, $J = 8.1, 0.9$ Hz, 1H), 6.91 – 6.82 (m, 2H), 6.27 (d, $J = 14.9$ Hz, 1H), 4.37 (d, $J = 7.8$ Hz, 2H), 3.98 – 3.61 (m, 2H), 3.56 –


3.40 (m, 1H), 3.39 – 3.17 (m, 1H), 3.05 – 2.89 (m, 1H), 2.72 – 2.62 (m, 2H), 2.52 – 2.41 (m, 2H), 2.23 (d, $J = 1.8$ Hz, 3H), 2.20 – 2.00 (m, 2H), 1.51 – 1.33 (m, 1H), 1.02 (dt, $J = 9.0, 5.4$ Hz, 1H), 0.78 (q, $J = 5.2$ Hz, 1H).

- 5 Example 49: (rac)-(2*s*,4*s*)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of
 10 potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{20}H_{21}F_3N_2O_4$, 410.1; m/z found, 411.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.31 (t, $J = 8.2$ Hz, 1H), 7.15 (dd, $J = 6.5, 1.3$ Hz, 1H), 7.05 (d, $J = 7.6$ Hz, 2H), 6.25 (d, $J = 14.0$ Hz, 1H), 4.38 (d, $J = 8.0$ Hz, 2H), 3.98 – 3.92 (m, 1H), 3.76 (ddd, $J =$
 15 15.3, 13.2, 3.3 Hz, 1H), 3.58 – 3.43 (m, 1H), 3.41 – 3.21 (m, 1H), 3.07 – 2.90 (m, 1H), 2.74 – 2.63 (m, 2H), 2.55 – 2.43 (m, 2H), 2.24 – 2.05 (m, 2H), 1.57 – 1.38 (m, 1H), 1.11 – 1.02 (m, 1H), 0.87 – 0.80 (m, 1H).


- 20 Example 50: (2*s*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 49 (Stationary phase: Chiralpak AD, 5 μ m 250 x 30 mm, Mobile phase: 25% MeOH with 0.2% TEA, 75% CO_2). MS (ESI): mass calcd. for $C_{20}H_{21}F_3N_2O_4$, 410.1; m/z found, 411.1 $[M+H]^+$. 1H


5 NMR (500 MHz, Chloroform-d) δ 7.35 – 7.28 (m, 1H), 7.17 – 7.13 (m, 1H), 7.08 – 7.03 (m, 2H), 5.90 (d, J = 23.3 Hz, 1H), 4.38 (d, J = 10.1 Hz, 2H), 4.00 – 3.90 (m, 1H), 3.85 – 3.65 (m, 1H), 3.56 – 3.44 (m, 1H), 3.39 – 3.22 (m, 1H), 3.05 – 2.91 (m, 1H), 2.70 – 2.59 (m, 2H), 2.54 – 2.44 (m, 2H), 2.21 – 2.05 (m, 2H), 1.55 – 1.40 (m, 1H), 1.07 (td, J = 8.7, 5.4 Hz, 1H), 0.84 (q, J = 5.5 Hz, 1H).

Example 51: (2*S*,4*S*)-2-((1*R*,6*S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



10 The title compound was prepared by chiral supercritical fluid chromatography of Example 49 (Stationary phase: Chiralpak AD, 5 μ m 250 x 30 mm, Mobile phase: 25% MeOH with 0.2% TEA, 75% CO₂). MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₄, 410.1; m/z found, 411.1 [M+H]⁺. ¹H NMR (500 MHz, Chloroform-d) δ 7.34 – 7.28 (m, 1H), 7.18 – 7.12 (m, 1H), 7.08 – 7.03 (m, 2H), 6.09 (d, J = 19.8 Hz, 1H), 4.38 (d, J = 10.0 Hz, 2H), 3.99 – 3.90 (m, 1H), 3.86 – 3.64 (m, 1H), 3.56 – 3.44 (m, 1H), 3.39 – 3.21 (m, 1H), 3.05 – 2.91 (m, 1H), 2.72 – 2.60 (m, 2H), 2.54 – 2.44 (m, 2H), 2.21 – 2.04 (m, 2H), 1.55 – 1.40 (m, 1H), 1.07 (td, J = 8.7, 5.4 Hz, 1H), 0.84 (q, J = 5.6 Hz, 1H).


20 Example 52: (rac)-(2*r*,4*s*)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate


5) and using 1-bromo-3-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; *m/z* found, 409.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.43 (t, *J* = 7.9 Hz, 1H), 7.29 (d, *J* = 7.3 Hz, 1H), 7.21 – 7.14 (m, 2H), 3.91 – 3.56 (m, 2H), 3.43 – 3.35 (m, 1H), 3.29 – 3.22 (m, 1H), 3.09 – 2.98 (m, 1H), 2.36 – 2.17 (m, 4H), 2.17 – 2.11 (m, 4H), 2.11 – 1.99 (m, 2H), 1.54 – 1.44 (m, 1H), 1.05 – 0.97 (m, 1H), 0.84 (t, *J* = 5.3 Hz, 1H).

10 Example 53: (rac)-(2*s*,4*s*)-2-(6-(*o*-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 2-bromotoluene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; *m/z* found, 341.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.10 (m, 4H), 5.78 (d, *J* = 23.5 Hz, 1H), 4.38 (d, *J* = 13.0 Hz, 2H), 4.05 – 3.92 (m, 1H), 3.90 – 3.63 (m, 2H), 3.34 – 3.22 (m, 1H), 3.10 – 2.91 (m, 1H), 2.71 – 2.61 (m, 2H), 2.56 – 2.44 (m, 2H), 2.38 (s, 3H), 2.11 – 1.87 (m, 2H), 1.48 – 1.34 (m, 1H), 1.04 – 0.94 (m, 1H), 0.74 (dd, *J* = 9.1, 5.1 Hz, 1H).

Example 54: (rac)-(2*s*,4*s*)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₄, 410.1; m/z found, 411.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.26 – 7.22 (m, 2H), 7.14 (d, *J* = 8.2 Hz, 2H), 6.00 (d, *J* = 15.6 Hz, 1H), 4.38 (d, *J* = 8.5 Hz, 2H), 4.03 – 3.65 (m, 2H), 3.59 – 3.41 (m, 1H), 3.40 – 3.18 (m, 1H), 3.08 – 2.92 (m, 1H), 2.73 – 2.61 (m, 2H), 2.57 – 2.43 (m, 2H), 2.20 – 2.02 (m, 2H), 1.55 – 1.38 (m, 1H), 1.09 – 1.00 (m, 1H), 0.86 – 0.77 (m, 1H).


Example 55: (*rac*)-(2*r*,4*s*)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(trifluoromethoxy)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.1 [M+H]⁺. ¹H NMR (400 MHz,


DMSO-*d*₆) δ 7.93 (s, 1H), 7.37 (d, *J* = 8.6 Hz, 2H), 7.27 (d, *J* = 8.2 Hz, 2H), 3.90 – 3.54 (m, 2H), 3.43 – 3.35 (m, 1H), 3.28 – 3.23 (m, 1H), 3.10 – 2.95 (m, 1H), 2.40 – 2.24 (m, 3H), 2.24 – 2.17 (m, 2H), 2.13 (s, 4H), 1.50 – 1.37 (m, 1H), 1.06 – 0.94 (m, 1H), 0.94 – 0.73 (m, Hz, 2H).

5 Example 56: (rac)-(2*s*,4*s*)-2-(6-(*p*-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of
 10 potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 4-bromotoluene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; *m/z* found, 341.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.16 – 7.08 (m, 4H), 5.88 (d, *J* = 19.8 Hz, 1H), 4.37 (d, *J* = 8.9 Hz, 2H), 4.03 – 3.62 (m, 2H), 3.48 (td, *J* = 6.7, 2.5 Hz, 1H), 3.40 – 3.18 (m, 1H), 3.09 – 2.92 (m, 1H), 2.71 – 2.60 (m, 2H),
 15 2.55 – 2.42 (m, 2H), 2.32 (s, 3H), 2.21 – 2.00 (m, 2H), 1.51 – 1.34 (m, 1H), 1.06 – 0.99 (m, 1H), 0.79 – 0.72 (m, 1H).

Example 57: (rac)-(2*s*,4*s*)-2-(6-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




20

The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate


5) and using 1-bromo-3-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.1; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.47 (dd, *J* = 5.6, 3.1 Hz, 2H), 7.42 (dd, *J* = 6.1, 1.5 Hz, 2H), 5.88 (d, *J* = 18.2 Hz, 1H), 4.38 (d, *J* = 8.7 Hz, 2H), 3.96 (d, *J* = 3.5 Hz, 1H), 3.77 (ddd, *J* = 15.2, 13.2, 3.2 Hz, 1H), 3.60 – 3.43 (m, 1H), 3.41 – 3.21 (m, 1H), 3.11 – 2.91 (m, 1H), 2.75 – 2.59 (m, 2H), 2.57 – 2.45 (m, 2H), 2.18 – 2.10 (m, 2H), 1.59 – 1.41 (m, 1H), 1.14 – 1.03 (m, 1H), 0.92 – 0.77 (m, 1H).

10 Example 58: (*rac*)-(2*s*,4*s*)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.1; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.55 (d, *J* = 8.2 Hz, 2H), 7.33 (d, *J* = 7.5 Hz, 2H), 6.35 (d, *J* = 11.1 Hz, 1H), 4.38 (d, *J* = 8.0 Hz, 2H), 3.99 – 3.90 (m, 1H), 3.89 – 3.65 (m, 1H), 3.60 – 3.43 (m, 1H), 3.43 – 3.21 (m, 1H), 3.07 – 2.88 (m, 1H), 2.74 – 2.63 (m, 2H), 2.54 – 2.42 (m, 2H), 2.24 – 2.06 (m, 2H), 1.59 – 1.41 (m, 1H), 1.12 – 1.03 (m, 1H), 0.86 (dd, *J* = 9.3, 5.3 Hz, 1H).

Example 59: (*rac*)-(2*r*,4*s*)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(trifluoromethyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₂, 392.2; *m/z* found, 393.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.64 (d, *J* = 8.3 Hz, 2H), 7.46 (d, *J* = 8.2 Hz, 2H), 3.90 – 3.59 (m, 2H), 3.44 – 3.35 (m, 1H), 3.29 – 3.25 (m, 1H), 3.11 – 2.97 (m, 1H), 2.35 – 2.26 (m, 2H), 2.24 – 2.01 (m, 8H), 1.57 – 1.45 (m, 1H), 1.10 – 0.99 (m, 1H), 0.88 (t, *J* = 5.4 Hz, 1H).


Example 60: (*rac*)-(2*s*,4*s*)-2-(6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-(*tert*-butyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₃H₃₀N₂O₃, 382.2; *m/z* found, 383.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.22 (m, 3H), 7.08 – 7.01 (m, 1H), 6.04 (d, *J* = 16.3 Hz, 1H), 4.38 (d, *J* = 9.0 Hz, 2H), 4.03 – 3.63 (m, 2H), 3.50 (t, *J* = 6.4 Hz, 1H), 3.41 – 3.19 (m, 1H), 3.08 – 2.92 (m, 1H),


2.73 – 2.61 (m, 2H), 2.55 – 2.41 (m, 2H), 2.26 – 2.05 (m, 2H), 1.55 – 1.38 (m, 1H), 1.31 (s, 9H), 1.09 – 0.99 (m, 1H), 0.82 – 0.73 (m, 1H).

Example 61: (rac)-(2*r*,4*s*)-2-(6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-(*tert*-butyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₄H₃₂N₂O₂, 380.2; m/z found, 381.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.25 – 7.16 (m, 3H), 7.08 – 7.01 (m, 1H), 3.92 – 3.55 (m, 2H), 3.32 – 3.17 (m, 2H), 3.10 – 2.95 (m, 1H), 2.36 – 2.16 (m, 4H), 2.15 – 2.12 (m, 4H), 2.08 – 1.94 (m, 2H), 1.47 – 1.36 (m, 1H), 1.26 (s, *J* = 11.3 Hz, 9H), 0.98 – 0.90 (m, 1H), 0.78 (q, *J* = 5.1 Hz, 1H).


Example 62: (rac)-(2*s*,4*s*)-2-(6-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of

potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) in Step A. MS (ESI): mass calcd. for C₂₃H₃₀N₂O₃, 382.2; m/z found, 383.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.29 (m, 2H), 7.15 (dd, *J* = 8.3, 1.2 Hz, 2H), 6.03 (d, *J* = 16.0 Hz, 1H), 4.37 (d, *J* = 8.2 Hz, 2H), 4.03 – 3.61 (m, 2H), 3.48 (t, *J* = 6.4 Hz, 1H), 3.39 – 3.17 (m, 1H),
 5 3.06 – 2.88 (m, 1H), 2.71 – 2.60 (m, 2H), 2.53 – 2.40 (m, 2H), 2.25 – 2.06 (m, 2H), 1.53 – 1.36 (m, 1H), 1.30 (s, 9H), 1.08 – 1.02 (m, 1H), 0.77 (dd, *J* = 11.4, 5.5 Hz, 1H).


Example 63: (*rac*)-(2*r*,4*s*)-2-(6-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



10


The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₄H₃₂N₂O₂, 380.2; m/z found, 381.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.29 (d, *J* = 8.3 Hz, 2H), 7.15 (d, *J* = 8.3 Hz, 2H), 3.90 – 3.55 (m, 2H), 3.42 – 3.37 (m, 1H), 3.29 – 3.17 (m, 1H), 3.11 – 2.94 (m, 1H), 2.37 – 2.18 (m, 4H), 2.13 (d, *J* = 6.1 Hz, 4H), 2.08 – 1.92 (m, 2H), 1.44 – 1.31 (m, 1H), 1.25 (s, 9H), 0.98 – 0.88 (m, 1H),
 15 0.76 (t, *J* = 4.8 Hz, 1H).
 20

Example 64: (*rac*)-(2*s*,4*s*)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-cyclopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₆N₂O₃, 366.2; m/z found, 367.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.18 (t, *J* = 7.6 Hz, 1H), 7.04 – 6.98 (m, 1H), 6.97 (br s, 1H), 6.87 (d, *J* = 7.6 Hz, 1H), 5.94 (d, *J* = 18.3 Hz, 1H), 4.37 (d, *J* = 8.8 Hz, 2H), 4.03 – 3.61 (m, 2H), 3.59 – 3.41 (m, 1H), 3.39 – 3.17 (m, 1H), 3.09 – 2.89 (m, 1H), 2.73 – 2.56 (m, 2H), 2.55 – 2.40 (m, 2H), 2.23 – 2.01 (m, 2H), 1.93 – 1.79 (m, 1H), 1.53 – 1.37 (m, 1H), 1.08 – 1.00 (m, 1H), 1.00 – 0.90 (m, 2H), 0.79 – 0.71 (m, 1H), 0.70 – 0.60 (m, 2H).


Example 65: (*rac*)-(2*r*,4*s*)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-cyclopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₃H₂₈N₂O₂, 364.2; m/z found, 365.2 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.15 (t, *J* = 7.6 Hz, 1H), 7.03 – 6.93 (m, 2H), 6.83 (d, *J* = 7.7 Hz, 1H), 3.89 – 3.56 (m, 2H), 3.41 – 3.36 (m, 1H), 3.30 – 3.19 (m, 1H), 3.10 – 2.95 (m, 1H), 2.35 – 2.16

(m, 4H), 2.16 – 2.11 (m, 4H), 2.06 – 1.95 (m, 2H), 1.88 (tt, $J = 8.4, 5.1$ Hz, 1H), 1.43 – 1.36 (m, 1H), 0.98 – 0.87 (m, 3H), 0.75 (t, $J = 5.2$ Hz, 1H), 0.66 – 0.61 (m, 2H).


Example 66: (rac)-(2*s*,4*s*)-2-(6-(4-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-cyclopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A.

MS (ESI): mass calcd. for $C_{22}H_{26}N_2O_3$, 366.2; m/z found, 367.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.14 – 7.08 (m, 2H), 7.03 – 6.98 (m, 2H), 5.89 (d, $J = 19.0$ Hz, 1H), 4.37 (d, $J = 8.8$ Hz, 2H), 4.01 – 3.61 (m, 2H), 3.53 – 3.40 (m, 1H), 3.38 – 3.17 (m, 1H), 3.07 – 2.88 (m, 1H), 2.71 – 2.59 (m, 2H), 2.52 – 2.42 (m, 2H), 2.21 – 2.00 (m, 2H), 1.91 – 1.82 (m, 1H), 1.50 – 1.34 (m, 1H), 1.05 – 0.98 (m, 1H), 0.97 – 0.91 (m, 2H), 0.75 (q, $J = 5.2$ Hz, 1H), 0.68 – 0.63 (m, 2H).


Example 67: (rac)-(2*s*,4*s*)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate


5) and using 1-bromo-3-chloro-4-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₃ClN₂O₃, 374.1; m/z found, 375.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.20 (dd, *J* = 6.3, 1.8 Hz, 1H), 7.14 (d, *J* = 7.9 Hz, 1H), 7.01 (dt, *J* = 7.8, 2.2 Hz, 1H), 5.83 (d, *J* = 20.5 Hz, 1H), 4.37 (d, *J* = 8.3 Hz, 2H), 4.01 – 3.87 (m, 1H), 3.73 (ddd, *J* = 15.3, 13.2, 3.3 Hz, 1H), 3.58 – 3.40 (m, 1H), 3.37 – 3.17 (m, 1H), 3.08 – 2.91 (m, 1H), 2.70 – 2.60 (m, 2H), 2.54 – 2.44 (m, 2H), 2.33 (s, 3H), 2.21 – 1.99 (m, 2H), 1.50 – 1.34 (m, 1H), 1.06 – 0.99 (m, 1H), 0.81 – 0.73 (m, 1H).

10 Example 68: (*rac*)-(2*r*,4*s*)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-chloro-4-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₁H₂₅ClN₂O₂, 372.2; m/z found, 373.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.25 (dd, *J* = 4.6, 2.8 Hz, 2H), 7.11 (dt, *J* = 7.9, 1.5 Hz, 1H), 3.90 – 3.54 (m, 2H), 3.31 – 3.18 (m, 2H), 3.10 – 2.95 (m, 1H), 2.33 – 2.24 (m, 5H), 2.23 – 2.16 (m, 2H), 2.16 – 2.10 (m, 4H), 2.06 – 1.94 (m, 2H), 1.49 – 1.36 (m, 1H), 1.01 – 0.90 (m, 1H), 0.76 (t, *J* = 5.3 Hz, 1H).

25 Example 69: (*rac*)-(2*s*,4*s*)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for $C_{23}H_{28}N_2O_3$, 380.2; m/z found, 381.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.21 – 7.10 (m, 4H), 5.84 (d, $J = 19.3$ Hz, 1H), 4.37 (d, $J = 8.6$ Hz, 2H), 4.02 – 3.60 (m, 2H), 3.47 (t, $J = 6.4$ Hz, 1H), 3.39 – 3.16 (m, 1H), 3.09 – 2.90 (m, 1H), 2.74 – 2.59 (m, 2H), 2.57 – 2.42 (m, 2H), 2.23 – 1.97 (m, 2H), 1.50 – 1.43 (m, 1H), 1.38 (s, 3H), 1.07 – 1.00 (m, 1H), 0.86 – 0.80 (m, 2H), 0.79 – 0.74 (m, 1H), 0.71 (dd, $J = 6.1, 4.2$ Hz, 2H).


Example 70: (*rac*)-(2*r*,4*s*)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for $C_{24}H_{30}N_2O_2$, 378.2; m/z found, 379.2 $[M+H]^+$. 1H NMR (400 MHz,


DMSO-*d*₆) δ 7.91 (s, 1H), 7.11 (s, 4H), 3.89 – 3.60 (m, 2H), 3.26 – 3.16 (m, 2H), 3.07 – 2.92 (m, 1H), 2.32 – 2.23 (m, 2H), 2.23 – 2.08 (m, 6H), 2.04 – 1.88 (m, 2H), 1.39 – 1.27 (m, 4H), 0.95 – 0.87 (m, 1H), 0.80 – 0.64 (m, 5H).

5 Example 71: (*rac*)-(2*s*,4*s*)-2-(6-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of
 10 potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-(1-methylcyclopropyl)benzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₃H₂₈N₂O₃, 380.2; *m/z* found, 381.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.21 (t, *J* = 7.6 Hz, 1H), 7.14 – 7.07 (m, 2H), 7.06 – 6.99 (m, 1H), 5.85 (d, *J* = 19.7 Hz, 1H), 4.38 (d, *J* = 8.8 Hz, 2H), 4.02 – 3.64 (m, 2H), 3.51 – 3.46 (m, 1H), 3.40 – 3.19
 15 (m, 1H), 3.07 – 2.93 (m, 1H), 2.72 – 2.60 (m, 2H), 2.56 – 2.43 (m, 2H), 2.24 – 2.04 (m, 2H), 1.52 – 1.41 (m, 1H), 1.39 (s, 3H), 1.10 – 0.99 (m, 1H), 0.86 – 0.82 (m, 2H), 0.78 (q, *J* = 5.4 Hz, 1H), 0.72 (dd, *J* = 6.1, 4.2 Hz, 2H).


20 Example 72: (*rac*)-(2*s*,4*s*)-2-(6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of


potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-cyclopropyl-2-methylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₃H₂₈N₂O₃, 380.2; m/z found, 381.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.06 (dd, *J* = 7.8, 4.1 Hz, 1H), 6.86 (s, 1H), 6.82 (d, *J* = 7.8 Hz, 1H), 5.78 (d, *J* = 24.4 Hz, 1H), 4.37 (d, *J* = 12.7 Hz, 2H), 4.00 – 3.94 (m, 1H), 3.89 – 3.59 (m, 2H), 3.36 – 3.16 (m, 1H), 3.11 – 2.90 (m, 1H), 2.72 – 2.59 (m, 2H), 2.55 – 2.43 (m, 2H), 2.34 (s, 3H), 2.05 – 1.77 (m, 3H), 1.44 – 1.29 (m, 1H), 1.00 – 0.88 (m, 3H), 0.71 (dd, *J* = 8.9, 5.1 Hz, 1H), 0.67 – 0.61 (m, 2H).

10 Example 73: (*rac*)-(2*s*,4*s*)-2-(6-(3-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-3-isopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.25 – 7.20 (m, 1H), 7.10 – 7.02 (m, 3H), 5.77 (d, *J* = 21.2 Hz, 1H), 4.37 (d, *J* = 8.9 Hz, 2H), 4.03 – 3.63 (m, 2H), 3.53 – 3.46 (m, 1H), 3.42 – 3.17 (m, 1H), 3.10 – 2.94 (m, 1H), 2.92 – 2.83 (m, 1H), 2.71 – 2.60 (m, 2H), 2.57 – 2.44 (m, 2H), 2.24 – 2.02 (m, 2H), 1.54 – 1.38 (m, 1H), 1.24 (d, *J* = 6.9 Hz, 6H), 1.09 – 1.03 (m, 1H), 0.78 (q, *J* = 5.2 Hz, 1H).

Example 74: (*rac*)-(2*s*,4*s*)-2-(6-(4-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 1-bromo-4-isopropylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.20 – 7.12 (m, 4H), 5.90 (d, *J* = 18.9 Hz, 1H), 4.37 (d, *J* = 8.5 Hz, 2H), 4.05 – 3.61 (m, 2H), 3.48 (t, *J* = 6.4 Hz, 1H), 3.40 – 3.16 (m, 1H), 3.06 – 2.93 (m, 1H), 2.91 – 2.83 (m, 1H), 2.74 – 2.59 (m, 2H), 2.56 – 2.41 (m, 2H), 2.24 – 2.00 (m, 2H), 1.53 – 1.35 (m, 1H), 1.23 (d, *J* = 6.9 Hz, 6H), 1.10 – 1.01 (m, 1H), 0.77 (q, *J* = 5.3 Hz, 1H).

Example 75: (*rac*)-(2*s*,4*s*)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 4-bromo-1-methyl-2-(trifluoromethoxy)benzene (Intermediate 8) instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₄, 424.2; m/z found, 425.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.17 (d, *J* = 7.9 Hz, 1H), 7.07 – 7.01 (m, 2H), 5.93 (d, *J* = 18.5 Hz, 1H), 4.37 (d, *J* = 8.2 Hz, 2H), 4.02 – 3.63 (m, 2H), 3.55 – 3.43 (m,

1H), 3.40 – 3.19 (m, 1H), 3.08 – 2.90 (m, 1H), 2.72 – 2.60 (m, 2H), 2.56 – 2.42 (m, 2H), 2.27 (s, 3H), 2.20 – 2.03 (m, 2H), 1.52 – 1.36 (m, 1H), 1.07 – 0.97 (m, 1H), 0.85 – 0.75 (m, 1H).


Example 76: (rac)-(2*r*,4*s*)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-

5 azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-6-yl)trifluoroborate (Intermediate 6) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate 5) and using 4-bromo-1-methyl-2-(trifluoromethoxy)benzene (Intermediate 8) instead of 1-bromo-4-(*tert*-butyl)benzene in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step C. MS (ESI): mass calcd. for C₂₂H₂₅F₃N₂O₃, 422.2; m/z found, 423.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 7.93 (s, 1H), 7.30 (d, *J* = 8.1 Hz, 1H), 7.18 (d, *J* = 8.0 Hz, 1H), 7.11 (s, 1H), 3.89 – 3.56 (m, 2H), 3.42 – 3.37 (m, 1H), 3.28 – 3.20 (m, 1H), 3.09 – 2.94 (m, 1H), 2.35 – 2.25 (m, 2H), 2.24 – 2.16 (m, 5H), 2.16 – 2.10 (m, 4H), 2.07 – 1.97 (m, 2H), 1.49 – 1.38 (m, 1H), 1.01 – 0.92 (m, 1H), 0.84 – 0.76 (m, 1H).


Example 77: (rac)-(2*s*,4*s*)-2-(1-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-
20 azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 5 using potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[4.1.0]heptan-1-yl)trifluoroborate (Intermediate 7) instead of potassium (3-(*tert*-butoxycarbonyl)-3-azabicyclo[3.1.0]hexan-1-yl)trifluoroborate (Intermediate

- 5) and using bromobenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; m/z found, 327.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.37 – 7.27 (m, 3H), 7.26 – 7.19 (m, 2H), 5.81 (d, *J* = 16.9 Hz, 1H), 4.53 – 4.30 (m, 2H), 4.00 – 3.40 (m, 3H), 3.25 – 2.86 (m, 2H), 2.75 – 2.32 (m, 4H), 2.25 – 2.13 (m, 1H), 1.91 – 1.73 (m, 1H), 1.46 – 1.31 (m, 1H), 1.14 – 1.04 (m, 1H), 0.63 (dd, *J* = 9.7, 5.1 Hz, 1H).

Example 78: (2*S*,4*S*)-2-(((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- 10 Step A: (3-(*tert*-Butyl)benzylidene)hydrazine. To hydrazine monohydrate (21.3 mL, 449 mmol) was added 3-*tert*-butylbenzaldehyde (7.1 g, 44 mmol) dropwise over 1 min at room temperature and the reaction mixture was stirred at room temperature for 20 min. The reaction mixture was poured into water and extracted with Et₂O. The combined organic layers were washed with water, dried over magnesium sulfate, filtered and evaporated under reduced pressure to give the
- 15 title compound (7.3 g, 94% yield) as a yellow oil which was used without further purification in the next step. MS (ESI): mass calcd. for C₁₁H₁₆N₂, 176.1; m/z found, 177.2 [M+H]⁺.
- Step B: (1*R*,5*S*,6*S*)-3-Benzyl-6-(3-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione. To a solution of (3-(*tert*-butyl)benzylidene)hydrazine (7.3 g, 41 mmol) in 1,4-dioxane (70 mL) was added manganese(IV) oxide (15.1 g, 173 mmol) and the reaction mixture was stirred at room
- 20 temperature for 2 h. The reaction mixture was filtered through a pad of Celite[®]. To the filtrate was added *N*-benzylmaleimide (7.7 g, 41 mmol) and the reaction mixture was stirred at 100 °C for 16 h. The reaction mixture was evaporated under reduced pressure and the residue was triturated with Et₂O to give the title compound (3.6 g, 26% yield) as a white powder. MS (ESI): mass calcd. for C₂₂H₂₃NO₂, 333.2; m/z found, 334.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ
- 25 7.38 – 7.32 (m, 2H), 7.32 – 7.27 (m, 3H), 7.27 – 7.21 (m, 3H), 7.00 – 6.94 (m, 1H), 4.45 (s, 2H), 3.14 – 3.08 (m, 2H), 3.08 – 3.03 (m, 1H), 1.27 (s, 9H).

- Step C: (1*R*,5*S*,6*S*)-3-Benzyl-6-(3-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane. To a suspension of (1*R*,5*S*,6*S*)-3-benzyl-6-(3-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione (3.5 g, 11 mmol) in freshly distilled THF (10 mL) was added lithium aluminum hydride (LiAlH₄) (42 mL, 1 M in THF) dropwise at 0 °C over 10 min and the reaction mixture was
- 5 stirred at 0 °C for 1 h under argon. The reaction mixture was allowed to warm to room temperature and stirred at room temperature for 16 h under argon. The reaction mixture was diluted with Et₂O and the reaction was quenched with sodium sulfate decahydrate. The mixture was filtered and the solid was washed with EtOAc. The combined filtrates were evaporated under reduced pressure and the residue was purified by FCC on silica (0-30% EtOAc in heptane)
- 10 to give the title compound (1.7 g, 53% yield) as a white crystalline solid. MS (ESI): mass calcd. for C₂₂H₂₇N, 305.2; m/z found, 306.5 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.37 – 7.28 (m, 4H), 7.27 – 7.21 (m, 1H), 7.16 – 7.11 (m, 2H), 7.11 – 7.09 (m, 1H), 6.81 – 6.73 (m, 1H), 3.61 (s, 2H), 3.02 (d, *J* = 8.9 Hz, 2H), 2.45 – 2.41 (m, 2H), 2.26 – 2.22 (m, 1H), 1.70 – 1.65 (m, 2H), 1.25 (s, 9H).
- 15 Step D: (1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane hydrochloride. To a solution of (1*R*,5*S*,6*S*)-3-benzyl-6-(3-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane (1.66 g, 5.43 mmol) in EtOH (15 mL) was added 10% Pd/C (580 mg, 0.54 mmol) and hydrogen chloride (HCl) (4.2 M in 1,4-dioxane, 3.9 mL). The reaction mixture was stirred at room temperature for 16 h under H₂ (1 bar). The reaction mixture was filtered through a pad of Celite[®]. To the filtrate
- 20 was added 10% Pd/C (580 mg, 0.54 mmol) and the reaction mixture was stirred at room temperature for 72 h under H₂ (1 bar). The reaction mixture was filtered through a pad of Celite[®] and the Celite[®] was washed with EtOH. The combined filtrates were evaporated under reduced pressure and the product was triturated with Et₂O to give the title compound (940 mg, 69% yield) as a white powder. MS (ESI): mass calcd. for C₁₅H₂₁N, 215.2; m/z found, 216.3 [M+H]⁺.
- 25 Step E: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. To a suspension of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 205 mg, 1.2 mmol) in DCM (5 mL) was added EDC (229 mg, 1.19 mmol), TEA (670 μL, 4.81 mmol) and HOBT (178 mg, 1.32 mmol). The reaction mixture was stirred at room temperature for 10 min. To the reaction mixture was added (1*R*,5*S*,6*S*)-6-(3-(*tert*-butyl)phenyl)-3-azabicyclo[3.1.0]hexane hydrochloride (300 mg, 1.19 mmol) and stirred at
- 30 room temperature for 18 h. The reaction mixture was diluted with DCM and washed with 1 M

potassium bisulfate, saturated NaHCO₃ and brine. The organic layer was dried over magnesium sulfate, filtered and evaporated under reduced pressure. The crude product was purified by preparative HPLC to give the title compound (235 mg, 54% yield) as a white powder. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ

5 8.07 (s, 1H), 7.20 – 7.14 (m, 2H), 7.13 – 7.10 (m, 1H), 6.83 – 6.77 (m, 1H), 4.37 (d, *J* = 9.3 Hz, 1H), 4.35 (d, *J* = 9.3 Hz, 1H), 3.74 (d, *J* = 11.9 Hz, 1H), 3.68 (d, *J* = 10.5 Hz, 1H), 3.55 (dd, *J* = 10.5, 4.3 Hz, 1H), 3.36 (dd, *J* = 11.9, 4.4 Hz, 1H), 2.94 – 2.83 (m, 1H), 2.44 – 2.27 (m, 4H), 1.95 – 1.90 (m, 1H), 1.88 – 1.82 (m, 1H), 1.64 – 1.59 (m, 1H), 1.25 (s, 9H).

10 Example 79: (2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 78 using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-

15 azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step E. MS (ESI): mass calcd. for C₂₃H₃₀N₂O₂, 366.2; m/z found, 367.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.23 – 7.17 (m, 2H), 7.08 (dd, *J* = 2.0, 1.0 Hz, 1H), 6.81 – 6.75 (m, 1H), 6.56 (s, 1H), 3.97 (d, *J* = 12.1 Hz, 1H), 3.72 – 3.58 (m, 2H), 3.54 (dd, *J* = 12.2, 3.9 Hz, 1H), 2.89 (p, *J* = 8.3 Hz, 1H), 2.61 – 2.50 (m, 2H), 2.43 – 2.31 (m, 4H), 2.25 – 2.17 (m, 2H), 1.88 (hept, *J* = 3.7 Hz, 2H), 1.63 (t, *J* = 3.5


20 Hz, 1H), 1.30 (s, 9H).

Example 80: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 78 using 4-trifluoromethylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₁₉H₁₉F₃N₂O₃, 380.1; m/z found, 381.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.59 (d, *J* = 8.1 Hz, 2H), 7.30 (d, *J* = 8.1 Hz, 2H), 4.37 (d, *J* = 8.7 Hz, 1H), 4.35 (d, *J* = 8.8 Hz, 1H), 3.77 (d, *J* = 12.0 Hz, 1H), 3.71 (d, *J* = 10.6 Hz, 1H), 3.57 (dd, *J* = 10.6, 4.3 Hz, 1H), 3.39 (dd, *J* = 12.0, 4.4 Hz, 1H), 2.94 – 2.85 (m, 1H), 2.45 – 2.38 (m, 1H), 2.37 – 2.26 (m, 3H), 2.08 – 2.02 (m, 1H), 1.99 – 1.95 (m, 1H), 1.80 – 1.76 (m, 1H).

Example 81: (2*r*,4*S*)-2-(((1*R*,5*S*,6*S*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 78 using 4-trifluoromethylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step E. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₂, 378.2; m/z found, 379.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.95 (s, 1H), 7.59 (d, *J* = 8.1 Hz, 2H), 7.30 (d, *J* = 8.1 Hz, 2H), 3.77 (d, *J* = 12.0 Hz, 1H), 3.73 (d, *J* = 10.6 Hz, 1H), 3.58 (dd, *J* = 10.6, 4.2 Hz, 1H), 3.38 (dd, *J* = 12.0, 4.3 Hz, 1H), 2.96 – 2.86 (m, 1H), 2.37 – 2.30 (m, 1H), 2.29 – 2.23 (m, 1H), 2.22 – 2.17 (m, 2H), 2.16 – 2.09 (m, 4H), 2.06 – 2.01 (m, 1H), 1.99 – 1.93 (m, 1H), 1.81 – 1.75 (m, 1H).

Example 82: (2*s*,4*S*)-2-(((1*R*,5*S*,6*S*)-6-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 78 using 4-*tert*-butylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{22}H_{28}N_2O_3$, 368.2; m/z found, 369.2 $[M+H]^+$. 1H NMR (500 MHz, DMSO- d_6) δ 8.06 (s, 1H), 7.30 – 7.21 (m, 2H), 7.03 – 6.94 (m, 2H), 4.37 (d, J = 9.1 Hz, 1H), 4.35 (d, J = 9.0 Hz, 1H), 3.73 (d, J = 11.9 Hz, 1H), 3.67 (d, J = 10.5 Hz, 1H), 3.54 (dd, J = 10.5, 4.3 Hz, 1H), 3.36 (dd, J = 11.9, 4.5 Hz, 1H), 2.94 – 2.84 (m, 1H), 2.44 – 2.37 (m, 1H), 2.37 – 2.27 (m, 3H), 1.93 – 1.86 (m, 1H), 1.85 – 1.78 (m, 1H), 1.59 – 1.54 (m, 1H), 1.24 (s, 9H).

- 10 Example 83: (2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(4-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




- The title compound was prepared in a manner analogous to Example 78 using 4-*tert*-butylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step E. MS (ESI): mass calcd. for $C_{23}H_{30}N_2O_2$, 366.2; m/z found, 367.2 $[M+H]^+$. 1H NMR (500 MHz, DMSO- d_6) δ 7.93 (s, 1H), 7.25 – 7.20 (m, 2H), 7.00 – 6.92 (m, 2H), 3.70 (d, J = 11.9 Hz, 1H), 3.67 (d, J = 10.5 Hz, 1H), 3.53 (dd, J = 10.5, 4.3 Hz, 1H), 3.33 (dd, J = 11.9, 4.4 Hz, 1H), 2.94 – 2.83 (m, 1H), 2.32 – 2.26 (m, 1H), 2.26 – 2.20 (m, 1H), 2.20 – 2.04 (m, 6H), 1.90 – 1.83 (m, 1H), 1.82 – 1.75 (m, 1H), 1.57 – 1.51 (m, 1H), 1.21 (s, 9H).

Example 84: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 78 using 3-isopropylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.05 (s, 1H), 7.13 (t, *J* = 7.6 Hz, 1H), 7.00 – 6.96 (m, 1H), 6.95 – 6.91 (m, 1H), 6.83 – 6.77 (m, 1H), 4.35 (d, *J* = 9.2 Hz, 1H), 4.32 (d, *J* = 9.0 Hz, 1H), 3.71 (d, *J* = 12.0 Hz, 1H), 3.65 (d, *J* = 10.5 Hz, 1H), 3.52 (dd, *J* = 10.5, 4.3 Hz, 1H), 3.34 (dd, *J* = 11.9, 4.4 Hz, 1H), 2.91 – 2.75 (m, 2H), 2.41 – 2.23 (m, 4H), 1.92 – 1.87 (m, 1H), 1.85 – 1.79 (m, 1H), 1.58 – 1.54 (m, 1H), 1.15 (d, *J* = 6.9 Hz, 6H).

Example 85: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 78 using 4-methyl-3-trifluoromethylbenzaldehyde instead of 3-*tert*-butylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₀H₂₁N₂O₃, 394.2; m/z found, 395.2 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 8.07 (s, 1H), 7.40 – 7.36 (m, 1H), 7.31 (d, *J* = 7.9 Hz, 1H), 7.25 – 7.20 (m, 1H), 4.38 (d, *J* = 9.2 Hz, 1H), 4.34 (d, *J* = 9.1 Hz, 1H), 3.75 (d, *J* = 11.9 Hz, 1H), 3.68 (d, *J* = 10.5 Hz, 1H), 3.55 (dd, *J* = 10.6, 4.3 Hz, 1H), 3.36 (dd, *J* = 12.0, 4.4 Hz, 1H), 2.93 – 2.82 (m, 1H), 2.39 – 2.36 (m, 3H), 2.43 – 2.27 (m, 4H), 2.02 – 1.97 (m, 1H), 1.94 – 1.89 (m, 1H), 1.77 – 1.72 (m, 1H).

Example 86: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



Step A: *N'*-(4-Ethylbenzylidene)-4-methylbenzenesulfonylhydrazide. To a solution of 4-ethylbenzaldehyde (2.0 g, 15 mmol) in THF (40 mL) was added 4-methylbenzenesulfonylhydrazide (2.8 g, 15 mmol) and the reaction stirred at room temperature for 3 h. Na₂SO₄ was added, the mixture was filtered, and the filtrate was concentrated under reduced pressure to afford the title compound as a white solid in quantitative yield. MS (ESI): mass calcd. for C₁₆H₁₈N₂O₂S, 302.1; m/z found, 302.9 [M+H]⁺.


Step B: (1*R*,5*S*,6*s*)-3-Benzyl-6-(4-ethylphenyl)-3-azabicyclo[3.1.0]hexane. To a solution of *N'*-(4-ethylbenzylidene)-4-methylbenzenesulfonylhydrazide (500 mg, 1.65 mmol) in THF (30 mL) was added NaH (60% dispersion in mineral oil, 80 mg, 2.00 mmol). The reaction was then heated with stirring at 60 °C for 1 h whereupon the reaction turned into a red slurry. After cooling to room temperature, the mixture was filtered, and the filtrate carefully concentrated *in vacuo* using a room temperature water bath to yield crude diazo intermediate. The crude residue was then dissolved in DCM (15 mL) and the solution added dropwise over 15 minutes to a stirring mixture of 1-benzyl-2,5-dihydro-1*H*-pyrrole (195 mg, 1.22 mmol) and ZnI₂ (41 mg, 0.13 mmol) in DCM (50 mL). Mild exotherm and gas evolution occurred during the addition. The reaction was stirred at room temperature for 1 h then quenched with H₂O and brine. The aqueous layer was extracted with EtOAc. The combined organic layers were dried over Na₂SO₄, filtered, and the filtrate concentrated under reduced pressure to give crude product. The crude oil was purified via FCC on silica (5% EtOAc in hexane) to afford the title compound (256 mg, 75% yield). MS (ESI): mass calcd. for C₂₀H₂₃N, 277.2; m/z found, 278.1 [M+H]⁺. ¹H NMR (500 MHz, DMSO-*d*₆) δ 7.36 – 7.28 (m, 5H), 7.06 – 7.04 (d, *J* = 8.1 Hz, 2H), 6.96 – 6.94 (d, *J* = 8.2 Hz, 2H), 3.61 (s, 2H), 3.02 – 3.0 (d, *J* = 8.9 Hz, 2H), 2.55 – 2.51 (m, 2H), 2.46 – 2.40 (br s, 2H), 2.21 (t, *J* = 3.3 Hz, 1H), 1.64 (s, 2H), 1.13 (t, *J* = 7.6 Hz, 3H).

Step C: (1*R*,5*S*,6*s*)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane. (1*R*,5*S*,6*s*)-3-Benzyl-6-(4-ethylphenyl)-3-azabicyclo[3.1.0]hexane (50 mg, 0.18 mmol) was taken up in EtOH (1.8 mL). 10% Pd/C (19 mg, 0.02 mmol) was added and the reaction vessel was evacuated and left under a

H₂ balloon to stir at rt for 16 h. The reaction mixture was filtered through Celite[®] with MeOH and concentrated under reduced pressure. The title compound was used without further purification in the next step. MS (ESI): mass calcd. for C₁₃H₁₇N, 187.1; m/z found, 188.1 [M+H]⁺.

- 5 Step D: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. (1*R*,5*S*,6*s*)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane (16 mg, 0.085 mmol) and (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 16 mg, 0.094 mmol) were taken up in DMF (0.6 mL). DIPEA (37 μL, 0.214 mmol) and HATU (37 mg, 0.094 mmol) were added and the reaction was stirred at rt for 2 h. The reaction mixture
- 10 was filtered through a PTFE filter with MeOH and purified via reverse phase HPLC (5-95% ACN in 20 mM NH₄OH in water) to afford the title compound (12 mg, 41% yield). MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.14 – 7.08 (m, 2H), 6.97 – 6.91 (m, 2H), 6.31 (s, 1H), 4.36 (s, 2H), 3.97 (d, *J* = 12.2 Hz, 1H), 3.65 (t, *J* = 2.1 Hz, 2H), 3.56 (dd, *J* = 12.1, 3.7 Hz, 1H), 2.87 (tt, *J* = 8.4, 7.2 Hz, 1H), 2.71
- 15 – 2.56 (m, 4H), 2.53 – 2.43 (m, 2H), 1.91 – 1.83 (m, 2H), 1.61 (t, *J* = 3.6 Hz, 1H), 1.21 (t, *J* = 7.6 Hz, 3H).


Example 87: (2*r*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



20


- The title compound was prepared in a manner analogous to Example 86 using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step D. MS (ESI): mass calcd. for C₂₁H₂₆N₂O₂, 338.2; m/z found, 339.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.14 – 7.08
- 25 (m, 2H), 6.97 – 6.90 (m, 2H), 6.22 (s, 1H), 3.96 (d, *J* = 12.2 Hz, 1H), 3.71 – 3.58 (m, 2H), 3.52 (dd, *J* = 12.1, 4.0 Hz, 1H), 2.89 (p, *J* = 8.2 Hz, 1H), 2.65 – 2.46 (m, 4H), 2.43 – 2.31 (m, 4H), 2.26 – 2.17 (m, 2H), 1.90 – 1.81 (m, 2H), 1.60 (t, *J* = 3.5 Hz, 1H), 1.21 (t, *J* = 7.6 Hz, 3H).

Example 88: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- 5 The title compound was prepared in a manner analogous to Example 86 using 3,4-dimethylbenzaldehyde instead of 4-ethylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{20}H_{24}N_2O_3$, 340.2; m/z found, 341.2 $[M+H]^+$. 1H NMR (500 MHz, Chloroform- d) δ 7.03 (d, J = 7.7 Hz, 1H), 6.81 (d, J = 2.0 Hz, 1H), 6.75 (dd, J = 7.8, 2.0 Hz, 1H), 6.26 (s, 1H), 4.36 (s, 2H), 3.96 (d, J = 12.2 Hz, 1H), 3.64 (t, J = 2.4 Hz, 2H), 3.55 (dd, J = 12.2, 3.6 Hz, 1H), 2.87 (tt, J = 8.5, 7.2 Hz, 1H), 2.70 – 2.58 (m, 2H), 2.52 – 2.42 (m, 2H), 2.22 (s, 3H), 2.22 (s, 3H), 1.86 (q, J = 3.1 Hz, 2H), 1.58 (t, J = 3.5 Hz, 1H).
- 10

Example 89: (2*r*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




- 15 The title compound was prepared in a manner analogous to Example 86 using 3,4-dimethylbenzaldehyde instead of 4-ethylbenzaldehyde in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step D. MS (ESI): mass calcd. for $C_{21}H_{26}N_2O_2$, 338.2; m/z found, 339.2 $[M+H]^+$. 1H NMR (500 MHz, Chloroform- d) δ 7.02 (d, J = 7.7 Hz, 1H), 6.80 (d, J = 1.9 Hz, 1H), 6.75 (dd, J = 7.8, 2.0 Hz, 1H), 6.32 (s, 1H), 3.95 (d, J = 12.2 Hz, 1H), 3.67 (d, J = 10.1 Hz, 1H), 3.62 (dd, J = 10.2, 3.8 Hz, 1H), 3.52 (dd, J = 12.1, 4.1 Hz, 1H), 2.89 (p, J = 8.3 Hz, 1H), 2.58 – 2.47 (m, 2H), 2.41 – 2.30 (m, 4H), 2.23 – 2.18 (m, 8H), 1.88 – 1.81 (m, 2H), 1.57 (t, J = 3.5 Hz, 1H).
- 20

Example 90: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- 5 The title compound was prepared in a manner analogous to Example 86 using 4-isopropylbenzaldehyde instead of 4-ethylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₁H₂₆N₂O₃, 354.2; m/z found, 355.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.16 – 7.11 (m, 2H), 6.98 – 6.93 (m, 2H), 6.30 (s, 1H), 4.36 (s, 2H), 3.96 (d, *J* = 12.2 Hz, 1H), 3.68 – 3.61 (m, 2H), 3.56 (dd, *J* = 12.2, 3.6 Hz, 1H), 2.92 – 2.80 (m, 2H), 2.70 - 2.60 (m, 2H), 2.53 - 2.43 (m, 2H), 1.92 – 1.84 (m, 2H), 1.61 (t, *J* = 3.6 Hz, 1H), 1.22 (d, *J* = 6.9 Hz, 6H).
- 10

Example 91: (2*r*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




- 15 The title compound was prepared in a manner analogous to Example 86 using 4-isopropylbenzaldehyde instead of 4-ethylbenzaldehyde in Step A and using (2*r*,4*s*)-6-oxo-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 4) instead of (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3) in Step D. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₂, 352.2; m/z found, 353.3 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-d) δ 7.16 – 7.11 (m, 2H), 6.97 – 6.93 (m, 2H), 6.17 (s, 1H), 3.96 (d, *J* = 12.1 Hz, 1H), 3.70 – 3.59 (m, 2H), 3.53 (dd, *J* = 12.2, 4.0 Hz, 1H), 2.94 – 2.81 (m, 2H), 2.58 – 2.47 (m, 2H), 2.44 – 2.31 (m, 4H), 2.25 – 2.17 (m, 2H), 1.90 – 1.81 (m, 2H), 1.60 (t, *J* = 3.5 Hz, 1H), 1.22 (d, *J* = 6.9 Hz, 6H).
- 20

Example 92: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(2,3-Dihydro-1*H*-inden-5-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 86 using 2,3-dihydro-1*H*-indene-5-carbaldehyde instead of 4-ethylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₁H₂₄N₂O₃, 352.2; m/z found, 353.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.12 (d, *J* = 7.6 Hz, 1H), 6.89 (d, *J* = 1.7 Hz, 1H), 6.80 (dd, *J* = 7.7, 1.7 Hz, 1H), 6.41 (s, 1H), 4.36 (s, 2H), 3.96 (d, *J* = 12.2 Hz, 1H), 3.65 (t, *J* = 2.1 Hz, 2H), 3.55 (dd, *J* = 12.2, 3.5 Hz, 1H), 2.86 (td, *J* = 7.4, 3.7 Hz, 5H), 2.71 – 2.59 (m, 2H), 2.53 – 2.41 (m, 2H), 2.05 (p, *J* = 7.4 Hz, 2H), 1.90 – 1.83 (m, 2H), 1.61 (t, *J* = 3.6 Hz, 1H).

Example 93: (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(3-(*tert*-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 86 using 3-*tert*-butylbenzaldehyde instead of 4-ethylbenzaldehyde in Step A and using 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) instead of 1-benzyl-2,5-dihydro-1*H*-pyrrole in Step B. MS (ESI): mass calcd. for C₂₃H₃₀N₂O₃, 382.2; m/z found, 383.3 [M+H]⁺. ¹H NMR (600 MHz, Chloroform-*d*) δ 7.25 – 7.20 (m, 2H), 7.13 (dt, *J* = 7.6, 1.8 Hz, 1H), 6.92 – 6.88 (m, 1H), 5.91 (br s, 1H), 4.35 (d, *J* = 9.4 Hz, 2H), 4.00 (dd, *J* = 40.6, 11.9 Hz, 1H), 3.74 – 3.59 (m, 2H), 3.40 (dd, *J* = 60.1, 9.9 Hz, 1H), 2.94 – 2.84 (m, 1H), 2.69 – 2.56 (m, 2H), 2.56 – 2.45 (m, 2H), 1.86 – 1.79 (m, 2H), 1.31 (s, 9H), 1.06 (s, 3H).

Example 94: (rac)-(2*s*,4*s*)-2-(1-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 5 using 1-bromo-4-ethylbenzene instead of 1-bromo-4-(*tert*-butyl)benzene in Step A. MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.21 – 7.06 (m, 4H), 6.16 (d, *J* = 13.2 Hz, 1H), 4.35 (d, *J* = 4.3 Hz, 2H), 4.23 – 3.94 (m, 1H), 3.85 – 3.55 (m, 3H), 2.93 – 2.81 (m, 1H), 2.70 – 2.59 (m, 4H), 2.54 – 2.39 (m, 2H), 1.94 – 1.82 (m, 1H), 1.22 (td, *J* = 7.6, 1.5 Hz, 3H), 1.18 – 1.10 (m, 1H), 0.79 – 0.69 (m, 1H).

Example 95: (2*r*,4**S*)-2-((1**R*,5**S*)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 26 (Stationary phase: Whelk-O1 (S,S), 5μm 250 x 21.2 mm, Mobile phase: 0.3% isopropylamine, 60% CO₂, 40% ACN/*i*PrOH (v/v 50/50)). MS (ESI): mass calcd. for C₂₃H₂₈N₂O₂, 364.2; m/z found, 365.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.23 – 7.16 (m, 2H), 7.15 – 7.05 (m, 2H), 6.15 (s, 1H), 4.23 – 3.91 (m, 1H), 3.85 – 3.51 (m, 3H), 2.94 – 2.84 (m, 1H), 2.57 – 2.45 (m, 2H), 2.44 – 2.28 (m, 4H), 2.26 – 2.15 (m, 2H), 1.91 – 1.80 (m, 1H), 1.39 (d, *J* = 1.9 Hz, 3H), 1.12 (dt, *J* = 9.0, 5.0 Hz, 1H), 0.87 – 0.79 (m, 2H), 0.77 – 0.68 (m, 3H).

Example 96: (2*r*,4**R*)-2-((1**S*,5**R*)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 26
 5 (Stationary phase: Whelk-O1 (S,S), 5 μ m 250 x 21.2 mm, Mobile phase: 0.3% isopropylamine, 60% CO₂, 40% ACN/iPrOH (v/v 50/50)). MS (ESI): mass calcd. for C₂₃H₂₈N₂O₂, 364.2; m/z found, 365.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.25 – 7.16 (m, 2H), 7.13 – 7.05 (m, 2H), 6.10 (s, 1H), 4.23 - 3.91 (m, 1H), 3.86 – 3.52 (m, 3H), 2.94 - 2.84 (m, 1H), 2.57 – 2.45 (m, 2H), 2.44 – 2.30 (m, 4H), 2.26 – 2.16 (m, 2H), 1.91 - 1.80 (m, 1H), 1.39 (d, *J* = 1.8 Hz, 3H), 1.12
 10 (dt, *J* = 9.1, 5.1 Hz, 1H), 0.87 – 0.79 (m, 2H), 0.77 – 0.68 (m, 3H).

Example 97: (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



Step A: 4-Methyl-*N'*-(2-methylbenzylidene)benzenesulfonylhydrazide. 4-Methylbenzenesulfonylhydrazide (3.1 g, 16.6 mmol) was added to a solution of 2-methylbenzaldehyde (2.0 g, 16.6 mmol) in MeOH (40 mL). The reaction mixture was stirred for 16 hours at room temperature. The precipitate was collected by filtration and washed with chilled MeOH before drying under reduced pressure to afford the title compound as a white solid
 20 (3.7 g, 77% yield). MS (ESI): mass calcd. for C₁₅H₁₆N₂O₂S 288.1; m/z found, 289.1 [M+H]⁺.

Step B: (rac)-(1**R*,5**S*,6**R*)-3-Benzyl-1-methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane.


Benzyltriethylammonium chloride (237 mg, 1.04 mmol) was added to a mixture of 4-methyl-*N'*-(2-methylbenzylidene)benzenesulfonylhydrazide (1.0 g, 3.47 mmol) in aq. NaOH (15%, 8 mL)

and toluene (8 mL). The reaction mixture was stirred vigorously at 80 °C for 1 hour. The toluene layer was separated, washed with sat. aq. NH₄Cl and brine, dried over anhydrous Na₂SO₄, and filtered to obtain 1-(diazomethyl)-2-methylbenzene in toluene (8 mL, crude). This solution was added dropwise over 30 minutes to a -10 °C mixture of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9, 500 mg, 2.89 mmol) and ZnI₂ (923 mg, 2.89 mmol) in DCM (30 mL). The reaction mixture was stirred at room temperature for 16 hours before being quenched with water and extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product, which was purified by FCC (5-13% EtOAc in ether) to afford the title compound (480 mg, 60% yield). MS (ESI): mass calcd. for C₂₀H₂₃N, 277.2; m/z found, 278.2 [M+H]⁺.

Step C: (rac)-(1 *R,5 *S,6 *R)-1-Methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane. (1 *R,5 *S,6 *R)-3-Benzyl-1-methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane (430 mg, 1.55 mmol) and dry Pd/C (100 mg, 10 wt.%) were taken up in MeOH (8 mL) and THF (40 mL). The resultant mixture was stirred under H₂ (15 psi) at room temperature for 6 hours. The suspension was filtered through a pad of Celite[®] and the pad washed with MeOH. The filtrate was concentrated under reduced pressure to afford the title product as a yellow oil (370 mg, crude), which was carried on without further purification. MS (ESI): mass calcd. for C₁₃H₁₇N, 187.1; m/z found, 188.2 [M+H]⁺.


Step D: (rac)-(2*s*,4*s*)-2-((1 *R,5 *S,6 *R)-1-Methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. T₃P[®] (1.2 mL, 50% in ethyl acetate, 2.0 mmol) was added to a solution of (1 *R,5 *S,6 *R)-1-methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane (360 mg, 1.9 mmol), (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 200 mg, 1.2 mmol), and DIPEA (1.2 mL, 6.8 mmol) in DCM (5 mL). The reaction was stirred at room temperature for 16 hours before being quenched with H₂O and extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product, which was purified by RP-HPLC (40-70% (v/v) CH₃CN in H₂O with 0.05% NH₃ + 10 mM NH₄HCO₃) to afford the title compound as a white solid (148 mg, 36% yield). MS (ESI): mass calcd. for C₂₀H₂₄N₂O₃, 340.2; m/z found, 341.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.22 - 7.10 (m, 3H), 7.07 - 6.98 (m, 1H), 6.16 - 6.04 (m, 1H), 4.38 (d, *J* = 7.3 Hz, 2H), 4.08 - 3.93 (m, 1H), 3.79 - 3.62 (m, 2H), 3.51 - 3.38 (m, 1H), 2.96 - 2.84 (m, 1H), 2.72 - 2.60 (m, 2H), 2.56 - 2.45 (m, 2H), 2.32 - 2.26 (m, 3H), 1.92 - 1.86 (m, 1H), 1.74 - 1.70 (m, 1H), 0.95 (s, 3H).

Example 98: (2*S*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(*o*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 5 The title compound was prepared in a manner analogous to Example 97 using 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for C₁₉H₂₂N₂O₃, 326.2; m/z found, 327.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.22 - 7.08 (m, 3H), 7.00 - 6.91 (m, 1H), 6.53 - 6.28 (m, 1H), 4.47 - 4.33 (m, 2H), 4.01 (d, *J* = 12.16 Hz, 1H), 3.73 - 3.66 (m, 2H), 3.60 (dd, *J* = 4.53, 12.16 Hz, 1H), 2.98 - 2.84 (m, 1H), 2.75 - 2.60 (m, 2H), 2.56 - 2.46 (m, 2H), 2.37 (s, 3H), 1.98 - 1.92 (m, 1H), 1.91 - 1.86 (m, 1H), 1.65 (t, *J* = 3.81 Hz, 1H).
- 10


Example 99: (2*S*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(3-(*tert*-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 15 The title compound was prepared by chiral supercritical fluid chromatography of Example 93 (Stationary phase: OD-H, 2 x 25 cm, Mobile phase: 0.1% TEA, 60% CO₂, 40% heptane/iPrOH (v/v 50/50)). MS (ESI): mass calcd. for C₂₃H₃₀N₂O₃, 382.2; m/z found, 383.2 [M+H]⁺. ¹H NMR (600 MHz, Chloroform-*d*) δ 7.25 - 7.20 (m, 2H), 7.16 - 7.10 (m, 1H), 6.93 - 6.87 (m, 1H), 5.97 - 5.91 (m, 1H), 4.36 (s, 1H), 4.35 (s, 1H), 4.00 (dd, *J* = 40.6, 12.0 Hz, 1H), 3.73 - 3.59 (m, 2H), 3.40 (dd, *J* = 61.4, 11.0 Hz, 1H), 2.95 - 2.84 (m, 1H), 2.68 - 2.57 (m, 2H), 2.55 - 2.45 (m, 2H), 1.85 - 1.79 (m, 2H), 1.31 (s, 9H), 1.05 (s, 3H).
- 20


Example 100: (2*S*,4**R*)-2-((1**S*,5**R*,6**S*)-6-(3-(*tert*-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.

25




The title compound was prepared by chiral supercritical fluid chromatography of Example 93 (Stationary phase: OD-H, 2 x 25 cm, Mobile phase: 0.1% TEA, 60% CO₂, 40% heptane/iPrOH (v/v 50/50)). MS (ESI): mass calcd. for C₂₃H₃₀N₂O₃, 382.2; m/z found, 383.2 [M+H]⁺. ¹H NMR (600 MHz, Chloroform-*d*) δ 7.25 – 7.20 (m, 2H), 7.16 – 7.10 (m, 1H), 6.93 – 6.87 (m, 1H), 5.97 – 5.91 (m, 1H), 4.36 (s, 1H), 4.35 (s, 1H), 4.00 (dd, *J* = 40.6, 12.0 Hz, 1H), 3.73 – 3.59 (m, 2H), 3.40 (dd, *J* = 61.4, 11.0 Hz, 1H), 2.95 – 2.84 (m, 1H), 2.68 – 2.57 (m, 2H), 2.55 – 2.45 (m, 2H), 1.85 – 1.79 (m, 2H), 1.31 (s, 9H), 1.05 (s, 3H).

- 10 Example 101: (2*S*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Isobutylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




- The title compound was prepared in a manner analogous to Example 97 using 3-isobutylbenzaldehyde (Intermediate 10) instead of 2-methylbenzaldehyde in Step A and 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for C₂₂H₂₈N₂O₃, 368.2; m/z found, 369.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.22 - 7.14 (m, 1H), 6.97 (d, *J* = 7.5 Hz, 1H), 6.87 - 6.79 (m, 2H), 6.48 (s, 1H), 4.37 (s, 2H), 3.99 (d, *J* = 12.0 Hz, 1H), 3.71 - 3.63 (m, 2H), 3.57 (dd, *J* = 3.5, 12.3 Hz, 1H), 2.94 - 2.82 (m, 1H), 2.74 - 2.61 (m, 2H), 2.55 - 2.40 (m, 4H), 1.94 - 1.82 (m, 3H), 1.64 - 1.60 (m, 1H), 0.90 (d, *J* = 6.5 Hz, 6H).

Example 102: (rac)-(2*S*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(3,4-Dimethylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 97 using 3,4-dimethylbenzaldehyde instead of 2-methylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{21}H_{26}N_2O_3$, 354.2; m/z found, 355.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.06 (d, $J = 7.6$ Hz, 1H), 6.90 (s, 1H), 6.86 - 6.81 (m, 1H), 5.98 (br s, 1H), 4.36 (d, $J = 6.3$ Hz, 2H), 4.03 - 3.92 (m, 1H), 3.74 - 3.57 (m, 2H), 3.46 - 3.32 (m, 1H), 2.95 - 2.84 (m, 1H), 2.70 - 2.57 (m, 2H), 2.57 - 2.44 (m, 2H), 2.30 - 2.20 (m, 6H), 1.83 - 1.73 (m, 2H), 1.05 (s, 3H).

Example 103: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl-5-D)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



Step A: (1*R*,5*S*,6*s*)-3-Benzyl-6-(3-(*tert*-butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane. The title compound was prepared in a manner analogous to Example 86, Steps A and B using 3-*tert*-butyl-5-iodobenzaldehyde (Intermediate 13) instead of 4-ethylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{22}H_{26}IN$, 431.1; m/z found, 432.1 $[M+H]^+$.

Step B: (1*R*,5*S*,6*s*)-6-(3-(*tert*-Butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane. (1*R*,5*S*,6*s*)-3-Benzyl-6-(3-(*tert*-butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane (23 g, 53.3 mmol) and TEA (22 mL, 160 mmol) were taken up in DCM (460 mL) under N_2 and cooled to 5 °C. To this was added dropwise 1-chloroethyl carbonochloridate (23 g, 160 mmol) and the resulting solution was stirred for 30 min at room temperature. The reaction mixture was concentrated under reduced pressure and diluted in MeOH (230 mL). The reaction was stirred for an additional 30 min while heating at reflux. After cooling to rt, the mixture was concentrated under reduced pressure and purified by RP-HPLC to provide the title compound as a white solid (4.6 g, 25% yield).

Step C: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 2.54 g, 14.8 mmol), DMF (100 mL), DIPEA (5.9 mL, 33.7 mmol), HATU (5.38 g, 14.2 mmol), and (1*R*,5*S*,6*s*)-6-(3-(*tert*-butyl)-5-iodophenyl)-3-

- 5 azabicyclo[3.1.0]hexane (4.60 g, 13.5 mmol) were combined under N₂. The resulting solution was stirred for 1 h at room temperature then quenched with ice water. The solids were collected by filtration to provide the title compound as a white solid (4.8 g, 72% yield). MS (ESI): mass calcd. for C₂₂H₂₇IN₂O₃, 494.1; m/z found, 495.2 [M+H]⁺. ¹H NMR (300 MHz, DMSO-*d*₆) δ 8.08 (s, 1H), 7.47 (t, *J* = 1.6 Hz, 1H), 7.20 (t, *J* = 1.6 Hz, 1H), 7.14 (t, *J* = 1.7 Hz, 1H), 4.37 (s, 2H), 3.76 (dd, *J* = 18.9, 11.2 Hz, 2H), 3.55 (dd, *J* = 10.5, 4.1 Hz, 1H), 3.51 - 3.32 (m, 1H), 2.88 (p, *J* = 8.8 Hz, 1H), 2.52 - 2.32 (m, 4H), 1.99 (dt, *J* = 7.4, 3.7 Hz, 1H), 1.91 (dt, *J* = 7.4, 3.7 Hz, 1H), 1.64 (t, *J* = 3.5 Hz, 1H), 1.24 (s, 9H).


Step D: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl-5-D)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.

- 15 Method A: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one (150 mg, 0.303 mmol) was taken up in CD₃OD (70 mL) and D-THF (2 mL). This solution was passed through an H-Cube[®] reactor once (10% Pd/C, 1 mL/min, 1 bar) using D₂O to generate D₂. The recovered solution was concentrated under reduced pressure. Analysis of the crude material by ¹H NMR indicated approximately 93%
20 deuterium incorporation. The crude product was purified via FCC (9/1 EtOAc/hexane) to provide the title compound (75 mg, 67% yield).

- Method B: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)-5-iodophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one (20 mg, 0.0404 mmol) was taken up in THF (20 mL) and CD₃OD (10 mL) then concentrated under reduced pressure at rt. This was repeated
25 once more before the residue was taken up in CD₃OD (20 mL). To this was added Pd/C (30 mg, 10 wt.%) that had been taken up in D₂O and CD₃OD (1:1, 10 mL) and stirred 5 min before filtering off the liquid portion. This was stirred at rt under an atmosphere of D₂ for 6 h. The reaction solution was filtered, and the filtrate was concentrated under reduced pressure at rt. This procedure was repeated seven times. The combined crude product was purified by RP-
30 HPLC (35-65% ACN in water with 0.05% TFA modifier) to provide the title compound as a light yellow solid (54 mg, 52% yield). MS (ESI): mass calcd. for C₂₂H₂₇DN₂O₃, 369.2; m/z

found, 370.2 $[M+H]^+$. 1H NMR (500 MHz, Methanol- d_4) δ 7.21 – 7.17 (m, 1H), 7.13 (t, J = 1.9 Hz, 1H), 6.84 – 6.81 (m, 1H), 4.48 (s, 2H), 3.88 (d, J = 12.1 Hz, 1H), 3.79 (d, J = 10.6 Hz, 1H), 3.68 (dd, J = 10.5, 4.3 Hz, 1H), 3.51 (dd, J = 12.0, 4.5 Hz, 1H), 3.04 – 2.96 (m, 1H), 2.60 – 2.51 (m, 2H), 2.51 – 2.43 (m, 2H), 1.99 – 1.92 (m, 1H), 1.94 – 1.87 (m, 1H), 1.63 (t, J = 3.6 Hz, 1H), 1.30 (s, 9H).

Example 104: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(1-Hydroxy-2-methylpropan-2-yl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



10 Step A: (1*R*,5*S*,6*s*)-3-Benzyl-6-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane. The title compound was prepared in a manner analogous to Example 97, Steps A and B using 3-bromobenzaldehyde instead of 2-methylbenzaldehyde in Step A and 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for $C_{18}H_{18}BrN$, 327.1; m/z found, 328.1 $[M+H]^+$.

15 Step B: Methyl 2-(3-((1*R*,5*S*,6*s*)-3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropanoate. (1*R*,5*S*,6*s*)-3-Benzyl-6-(3-bromophenyl)-3-azabicyclo[3.1.0]hexane (1.8 g, 5.5 mmol), ((1-methoxy-2-methylprop-1-en-1-yl)oxy)trimethylsilane (1.9 g, 11.0 mmol), and ZnF_2 (0.17 g, 1.6 mmol) were dissolved in DMF (20 mL). The resultant mixture was sparged with N_2 for 5 minutes and then treated with $P(t-Bu)_3$ (3.7 g, 2.7 mmol) and $Pd_2(dba)_3$ (1.0 g, 1.1 mmol). The resultant mixture was sparged with N_2 for 5 minutes and then stirred while heating at 90 °C for 6 hours. After cooling to room temperature, the reaction was quenched with H_2O and extracted with ethyl acetate. The combined organic extracts were dried over anhydrous Na_2SO_4 , filtered, and concentrated under reduced pressure to give the crude product, which was purified by FCC (9-25% EtOAc in ether) to afford the title compound (350 mg, 18% yield). MS (ESI): mass calcd. for $C_{23}H_{27}NO_2$, 349.2; m/z found, 350.2 $[M+H]^+$.

Step C: 2-(3-((1*R*,5*S*,6*s*)-3-Benzyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropan-1-ol. $LiAlH_4$ (65 mg, 1.7 mmol) was added to a -50 °C solution of methyl 2-(3-((1*R*,5*S*,6*s*)-3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropanoate (300 mg, 0.86 mmol) in THF (10


mL). The resultant mixture was stirred at -50 °C for 3 hours before slowly quenching with H₂O (0.1 mL) and NaOH (15% in water, 0.1 mL). The resultant mixture was stirred at room temperature for 30 minutes before additional H₂O (0.3 mL) was added. This was stirred at room temperature for 30 minutes then dried over anhydrous MgSO₄. The suspension was filtered
5 through a pad of Celite[®] and the pad washed with ethyl acetate. The filtrate was concentrated under reduced pressure to give the crude product (280 mg, quant.), which was used in the next step without further purification. MS (ESI): mass calcd. for C₂₂H₂₇NO, 321.2; m/z found, 322.2 [M+H]⁺.

Step D: 2-(3-((1*R*,5*S*,6*S*)-3-Azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropan-1-ol. 2-(3-
10 ((1*R*,5*S*,6*S*)-3-Benzyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropan-1-ol (280 mg, 0.871 mmol) and dry Pd/C (150 mg, 10 wt%) were taken up in a mixture of THF:MeOH (5:1, 18 mL). The resultant mixture was stirred at room temperature for 5 hours under H₂ (15 psi). The suspension was filtered through a pad of Celite[®] and the pad washed with THF. The filtrate was concentrated under reduced pressure to afford the title product (200 mg, crude), which was used
15 in the next step without further purification.

Step E: (2*S*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(1-Hydroxy-2-methylpropan-2-yl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. T₃P[®] (825 mg, 50% in ethyl acetate, 1.30 mmol) was added to a solution of 2-(3-((1*R*,5*S*,6*S*)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropan-1-ol (200 mg, 0.865 mmol), (2*S*,4*S*)-6-oxo-7-oxa-5-
20 azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 163 mg, 0.952 mmol), and Et₃N (0.36 mL, 2.59 mmol) in DCM (10 mL). The mixture was stirred at room temperature for 3 hours before being quenched with H₂O and extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product, which was purified by RP-HPLC (22-52% (v/v) CH₃CN in H₂O with 0.05% ammonium hydroxide) to afford the title compound as a white solid (46.5 mg, 14% yield). MS
25 (ESI): mass calcd. for C₂₂H₂₈N₂O₄, 384.2; m/z found, 385.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 8.09 (s, 1H), 7.22 - 7.07 (m, 3H), 6.85 - 6.75 (m, 1H), 4.62 (t, *J* = 5.4 Hz, 1H), 4.43 - 4.32 (m, 2H), 3.77 - 3.66 (m, 2H), 3.59 - 3.52 (m, 1H), 3.41 - 3.36 (m, 3H), 2.95 - 2.84 (m, 1H), 2.44 - 2.29 (m, 4H), 1.97 - 1.79 (m, 2H), 1.65 - 1.57 (m, 1H), 1.19 (s, 6H).

30

Example 105: 2-Methyl-2-(3-((1*R*,5*S*,6*S*)-3-((2*S*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoic acid.



Step A: Methyl 2-(3-((1*R*,5*S*,6*S*)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropanoate.

- 5 Methyl 2-(3-((1*R*,5*S*,6*S*)-3-benzyl-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropanoate (from Example 104, Step B) (330 mg, 0.944 mmol) and dry Pd/C (100 mg, 10 wt%) were taken up in a mixture of THF:MeOH (10:1, 22 mL). The resultant mixture was stirred under H₂ (15 psi) at room temperature for 16 hours. The suspension was filtered through a pad of Celite[®] and the pad washed with THF. The filtrate was concentrated under reduced pressure to afford the
- 10 title product (250 mg, quant.), which was used in the next step without further purification. MS (ESI): mass calcd. for C₁₆H₂₁NO₂, 259.2; m/z found, 260.2 [M+H]⁺.

Step B: Methyl 2-methyl-2-(3-((1*R*,5*S*,6*S*)-3-((2*S*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoate. T₃P[®] (920 mg, 50% in ethyl


- acetate, 1.45 mmol) was added to a solution of methyl 2-(3-((1*R*,5*S*,6*S*)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)-2-methylpropanoate (250 mg, 0.964 mmol), (2*S*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 165 mg, 0.964 mmol), and Et₃N (0.40 mL, 2.90 mmol) in DCM (10 mL). The mixture was stirred at room temperature for 3
- 15 hours before being quenched with H₂O and extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the
- 20 crude product (300 mg, 76% yield), which was used in the next step without further purification. MS (ESI): mass calcd. for C₂₃H₂₈N₂O₅, 412.2; m/z found, 413.2 [M+H]⁺.

Step C: 2-Methyl-2-(3-((1*R*,5*S*,6*S*)-3-((2*S*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoic acid. LiOH·H₂O (131 mg, 3.12 mmol) was

- added to a solution of methyl 2-methyl-2-(3-((1*R*,5*S*,6*S*)-3-((2*S*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoate (280 mg, 0.679 mmol) in 1,4-dioxane (5 mL) and H₂O (5 mL). The resulting mixture was stirred at room
- 25 temperature for 16 hours before being quenched with H₂O and washed with ethyl acetate. The aqueous phase was separated, adjusted to pH 5-6 with 1 M HCl, and extracted with ethyl acetate.


The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product, which was purified by RP-HPLC (16-56% (v/v) CH₃CN in H₂O with 0.225% HCOOH). Further purification by SFC (DAICEL CHIRALPAK AS 250 mm x 30 mm, 10 μm; isocratic elution: 30-70% EtOH (containing 0.1% of 25% aq. NH₃) in supercritical CO₂ (v/v)) afforded the title compound as a white solid (26 mg, 20% yield). MS (ESI): mass calcd. for C₂₂H₂₆N₂O₅, 398.2; m/z found, 399.1 [M+H]⁺. ¹H NMR (400 MHz, DMSO-*d*₆) δ 12.27 (br s, 1H), 8.09 (s, 1H), 7.24 - 7.17 (m, 1H), 7.13 - 7.05 (m, 2H), 6.90 - 6.83 (m, 1H), 4.40 - 4.33 (m, 2H), 3.78 - 3.65 (m, 2H), 3.58 - 3.51 (m, 1H), 3.39 - 3.38 (m, 1H), 2.95 - 2.83 (m, 1H), 2.44 - 2.26 (m, 4H), 1.96 - 1.80 (m, 2H), 1.67 - 1.61 (m, 1H), 1.44 (s, 6H).

Example 106: (rac)-(2*S*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




The title compound was prepared in a manner analogous to Example 97 using 3-(trifluoromethyl)benzaldehyde instead of 2-methylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.2; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.51 - 7.46 (m, 1H), 7.45 - 7.40 (m, 1H), 7.39 - 7.35 (m, 1H), 7.34 - 7.28 (m, 1H), 6.36 - 6.27 (m, 1H), 4.37 (d, *J* = 6.0 Hz, 2H), 4.07 - 3.97 (m, 1H), 3.77 - 3.61 (m, 2H), 3.50 - 3.34 (m, 1H), 2.94 - 2.83 (m, 1H), 2.72 - 2.61 (m, 2H), 2.55 - 2.44 (m, 2H), 1.93 - 1.86 (m, 2H), 1.07 - 1.03 (m, 3H).

Example 107: (rac)-(2*S*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 97 using 4-(trifluoromethoxy)benzaldehyde instead of 2-methylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{20}H_{21}F_3N_2O_4$, 410.1; m/z found, 411.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.19 - 7.11 (m, 4H), 6.39 - 6.23 (m, 1H), 4.37 (d, $J = 5.84$ Hz, 2H), 4.07 - 3.94 (m, 1H), 3.76 - 3.60 (m, 2H), 3.50 - 3.31 (m, 1H), 2.94 - 2.84 (m, 1H), 2.72 - 2.61 (m, 2H), 2.55 - 2.43 (m, 2H), 1.87 - 1.78 (m, 2H), 1.05 (s, 3H).

Example 108: (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(4-Cyclopropylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




10

The title compound was prepared in a manner analogous to Example 97 using 4-cyclopropylbenzaldehyde instead of 2-methylbenzaldehyde in Step A. MS (ESI): mass calcd. for $C_{22}H_{26}N_2O_3$, 366.2; m/z found, 367.2 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.09 - 6.91 (m, 4H), 6.56 - 6.31 (m, 1H), 4.37 (d, $J = 6.02$ Hz, 2H), 4.04 - 3.89 (m, 1H), 3.76 - 3.57 (m, 2H), 3.48 - 3.29 (m, 1H), 2.95 - 2.79 (m, 1H), 2.75 - 2.61 (m, 2H), 2.56 - 2.29 (m, 2H), 1.89 - 1.84 (m, 1H), 1.82 - 1.76 (m, 2H), 1.03 (s, 3H), 0.98 - 0.89 (m, 2H), 0.72 - 0.61 (m, 2H).

15

Example 109: (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carboxylate.



20

Step A: tert-Butyl (1*R*,5*S*,6*S*)-6-(4-cyclopropyl-2-methylphenyl)-2,4-dioxo-3-azabicyclo[3.1.0]hexane-3-carboxylate. The title compound was prepared in a manner analogous to Example 78, Steps A and B using 4-cyclopropyl-2-methylbenzaldehyde (Intermediate 12)

instead of 3-*tert*-butylbenzaldehyde in Step A and *tert*-butyl 2,5-dioxo-2,5-dihydro-1*H*-pyrrole-1-carboxylate instead of *N*-benzylmaleimide in Step B. ¹H NMR (300 MHz, CDCl₃) δ 7.21 (d, *J* = 8.3 Hz, 1H), 6.95 (s, 1H), 6.84 (s, 1H), 2.87 (t, *J* = 3.1 Hz, 1H), 2.72 (d, *J* = 3.2 Hz, 2H), 2.40 (s, 3H), 1.90 – 1.82 (m, 1H), 1.57 (s, 9H), 0.96 – 0.90 (m, 2H), 0.68 – 0.61 (m, 2H).

5 Step B: (1*R*,5*S*,6*s*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione.


tert-Butyl (1*R*,5*S*,6*s*)-6-(4-cyclopropyl-2-methylphenyl)-2,4-dioxo-3-azabicyclo[3.1.0]hexane-3-carboxylate (560 mg, 1.64 mmol) was taken up in DCM (7 mL) and cooled to 0 °C. To this was added TFA (1.5 mL, 19.7 mmol) and the mixture was stirred at rt for 1 h before being concentrated under reduced pressure. The crude product was purified by FCC (0-65% EtOAc in heptane) to yield the title compound as a white solid (209 mg, 53% yield). ¹H NMR (300 MHz, CDCl₃) δ 7.51 (br s, 1H), 6.91 (s, 1H), 6.85 (s, 2H), 2.90 (t, *J* = 3.0 Hz, 1H), 2.71 (d, *J* = 1.5 Hz, 2H), 2.40 (s, 3H), 1.94 – 1.77 (m, 1H), 0.99 – 0.88 (m, 2H), 0.66 (d, *J* = 5.0 Hz, 2H).

Step C: (1*R*,5*S*,6*s*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane. (1*R*,5*S*,6*s*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-2,4-dione (209 mg, 0.866 mmol) was taken up in anhydrous THF (5 mL). NaBH₄ (72.1 mg, 1.91 mmol) was added and this was stirred at rt for 15 min. BF₃•OEt₂ (0.29 mL, 2.34 mmol) was added dropwise and the mixture was heated at 50 °C for 16 h. Additional NaBH₄ (32.7 mg, 0.866 mmol) was added and the mixture was stirred at rt for 15 min. Then, BF₃•OEt₂ (0.11 mL, 0.866 mmol) was added and the mixture was stirred at 50 °C for 3 h. The reaction was cooled to 0 °C and water was added dropwise. Finally, MeOH (15 mL) was added and the mixture was stirred at 100 °C for 16 h. The mixture was concentrated under reduced pressure and purified by FCC (0-80% DCM/MeOH (9:1) in DCM) to yield the title compound as a white solid (185 mg, quant.).

Step D: (2*s*,4*s*)-2-((1*R*,5*S*,6*s*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. (1*R*,5*S*,6*s*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane (185 mg, 0.866 mmol) and (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 179 mg, 1.04 mmol) were taken up in DMF (5 mL). To this was added T₃P® (0.67 mL, 50% in EtOAc, 1.13 mmol) and DIPEA (0.45 mL, 2.60 mmol). The mixture was stirred at rt for 1 h. Sat. aq. NaHCO₃ was added and the mixture was extracted with EtOAc. The organic layers were dried over MgSO₄, filtered, and concentrated under reduced pressure. The crude product was purified by FCC (0-30% DCM/MeOH (20:1) in DCM) to yield the title compound as a white foam (93 mg, 94% yield). MS (ESI): mass calcd. for C₂₂H₂₆N₂O₃,


366.2; m/z found, 367.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 6.88 (s, 1H), 6.86 – 6.79 (m, 2H), 6.23 (s, 1H), 4.36 (s, 2H), 3.98 (d, $J = 12.2$ Hz, 1H), 3.70 – 3.62 (m, 2H), 3.57 (dd, $J = 12.2$, 4.5 Hz, 1H), 2.92 – 2.84 (m, 1H), 2.71 – 2.58 (m, 2H), 2.53 – 2.44 (m, 2H), 2.32 (s, 3H), 1.92 – 1.87 (m, 1H), 1.86 – 1.78 (m, 2H), 1.58 (t, $J = 3.8$ Hz, 1H), 0.96 – 0.87 (m, 2H), 0.67 – 0.61 (m, 2H).

Example 110: (2*s*,4*s*)-2-(((1*R*,5*S*,6*S*)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- 10 The title compound was prepared in a manner analogous to Example 109 using 3-chloro-4-methylbenzaldehyde instead of 4-cyclopropyl-2-methylbenzaldehyde (Intermediate 12) in Step A. MS (ESI): mass calcd. for $C_{19}H_{21}ClN_2O_3$, 360.1; m/z found, 361.1 $[M+H]^+$. 1H NMR (400 MHz, $CDCl_3$) δ 7.11 (d, $J = 7.9$ Hz, 1H), 6.99 (d, $J = 1.7$ Hz, 1H), 6.82 (dd, $J = 7.8$, 1.8 Hz, 1H), 6.10 (s, 1H), 4.36 (s, 2H), 3.97 (d, $J = 12.3$ Hz, 1H), 3.69 – 3.61 (m, 2H), 3.55 (dd, $J = 12.3$, 3.5
- 15 Hz, 1H), 2.93 – 2.82 (m, 1H), 2.69 – 2.58 (m, 2H), 2.55 – 2.43 (m, 2H), 2.32 (s, 3H), 1.92 – 1.83 (m, 2H), 1.59 (t, $J = 3.5$ Hz, 1H).

Example 111: (2*s*,4*s*)-2-(((1*R*,5*S*,6*S*)-6-(3-Ethyl-4-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.




20

The title compound was prepared in a manner analogous to Example 97 using 3-ethyl-4-fluorobenzaldehyde (Intermediate 11) instead of 2-methylbenzaldehyde in Step A and 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for $C_{20}H_{23}FN_2O_3$, 358.2; m/z found, 359.1 $[M+H]^+$. 1H NMR

(400 MHz, CDCl₃) δ 6.95 - 6.84 (m, 2H), 6.82 - 6.76 (m, 1H), 6.08 (br s, 1H), 4.37 (s, 2H), 3.98 (d, J = 12.2 Hz, 1H), 3.69 - 3.63 (m, 2H), 3.59 - 3.52 (m, 1H), 2.94 - 2.84 (m, 1H), 2.69 - 2.59 (m, 4H), 2.56 - 2.45 (m, 2H), 1.90 - 1.83 (m, 2H), 1.62 - 1.59 (m, 1H), 1.22 (t, J = 7.6 Hz, 3H).


- 5 Example 112: (rac)-(2*S*,4*S*)-2-((1*R*,5*S*,6*R*)-1-Methyl-6-(4-methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- The title compound was prepared in a manner analogous to Example 97 using 4-methyl-3-(trifluoromethyl)benzaldehyde instead of 2-methylbenzaldehyde in Step A. MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.38 - 7.32 (m, 1H), 7.24 - 7.13 (m, 2H), 6.24 - 6.13 (m, 1H), 4.37 (d, J = 6.0 Hz, 2H), 4.00 (dd, J = 12.0, 20.0 Hz, 1H), 3.76 - 3.59 (m, 2H), 3.49 - 3.33 (m, 1H), 2.94 - 2.83 (m, 1H), 2.72 - 2.59 (m, 2H), 2.56 - 2.41 (m, 5H), 1.90 - 1.79 (m, 2H), 1.09 - 0.99 (m, 3H).

15


- Example 113: (2*S*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(2-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



- The title compound was prepared in a manner analogous to Example 97 using 2-methyl-3-(trifluoromethyl)benzaldehyde instead of 2-methylbenzaldehyde in Step A and 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.2; m/z found, 395.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.54 - 7.49 (m, 1H), 7.25 - 7.19 (m, 2H), 6.06 (br s, 1H), 4.38 (s, 2H), 4.07 - 4.02 (m, 1H), 3.76 - 3.68 (m, 2H), 3.65 - 3.59 (m, 1H), 2.96 - 2.87 (m, 1H), 2.70 - 2.60 (m, 2H), 2.56 - 2.47 (m, 5H), 1.99 - 1.88 (m, 2H), 1.71 - 1.67 (m, 1H).

25

Example 114: (rac)-(2*s*,4*s*)-2-((1*R*,5*S*,6*R*)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



5

Step A: *N*-(4-Bromo-3-(trifluoromethoxy)benzylidene)-4-methylbenzenesulfonohydrazide. 4-Methylbenzenesulfonohydrazide (1.7 g, 9.29 mmol) was added to a solution of 4-bromo-3-(trifluoromethoxy)benzaldehyde (2.5 g, 9.29 mmol) in MeOH (50 mL). The reaction mixture was stirred for 16 hours at room temperature and then cooled to -10 °C. The precipitate was

10 collected by filtration and washed with cold MeOH before drying under reduced pressure to afford the title compound as a white solid (3.2 g, 78% yield), which was carried on without further purification. ¹H NMR (400 MHz, DMSO-*d*₆) δ 11.75 (br s, 1H), 7.92 (s, 1H), 7.86 - 7.81 (m, 1H), 7.79 - 7.72 (m, 2H), 7.66 (s, 1H), 7.57 - 7.50 (m, 1H), 7.43 - 7.36 (m, 2H), 2.36 (s, 3H).

Step B: (rac)-(1*R*,5*S*,6*R*)-3-Benzyl-6-(4-bromo-3-(trifluoromethoxy)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane. Benzyltriethylammonium chloride (156 mg, 0.685 mmol) was added to a mixture of *N*-(4-bromo-3-(trifluoromethoxy)benzylidene)-4-methylbenzenesulfonohydrazide (1.0 g, 2.30 mmol) in aq. NaOH (15%, 8 mL) and toluene (8 mL). The reaction mixture was stirred vigorously at 80 °C for 1 hour before cooling to room temperature. The toluene layer was separated, washed with sat. aq. NH₄Cl and brine, dried over

20 anhydrous Na₂SO₄, and filtered to obtain 1-bromo-4-(diazomethyl)-2-(trifluoromethoxy)benzene (8 mL in toluene, crude). This was added dropwise over 30 minutes to a -10 °C mixture of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9, 400 mg, 2.31 mmol) and ZnI₂ (737 mg, 2.31 mmol) in DCM (30 mL). The reaction mixture was stirred room temperature for 16 hours before being quenched with water and extracted with DCM. The combined organic

25 extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product, which was purified by FCC (0-13% EtOAc in ether) to afford the title

compound as a yellow oil (187 mg, 16% yield). MS (ESI): mass calcd. for C₂₀H₁₉BrF₃NO, 425.1; m/z found, 425.9 [M+H]⁺.

Step C: (rac)-(1 *R,5 *S,6 *R)-3-Benzyl-1-methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane. (rac)-(1 *R,5 *S,6 *R)-3-Benzyl-6-(4-bromo-3-

- 5 (trifluoromethoxy)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane (167 mg, 0.392 mmol), 2,4,6-trimethyl-1,3,5,2,4,6-trioxatriborinane (148 mg, 1.18 mmol), and Cs₂CO₃ (383 mg, 1.18 mmol) were taken up in H₂O (2 mL) and 1,4-dioxane (8 mL). The mixture was sparged with N₂ for 5 minutes and then treated with Pd(dppf)Cl₂•CH₂Cl₂ (32 mg, 0.039 mmol). The resultant mixture was sparged with N₂ for 5 minutes and then stirred while heating under microwave irradiation at
10 120 °C for 1 hour before cooling to room temperature. The reaction mixture was concentrated under reduced pressure and purified by FCC (0-13% EtOAc in ether) to afford the title compound as a yellow oil (120 mg, 85% yield). MS (ESI): mass calcd. for C₂₁H₂₂F₃NO, 361.2; m/z found, 362.1 [M+H]⁺.

Step D: (rac)-(1 *R,5 *S,6 *R)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-


- 15 azabicyclo[3.1.0]hexane. (rac)-(1 *R,5 *S,6 *R)-3-Benzyl-1-methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane (100 mg, 0.277 mmol) and dry Pd/C (100 mg, 10 wt.%) were taken up in MeOH (2 mL) and THF (10 mL). The resultant mixture was stirred under H₂ (15 psi) at room temperature for 1 hour. The suspension was filtered through a pad of Celite[®] and the pad washed with MeOH. The filtrate was concentrated under reduced
20 pressure to afford the title product as a yellow oil (90 mg, quant.), which was used in the next step without further purification. MS (ESI): mass calcd. for C₁₄H₁₆F₃NO, 271.1; m/z found, 272.1 [M+H]⁺.

Step E: (rac)-(2s,4 *S)-2-((1 *R,5 *S,6 *R)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. T₃P[®] (0.30 mL, 50% in

- 25 ethyl acetate, 0.50 mmol) was added to a solution of (rac)-(1 *R,5 *S,6 *R)-1-methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane (90 mg, 0.33 mmol), (2s,4s)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 56 mg, 0.33 mmol), and DIPEA (0.29 mL, 1.6 mmol) in DCM (10 mL). The reaction was stirred at room temperature for 16 hours before being quenched with H₂O and extracted with DCM. The combined organic extracts
30 were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to give the crude product, which was purified by RP-HPLC (40-70% (v/v) CH₃CN in H₂O with 0.05% NH₃


+ 10 mM NH_4HCO_3) to afford the title compound as a pale solid (23 mg, 16% yield). MS (ESI): mass calcd. for $\text{C}_{21}\text{H}_{23}\text{F}_3\text{N}_2\text{O}_4$, 424.2; m/z found, 425.1 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CDCl_3) δ 7.17 (d, $J = 8.0$ Hz, 1H), 6.99 - 6.92 (m, 2H), 6.00 - 5.91 (m, 1H), 4.36 (d, $J = 5.6$ Hz, 2H), 4.06 - 3.94 (m, 1H), 3.75 - 3.57 (m, 2H), 3.48 - 3.32 (m, 1H), 2.94 - 2.83 (m, 1H), 2.69 - 2.57 (m, 2H),
 5 2.56 - 2.45 (m, 2H), 2.29 (s, 3H), 1.83 - 1.79 (m, 2H), 1.05 (s, 3H).

Example 115: (2*s*,4*s*)-2-((1*R*,5*S*,6*S*)-6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



10 The title compound was prepared in a manner analogous to Example 114 using 1-benzyl-2,5-dihydro-1*H*-pyrrole instead of 1-benzyl-3-methyl-2,5-dihydro-1*H*-pyrrole (Intermediate 9) in Step B. MS (ESI): mass calcd. for $\text{C}_{20}\text{H}_{21}\text{F}_3\text{N}_2\text{O}_4$, 410.1; m/z found, 411.2 $[\text{M}+\text{H}]^+$. ^1H NMR (400 MHz, CDCl_3) δ 7.18 - 7.10 (m, 1H), 6.90 - 6.80 (m, 2H), 6.15 (br s, 1H), 4.40 - 4.32 (m, 2H), 4.03 - 3.94 (m, 1H), 3.71 - 3.62 (m, 2H), 3.60 - 3.52 (m, 1H), 2.94 - 2.82 (m, 1H), 2.70 -
 15 2.58 (m, 2H), 2.55 - 2.43 (m, 2H), 2.30 - 2.23 (m, 3H), 1.93 - 1.84 (m, 2H), 1.63 - 1.61 (m, 1H).

Example 116: (2*s*,4*s*)-2-((1*R*,5*S*,6*R*)-6-(6-(*tert*-Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



20 Step A: *tert*-Butyl (1*R*,5*S*,6*s*)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. TMEDA (1.42 mL, 9.47 mmol) was added to a solution of CrCl_2 (1.16 g, 9.44 mmol) in THF (30 mL). The resultant blue mixture was stirred at room temperature for 15 mins. *tert*-Butyl 2,5-dihydro-1*H*-pyrrole-1-carboxylate (200 mg, 1.18 mmol) in THF (10 mL) was added followed by a solution of 2-(dichloromethyl)-4,4,5,5-tetramethyl-

1,3,2-dioxaborolane (500 mg, 2.37 mmol) and LiI (633 mg, 4.73 mmol) in THF (15 mL). The mixture was stirred at room temperature for 16 hours before being quenched with water and extracted with ethyl acetate. The combined organic layers were dried over Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product, which was purified by FCC (0-5% EtOAc in ether) to give the product as colorless oil (300 mg, 82% yield). ¹H NMR (400 MHz, CDCl₃) δ 3.65 - 3.49 (m, 2H), 3.39 - 3.28 (m, 2H), 1.72 - 1.63 (m, 2H), 1.45 - 1.39 (m, 9H), 1.22 (s, 12H), 0.15 - -0.29 (m, 1H).

Step B: *tert*-Butyl (1*R*,5*S*,6*r*)-6-(6-(*tert*-butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate. *tert*-Butyl (1*R*,5*S*,6*s*)-6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3-


azabicyclo[3.1.0]hexane-3-carboxylate (200 mg, 0.647 mmol), 2-bromo-6-(*tert*-butyl)pyridine (166 mg, 0.775 mmol), and Cs₂CO₃ (632 mg, 1.94 mmol) were taken up in 2-methyl-2-butanol (4 mL) and H₂O (1 mL). The resultant mixture was sparged with N₂ for 5 minutes and then treated with CataCXium A Pd G₃ (24 mg, 0.033 mmol). The mixture was sparged with N₂ for another 5 minutes and then stirred at 90 °C for 1 hour under microwave irradiation before cooling to room temperature. The reaction mixture was quenched with water and extracted with DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product, which was purified by FCC (0-13% EtOAc in ether) to afford the title compound as a yellow oil (300 mg, quant.). MS (ESI): mass calcd. for C₁₉H₂₈N₂O₂, 316.2; m/z found, 317.2 [M+H]⁺.

Step C: (1*R*,5*S*,6*r*)-6-(6-(*tert*-Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane. *tert*-Butyl (1*R*,5*S*,6*r*)-6-(6-(*tert*-butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carboxylate (300 mg, 0.948 mmol) and TFA (3 mL, 17.7 mmol) in DCM (6 mL) was stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to afford the title compound as a yellow oil (350 mg, crude), which was used in the next step without further purification. MS (ESI): mass calcd. for C₁₄H₂₀N₂, 216.2; m/z found, 217.2 [M+H]⁺.

Step D: (2*s*,4*S*)-2-((1*R*,5*S*,6*R*)-6-(6-(*tert*-Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one. T₃P[®] (0.83 mL, 50% in ethyl acetate, 1.40 mmol) was added to a solution of 6-(6-(*tert*-butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane (350 mg, crude, 1.62 mmol), (2*s*,4*s*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carboxylic acid (Intermediate 3, 160 mg, 0.935 mmol), and DIPEA (0.83 mL, 4.70 mmol) in DCM (10 mL). The reaction was stirred at room temperature for 16 hours before being quenched with H₂O and extracted with

DCM. The combined organic extracts were dried over anhydrous Na₂SO₄, filtered, and concentrated under reduced pressure to afford the crude product, which was purified by RP-HPLC (38-68% (v/v) CH₃CN in H₂O with 0.05% NH₃ + 10 mM NH₄HCO₃) to afford the title compound as a white solid (45 mg, 13% yield). MS (ESI): mass calcd. for C₂₁H₂₇N₃O₃, 369.2; m/z found, 370.1 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.50 - 7.44 (m, 1H), 7.09 (d, *J* = 7.7 Hz, 1H), 6.93 (d, *J* = 7.5 Hz, 1H), 5.94 (br s, 1H), 4.37 (s, 2H), 3.97 (d, *J* = 12.3 Hz, 1H), 3.71 - 3.63 (m, 2H), 3.58 (dd, *J* = 4.3, 12.3 Hz, 1H), 2.95 - 2.86 (m, 1H), 2.68 - 2.60 (m, 2H), 2.57 - 2.46 (m, 2H), 2.28 - 2.18 (m, 2H), 1.73 (t, *J* = 3.2 Hz, 1H), 1.30 (s, 9H).


10 Example 117: (2*S*,4*R*)-2-((1*S*,6*R*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 58 (Stationary phase: OJ-H, 2 x 25 cm, Mobile phase: 15% EtOH, 85% CO₂). MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.2; m/z found, 395.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.59 - 7.51 (m, 2H), 7.37 - 7.29 (m, 2H), 6.03 (d, *J* = 19.4 Hz, 1H), 4.38 (d, *J* = 10.1 Hz, 2H), 4.01 - 3.90 (m, 1H), 3.87 - 3.66 (m, 1H), 3.59 - 3.43 (m, 1H), 3.40 - 3.21 (m, 1H), 3.06 - 2.91 (m, 1H), 2.72 - 2.60 (m, 2H), 2.54 - 2.44 (m, 2H), 2.23 - 2.07 (m, 2H), 1.58 - 1.42 (m, 1H), 1.09 (dt, *J* = 9.0, 5.3 Hz, 1H), 0.87 (q, *J* = 5.3 Hz, 1H).


20

Example 118: (2*S*,4*S*)-2-((1*R*,6*S*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 58 (Stationary phase: OJ-H, 2 x 25 cm, Mobile phase: 15% EtOH, 85% CO₂). MS (ESI): mass calcd. for C₂₀H₂₁F₃N₂O₃, 394.2; m/z found, 395.2 [M+H]⁺. ¹H NMR (500 MHz, CDCl₃) δ 7.55 (d, *J* = 8.1 Hz, 2H), 7.36 – 7.30 (m, 2H), 6.30 (d, *J* = 14.6 Hz, 1H), 4.38 (d, *J* = 10.0 Hz, 2H), 4.00 – 3.91 (m, 1H), 3.87 – 3.66 (m, 1H), 3.58 – 3.42 (m, 1H), 3.41 – 3.23 (m, 1H), 3.06 – 2.91 (m, 1H), 2.73 – 2.63 (m, 2H), 2.52 – 2.41 (m, 2H), 2.22 – 2.07 (m, 2H), 1.58 – 1.41 (m, 1H), 1.12 – 1.04 (m, 1H), 0.86 (q, *J* = 5.3 Hz, 1H).


10 Example 119: (2*r*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 52 (Stationary phase: CHIRALPAK AD-H, 5 μm 250 x 21.2 mm, Mobile phase: 22% EtOH, 78% CO₂). MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.2 [M+H]⁺. ¹H NMR (400 MHz, CDCl₃) δ 7.34 – 7.28 (m, 1H), 7.20 – 7.11 (m, 1H), 7.10 – 7.02 (m, 2H), 5.95 (d, *J* = 12.1 Hz, 1H), 3.94 (d, *J* = 3.8 Hz, 1H), 3.85 – 3.65 (m, 1H), 3.58 – 3.21 (m, 2H), 3.00 (dt, *J* = 17.7, 8.4 Hz, 1H), 2.60 – 2.47 (m, 2H), 2.45 – 2.32 (m, 4H), 2.28 – 2.17 (m, 2H), 2.17 – 2.05 (m, 2H), 1.54 – 1.39 (m, 1H), 1.06 (dt, *J* = 9.1, 5.7 Hz, 1H), 0.84 (q, *J* = 5.3 Hz, 1H).


20

Example 120: (2*r*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 52 (Stationary phase: CHIRALPAK AD-H, 5 μ m 250 x 21.2 mm, Mobile phase: 22% EtOH, 78% CO₂). MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.34 – 7.28 (m, 1H), 7.18 – 7.13 (m, 1H), 7.10 – 7.02 (m, 2H), 5.95 (d, *J* = 11.9 Hz, 1H), 3.94 (d, *J* = 3.7 Hz, 1H), 3.85 – 3.65 (m, 1H), 3.58 – 3.20 (m, 2H), 3.00 (dt, *J* = 17.8, 8.4 Hz, 1H), 2.60 – 2.47 (m, 2H), 2.44 – 2.32 (m, 4H), 2.26 – 2.17 (m, 2H), 2.17 – 2.04 (m, 2H), 1.53 – 1.38 (m, 1H), 1.06 (dt, *J* = 9.1, 5.6 Hz, 1H), 0.83 (q, *J* = 5.3 Hz, 1H).


- 10 Example 121: (2*r*,4*S)-2-((1*R,6*S)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.



The title compound was prepared by chiral supercritical fluid chromatography of Example 55 (Stationary phase: CHIRALPAK AD-H, 5 μ m 250 x 30 mm, Mobile phase: 50% MeOH, 50% CO₂). MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.26 – 7.21 (m, 2H), 7.16 – 7.10 (m, 2H), 6.17 – 6.05 (m, 1H), 4.00 – 3.86 (m, 1H), 3.86 – 3.65 (m, 1H), 3.58 – 3.39 (m, 1H), 3.40 – 3.19 (m, 1H), 3.00 (dt, *J* = 18.3, 8.5 Hz, 1H), 2.60 – 2.48 (m, 2H), 2.44 – 2.31 (m, 4H), 2.27 – 2.17 (m, 2H), 2.11 (tt, *J* = 7.6, 4.7 Hz, 2H), 1.50 – 1.36 (m, 1H), 1.07 – 0.99 (m, 1H), 0.81 (td, *J* = 5.4, 3.2 Hz, 1H).


20

- Example 122: (2*r*,4*R)-2-((1*S,6*R)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one.




The title compound was prepared by chiral supercritical fluid chromatography of Example 55 (Stationary phase: CHIRALPAK AD-H, 5 μ m 250 x 30 mm, Mobile phase: 50% MeOH, 50% CO₂). MS (ESI): mass calcd. for C₂₁H₂₃F₃N₂O₃, 408.2; m/z found, 409.2 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.26 – 7.20 (m, 2H), 7.17 – 7.10 (m, 2H), 6.04 (d, *J* = 11.0 Hz, 1H), 4.01 – 3.86 (m, 1H), 3.85 – 3.64 (m, 1H), 3.57 – 3.40 (m, 1H), 3.40 – 3.19 (m, 1H), 3.00 (dt, *J* = 18.3, 8.4 Hz, 1H), 2.61 – 2.47 (m, 2H), 2.44 – 2.30 (m, 4H), 2.27 – 2.19 (m, 2H), 2.11 (tt, *J* = 8.3, 5.4 Hz, 2H), 1.50 – 1.36 (m, 1H), 1.03 (dt, *J* = 9.2, 4.8 Hz, 1H), 0.81 (td, *J* = 5.4, 3.2 Hz, 1H).

- 10 Example 123: (rac)-(2*s*,4*s*)-2-(7-Chloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 1 using 7-chloro-6-phenyl-3-azabicyclo[4.1.0]heptane instead of 1-(*p*-tolyl)-3-azabicyclo[3.1.0]hexane. MS (ESI): mass calcd. for C₁₉H₂₁ClN₂O₃, 360.1; m/z found, 361.1 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.41 – 7.32 (m, 2H), 7.32 – 7.21 (m, 3H), 5.92 (d, *J* = 15.4 Hz, 1H), 4.38 (d, *J* = 20.2 Hz, 2H), 4.17 – 3.77 (m, 2H), 3.75 – 3.12 (m, 2H), 3.10 – 2.86 (m, 2H), 2.72 – 2.60 (m, 2H), 2.58 – 2.41 (m, 2H), 2.23 – 2.06 (m, 2H), 1.93 – 1.81 (m, 1H).

- 20 Example 124: (rac)-(2*s*,4*s*)-2-(7,7-Dichloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.



The title compound was prepared in a manner analogous to Example 1 using 7,7-dichloro-6-phenyl-3-azabicyclo[4.1.0]heptane instead of 1-(*p*-tolyl)-3-azabicyclo[3.1.0]hexane. MS (ESI): mass calcd. for C₁₉H₂₀Cl₂N₂O₃, 394.1; *m/z* found, 395.0 [M+H]⁺. ¹H NMR (400 MHz, Chloroform-*d*) δ 7.43 – 7.33 (m, 2H), 7.34 – 7.28 (m, 1H), 7.26 – 7.21 (m, 2H), 5.95 (d, *J* = 16.4 Hz, 1H), 4.38 (d, *J* = 25.5 Hz, 2H), 4.27 – 3.39 (m, 3H), 3.15 – 3.03 (m, 1H), 2.95 – 2.50 (m, 4H), 2.50 – 2.31 (m, 2H), 2.25 – 2.08 (m, 2H).

10

BIOLOGICAL DATA

The assay used to measure the *in vitro* activity of MGL is adapted from the assay used for another serine hydrolase (FAAH) described in Wilson et al., 2003 (A high-throughput-compatible assay for determining the activity of fatty acid amide hydrolase. Wilson SJ, Lovenberg TW, Barbier AJ. Anal Biochem. 2003 Jul 15;318(2):270-5.). The assay consists of combining endogenously expressed MGL from HeLa cells with test compounds, adding [glycerol-1,3-³H]-oleoyl glycerol, incubating for one hour, and then measuring the amount of cleaved [1,3-³H]-glycerol that passes through an activated carbon filter. The amount of cleaved, tritiated glycerol passing through the carbon filter is proportional to the activity of the MGL enzyme in a particular well/test condition.

20

Standard conditions for this assay combine 300 nM [Glycerol-1,3-³H]-oleoyl glycerol with human MGL from HeLa cells and test compounds for one hour, after which the reaction is filtered through activated carbon and tritium is measured in the flow through. The test compound concentration in screening mode is 10 μM, while the highest compound concentration in IC₅₀ assays is determined empirically. MGL is the predominant hydrolase in HeLa cells/cell homogenates.

25

Table 3.

Ex #	Compound Name	MGL IC ₅₀ (nM)
1	(rac)-(2s,4s)-2-(1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.9
2	(2s,4*R)-2-((1*S,5*R)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	17
3	(2s,4*S)-2-((1*R,5*S)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	8.5
4	(rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	49
5	(rac)-(2s,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.4
6	(rac)-(2s,4s)-2-(1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	6.9
7	(2s,4*S)-2-((1*R,5*S)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.0
8	(2s,4*R)-2-((1*S,5*R)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	11
9	(rac)-(2s,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.2
10	(2s,4*S)-2-((1*R,5*S)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.3
11	(2s,4*R)-2-((1*S,5*R)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.3
12	(rac)-(2r,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	14
13	(rac)-(2r,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	9.2
14	(2r,4*S)-2-((1*R,5*S)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	23
15	(2r,4*R)-2-((1*S,5*R)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	12
16	(rac)-(2s,4s)-2-(1-(3-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.6
17	(rac)-(2s,4s)-2-(1-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.8
18	(rac)-(2s,4s)-2-(1-(4-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	4.4

Ex #	Compound Name	MGL IC ₅₀ (nM)
19	(rac)-(2s,4s)-2-(1-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	11
20	(rac)-(2s,4s)-2-(1-(o-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	6.5
21	(rac)-(2s,4s)-2-(1-(m-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	14
22	(rac)-(2s,4s)-2-(1-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	16
23	(rac)-(2s,4s)-2-(1-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	14
24	(rac)-(2s,4s)-2-(1-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	15
25	(rac)-(2s,4s)-2-(1-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.6
26	(rac)-(2s,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.4
27	(rac)-(2r,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	9.5
28	(rac)-(2s,4s)-2-(1-(4-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.7
29	(rac)-(2s,4s)-2-(1-(3-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.5
30	(rac)-(2s,4s)-2-(1-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.9
31	(rac)-(2s,4s)-2-(1-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.1
32	(rac)-(2s,4s)-2-(1-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.35
33	(rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.5
34	(rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.1
35	(rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	6.5
36	(rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.2

Ex #	Compound Name	MGL IC ₅₀ (nM)
37	(rac)-(2s,4s)-2-(1-(3-Fluoro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	10
38	(2s,4S)-2-((1R,5S,6S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	21
39	(rac)-(2s,4s)-2-(6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	20
40	(2s,4S)-2-((1R,6S)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	136
41	(2s,4R)-2-((1S,6R)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	9.6
42	(rac)-(2s,4s)-2-(7,7-Difluoro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	203
43	(rac)-(2s,4s)-2-(6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	8.2
44	(2s,4*R)-2-((1*S,6*R)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.8
45	(2s,4*S)-2-((1*R,6*S)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	32
46	(rac)-(2s,4s)-2-(6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.7
47	(2s,4*R)-2-((1*S,6*R)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	21
48	(2s,4*S)-2-((1*R,6*S)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.3
49	(rac)-(2s,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.6
50	(2s,4*R)-2-((1*S,6*R)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	4.2
51	(2s,4*S)-2-((1*R,6*S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.52
52	(rac)-(2r,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	4.8
53	(rac)-(2s,4s)-2-(6-(o-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	51
54	(rac)-(2s,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.5

Ex #	Compound Name	MGL IC ₅₀ (nM)
55	(rac)-(2r,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	10
56	(rac)-(2s,4s)-2-(6-(p-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	7.7
57	(rac)-(2s,4s)-2-(6-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.9
58	(rac)-(2s,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.4
59	(rac)-(2r,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	18
60	(rac)-(2s,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.0072
61	(rac)-(2r,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	0.25
62	(rac)-(2s,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.019
63	(rac)-(2r,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	0.41
64	(rac)-(2s,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.65
65	(rac)-(2r,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	4.0
66	(rac)-(2s,4s)-2-(6-(4-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.69
67	(rac)-(2s,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.075
68	(rac)-(2r,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	5.6
69	(rac)-(2s,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.034
70	(rac)-(2r,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	0.52
71	(rac)-(2s,4s)-2-(6-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.024
72	(rac)-(2s,4s)-2-(6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.1

Ex #	Compound Name	MGL IC ₅₀ (nM)
73	(rac)-(2s,4s)-2-(6-(3-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.25
74	(rac)-(2s,4s)-2-(6-(4-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.21
75	(rac)-(2s,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.34
76	(rac)-(2r,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	2.6
77	(rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	241
78	(2s,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.99
79	(2r,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	7.2
80	(2s,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	33
81	(2r,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	206
82	(2s,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.69
83	(2r,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	2.9
84	(2s,4S)-2-((1R,5S,6S)-6-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.5
85	(2s,4S)-2-((1R,5S,6S)-6-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	4.4
86	(2s,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	25
87	(2r,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	131
88	(2s,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	29
89	(2r,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	178
90	(2s,4S)-2-((1R,5S,6S)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	2.8


Ex #	Compound Name	MGL IC ₅₀ (nM)
91	(2 <i>r</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	20
92	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(2,3-Dihydro-1 <i>H</i> -inden-5-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	4.7
93	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-6-(3-(<i>tert</i> -Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.76
94	(<i>rac</i>)-(2 <i>s</i> ,4 <i>s</i>)-2-(1-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	3.5
95	(2 <i>r</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i>)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	7.5
96	(2 <i>r</i> ,4* <i>R</i>)-2-((1* <i>S</i> ,5* <i>R</i>)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	8.5
97	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-1-Methyl-6-(<i>o</i> -tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	180
98	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(<i>o</i> -Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	150
99	(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-6-(3-(<i>tert</i> -Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.64
100	(2 <i>s</i> ,4* <i>R</i>)-2-((1* <i>S</i> ,5* <i>R</i> ,6* <i>S</i>)-6-(3-(<i>tert</i> -Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	8.3
101	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Isobutylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.5
102	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-6-(3,4-Dimethylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	23
103	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-(<i>tert</i> -Butyl)phenyl-5- <i>D</i>)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	0.93
104	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-(1-Hydroxy-2-methylpropan-2-yl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	19
105	2-Methyl-2-(3-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-3-((2 <i>s</i> ,4 <i>S</i>)-6-oxo-7-oxa-5-azaspiro[3.4]octan-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoic acid;	300
106	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-1-Methyl-6-(3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	28
107	(<i>rac</i>)-(2 <i>s</i> ,4* <i>S</i>)-2-((1* <i>R</i> ,5* <i>S</i> ,6* <i>R</i>)-1-Methyl-6-(4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	73

Ex #	Compound Name	MGL IC ₅₀ (nM)
108	(rac)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-6-(4-Cyclopropylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	38
109	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.6
110	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	17
111	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(3-Ethyl-4-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	11
112	(rac)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(4-methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	6.0
113	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(2-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	78
114	(rac)-(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,5 <i>*S</i> ,6 <i>*R</i>)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	4.1
115	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>S</i>)-6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.2
116	(2 <i>s</i> ,4 <i>S</i>)-2-((1 <i>R</i> ,5 <i>S</i> ,6 <i>R</i>)-6-(6-(<i>tert</i> -Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	5.2
117	(2 <i>s</i> ,4 <i>*R</i>)-2-((1 <i>*S</i> ,6 <i>*R</i>)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	22
118	(2 <i>s</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,6 <i>*S</i>)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;	1.6
119	(2 <i>r</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,6 <i>*S</i>)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	5.2
120	(2 <i>r</i> ,4 <i>*R</i>)-2-((1 <i>*S</i> ,6 <i>*R</i>)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	23
121	(2 <i>r</i> ,4 <i>*S</i>)-2-((1 <i>*R</i> ,6 <i>*S</i>)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	42
122	(2 <i>r</i> ,4 <i>*R</i>)-2-((1 <i>*S</i> ,6 <i>*R</i>)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;	12
123	(rac)-(2 <i>s</i> ,4 <i>s</i>)-2-(7-Chloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and	200
124	(rac)-(2 <i>s</i> ,4 <i>s</i>)-2-(7,7-Dichloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one.	32

NT means not tested.

The invention also provides the following numbered embodiments:



1. A compound of Formula (I),



wherein

X is CH₂ or O;

Y is selected from the group consisting of:



10 R¹ is H;

R^{2a} and R^{2b} are each independently H;

R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁₋₆alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH, C₁₋₆alkyl substituted with CO₂H, C₁₋₆haloalkyl, OC₁₋₆haloalkyl, C₃₋₆cycloalkyl, O-phenyl, and C₃₋₆cycloalkyl substituted with CH₃;




















R^a and R^b are each independently selected from the group consisting of: H and halo; and

R^c is H or CH₃;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.


20 2. A compound of embodiment 1, wherein X is CH₂.

3. A compound of embodiment 1, wherein X is O.

4. A compound of any of embodiments 1-3, wherein Y is , , or .
5. A compound of any of embodiments 1-3, wherein Y is , , , , , or .
6. A compound of any of embodiments 1-3, wherein Y is , , , , , , , or .
7. A compound of any of embodiments 1-3, wherein R^a and R^b are H.
8. A compound of any of embodiments 1-3, wherein R^a and R^b are each independently selected from the group consisting of: H and Cl.
9. A compound of any of embodiments 1-3, wherein R^a and R^b are F.
10. A compound of any of embodiments 1-9, wherein R³ is  or .
11. A compound of any of embodiments 1-9, wherein R³ is phenyl, or phenyl substituted with one or two members each independently selected from the group consisting of: Cl, F,

CH₃, CH₂CH₃, CH(CH₃)₂, C(CH₃)₃, CH₂CH(CH₃)₂, C(CH₃)₂CH₂OH, C(CH₃)₂CH₂CO₂H, CF₃, OCF₃, cyclopropyl, cyclopropyl substituted with CH₃, and O-phenyl.

12. A compound of any of embodiments 1-11, wherein R³ is



- 5 13. A compound of any of embodiments 1-12, wherein R³ is 3-tert-butylphenyl, 4-tert-butylphenyl, 4-methyl-3-trifluoromethylphenyl, or 3,4-dimethylphenyl.

14. A compound selected from the group consisting of:

(rac)-(2s,4s)-2-(1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

10 (2s,4*R)-2-((1*S,5*R)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

(2s,4*S)-2-((1*R,5*S)-1-(p-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

15 (rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

- (rac)-(2s,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (2s,4*S)-2-((1*R,5*S)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4*R)-2-((1*S,5*R)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (2s,4*S)-2-((1*R,5*S)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4*R)-2-((1*S,5*R)-1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2r,4s)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (2r,4*S)-2-((1*R,5*S)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 20 (2r,4*R)-2-((1*S,5*R)-1-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 25 (rac)-(2s,4s)-2-(1-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-Cyclopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 30 (rac)-(2s,4s)-2-(1-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

- (rac)-(2s,4s)-2-(1-(o-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(m-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (rac)-(2s,4s)-2-(1-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (rac)-(2s,4s)-2-(1-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2s,4s)-2-(1-(4-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-Phenoxyphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 20 (rac)-(2s,4s)-2-(1-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 25 (rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(2-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 30

- (rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(3-Methyl-4-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (rac)-(2s,4s)-2-(1-(3-Fluoro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,5S,6S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-
- 10 azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,6S)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4R)-2-((1S,6R)-6-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2s,4s)-2-(7,7-Difluoro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4*R)-2-((1*S,6*R)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-
- 20 azaspiro[3.4]octan-6-one;
- (2s,4*S)-2-((1*R,6*S)-6-(m-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 25 (2s,4*R)-2-((1*S,6*R)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4*S)-2-((1*R,6*S)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-
- 30 oxa-5-azaspiro[3.4]octan-6-one;

- (2s,4*R)-2-((1*S,6*R)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4*S)-2-((1*R,6*S)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (rac)-(2r,4s)-2-(6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(o-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (rac)-(2r,4s)-2-(6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(p-Tolyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2s,4s)-2-(6-(3-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 20 (rac)-(2s,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(6-(3-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 25 (rac)-(2s,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(6-(4-(tert-Butyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 30 (rac)-(2s,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

- (rac)-(2r,4s)-2-(6-(3-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(4-Cyclopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (rac)-(2s,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(6-(3-Chloro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (rac)-(2r,4s)-2-(6-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(3-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2s,4s)-2-(6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(3-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(6-(4-Isopropylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 20 (rac)-(2s,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2r,4s)-2-(6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 25 (rac)-(2s,4s)-2-(1-Phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2r,4S)-2-((1R,5S,6S)-6-(3-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 30

- (2s,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2r,4S)-2-((1R,5S,6S)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 5 (2s,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2r,4S)-2-((1R,5S,6S)-6-(4-(tert-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,5S,6S)-6-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (2s,4S)-2-((1R,5S,6S)-6-(4-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (2r,4S)-2-((1R,5S,6S)-6-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (2s,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2r,4S)-2-((1R,5S,6S)-6-(3,4-Dimethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 20 (2s,4S)-2-((1R,5S,6S)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2r,4S)-2-((1R,5S,6S)-6-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 25 (2s,4S)-2-((1R,5S,6S)-6-(2,3-Dihydro-1H-inden-5-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4*S)-2-((1*R,5*S,6*R)-6-(3-(tert-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2s,4s)-2-(1-(4-Ethylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 30


- (2*r*,4**S*)-2-((1**R*,5**S*)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (2*r*,4**R*)-2-((1**S*,5**R*)-1-(4-(1-Methylcyclopropyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 5 (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(*o*-tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(*o*-Tolyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(3-(*tert*-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (2*s*,4**R*)-2-((1**S*,5**R*,6**S*)-6-(3-(*tert*-Butyl)phenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Isobutylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(3,4-Dimethylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl-5-*D*)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(1-Hydroxy-2-methylpropan-2-yl)phenyl)-3-
- 20 azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 2-Methyl-2-(3-((1*R*,5*S*,6*S*)-3-((2*s*,4*S*)-6-oxo-7-oxa-5-azaspiro[3.4]octane-2-carbonyl)-3-azabicyclo[3.1.0]hexan-6-yl)phenyl)propanoic acid;
- (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 25 (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(4-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (rac)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-6-(4-Cyclopropylphenyl)-1-methyl-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(4-Cyclopropyl-2-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-
- 30 carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;

- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Ethyl-4-fluorophenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 5 (*rac*)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(4-methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(2-Methyl-3-(trifluoromethyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (*rac*)-(2*s*,4**S*)-2-((1**R*,5**S*,6**R*)-1-Methyl-6-(4-methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 10 (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(4-Methyl-3-(trifluoromethoxy)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*R*)-6-(6-(*tert*-Butyl)pyridin-2-yl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- 15 (2*s*,4**R*)-2-((1**S*,6**R*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**S*)-2-((1**R*,6**S*)-6-(4-(Trifluoromethyl)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*r*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 20 (2*r*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (2*r*,4**S*)-2-((1**R*,6**S*)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- 25 (2*r*,4**R*)-2-((1**S*,6**R*)-6-(4-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- (*rac*)-(2*s*,4*s*)-2-(7-Chloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and
- (*rac*)-(2*s*,4*s*)-2-(7,7-Dichloro-6-phenyl-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one
- 30


and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof.

15. A compound selected from the group consisting of:
- (*rac*)-(2*s*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one;
- (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one; and
- (2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one;
- and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers.
16. A compound of embodiment 14, wherein the compound is (*rac*)-(2*s*,4*s*)-2-(1-(4-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
17. A compound of embodiment 14, wherein the compound is (2*s*,4**R*)-2-((1**S*,5**R*)-1-(3-Isopropylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
18. A compound of embodiment 14, wherein the compound is (2*s*,4**R*)-2-((1**S*,6**R*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
19. A compound of embodiment 14, wherein the compound is (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-(Trifluoromethoxy)phenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.

20. A compound of embodiment 14, wherein the compound is (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-Chloro-4-methylphenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
- 5 21. A compound of embodiment 14, wherein the compound is (2*s*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
- 10 22. A compound of embodiment 14, wherein the compound is (2*s*,4**S*)-2-((1**R*,6**S*)-6-(3-Fluoro-4-methylphenyl)-3-azabicyclo[4.1.0]heptane-3-carbonyl)-7-oxa-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
- 15 23. A compound of embodiment 14, wherein the compound is (2*r*,4*S*)-2-((1*R*,5*S*,6*S*)-6-(3-(*tert*-Butyl)phenyl)-3-azabicyclo[3.1.0]hexane-3-carbonyl)-5-azaspiro[3.4]octan-6-one, and pharmaceutically acceptable salts thereof.
24. The compound of embodiment 1, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IA):



- 20 wherein
X is CH₂ or O; and
R³ is selected from the group consisting of: phenyl; phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆haloalkyl, OC₁₋₆haloalkyl, C₃₋₆cycloalkyl, O-phenyl, and C₃₋₆cycloalkyl substituted with CH₃.
- 25 25. The compound of embodiment 1, and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers thereof, having the structure of Formula (IB):




wherein

X is CH₂ or O;

R³ is selected from the group consisting of: 2,3-dihydro-1*H*-indene; pyridyl substituted with C₁-
 5 6alkyl; phenyl substituted with one or two members each independently selected from the
 group consisting of: halo, C₁-6alkyl, C₁-6alkyl substituted with OH, C₁-6alkyl substituted
 with CO₂H, C₁-6haloalkyl, OC₁-6haloalkyl and cyclopropyl; and

R^c is H or CH₃.

26. The compound of embodiment 1, and pharmaceutically acceptable salts, isotopes, N-
 10 oxides, solvates, and stereoisomers thereof, having the structure of Formula (IC):



wherein


X is CH₂ or O;

R³ is selected from the group consisting of: phenyl; phenyl substituted with one or two members
 15 each independently selected from the group consisting of: halo, C₁-6alkyl, C₁-6haloalkyl,
 OC₁-6haloalkyl, C₃-6cycloalkyl, and C₃-6cycloalkyl substituted with CH₃; and

R^a and R^b are each independently selected from the group consisting of: H, Cl and F.

27. A pharmaceutical composition comprising:

(A) a therapeutically effective amount of at least one compound of Formula (I):




20


wherein

X is CH₂ or O;

Y is selected from the group consisting of:



, and



R^1 is H;

R^{2a} and R^{2b} are each independently H;


- 5 R^3 is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C_{1-6} alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C_{1-6} alkyl, C_{1-6} alkyl substituted with OH, C_{1-6} alkyl substituted with CO_2H , C_{1-6} haloalkyl, OC_{1-6} haloalkyl, C_{3-6} cycloalkyl, O-phenyl, and C_{3-6} cycloalkyl substituted with CH_3 ;

- 10 R^a and R^b are each independently selected from the group consisting of: H and halo; and R^c is H or CH_3 ;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of compounds of Formula (I); and

(B) at least one pharmaceutically acceptable excipient.



- 15 28. A pharmaceutical composition comprising a therapeutically effective amount of at least one compound of any of embodiments 1-26 and at least one pharmaceutically acceptable excipient.
29. A method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in
- 20 need of such treatment a therapeutically effective amount of at least one compound of Formula (I):



wherein

X is CH₂ or O;

Y is selected from the group consisting of:



R¹ is H;

5 R^{2a} and R^{2b} are each independently H;


R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁-
6alkyl; phenyl; and phenyl substituted with one or two members each independently
selected from the group consisting of: halo, C₁-6alkyl, C₁-6alkyl substituted with OH, C₁-
6alkyl substituted with CO₂H, C₁-6haloalkyl, OC₁-6haloalkyl, C₃-6cycloalkyl, O-phenyl, and
10 C₃-6cycloalkyl substituted with CH₃;

R^a and R^b are each independently selected from the group consisting of: H and halo; and

R^c is H or CH₃;

and pharmaceutically acceptable salts, isotopes, N-oxides, solvates, and stereoisomers of
compounds of Formula (I).



- 15 30. The method of embodiment 29, wherein the MGL receptor mediated disease, disorder, or
condition is selected from the group consisting of: pain, psychiatric conditions,
neurological conditions, cancers, and eye conditions.
31. The method of embodiment 30, wherein the MGL receptor mediated disease, disorder or
condition is selected from the group consisting of major depressive disorder, treatment
20 resistant depression, anxious depression, and bipolar disorder.
32. The method of embodiment 30, wherein the MGL receptor mediated disease, disorder or
condition is inflammatory pain.
33. At least one compound of Formula (I), or a pharmaceutically acceptable salt, isotope, N-
oxide, solvate, or stereoisomer thereof, for use in therapy, wherein Formula (I):



wherein

X is CH₂ or O;

Y is selected from the group consisting of:



5

R¹ is H;

R^{2a} and R^{2b} are each independently H;

R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁₋₆alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH, C₁₋₆alkyl substituted with CO₂H, C₁₋₆haloalkyl, OC₁₋₆haloalkyl, C₃₋₆cycloalkyl, O-phenyl, and C₃₋₆cycloalkyl substituted with CH₃;


10

R^a and R^b are each independently selected from the group consisting of: H and halo; and

R^c is H or CH₃.

15

34. At least one compound of Formula (I), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate, or stereoisomer thereof, for use in a method of treating a subject suffering from or diagnosed with a disease, disorder, or condition mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula (I):





20

wherein

X is CH₂ or O;

Y is selected from the group consisting of:



5 R¹ is H;

R^{2a} and R^{2b} are each independently H;


R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁-alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁-alkyl, C₁-alkyl substituted with OH, C₁-alkyl substituted with CO₂H, C₁-haloalkyl, OC₁-haloalkyl, C₃-cycloalkyl, O-phenyl, and C₃-cycloalkyl substituted with CH₃;

R^a and R^b are each independently selected from the group consisting of: H and halo; and

R^c is H or CH₃.

35. The at least one compound of Formula (I) for use according to embodiment 34, wherein the MGL receptor mediated disease, disorder, or condition is selected from the group consisting of: pain, psychiatric conditions, neurological conditions, cancers, and eye conditions.
36. The at least one compound of Formula (I) for use according to embodiment 35, wherein the MGL receptor mediated disease, disorder or condition is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression, and bipolar disorder.
37. The at least one compound of Formula (I) for use according to embodiment 35, wherein the MGL receptor mediated disease, disorder or condition is inflammatory pain.
38. Use of at least one compound of Formula (I), or a pharmaceutically acceptable salt, isotope, N-oxide, solvate, or stereoisomer thereof, for the manufacture of a medicament for treating a subject suffering from or diagnosed with a disease, disorder, or condition



mediated by MGL receptor activity, comprising administering to a subject in need of such treatment a therapeutically effective amount of at least one compound of Formula (I):



5 wherein

X is CH₂ or O;

Y is selected from the group consisting of:



R¹ is H;

10 R^{2a} and R^{2b} are each independently H;

R³ is selected from the group consisting of: 2,3-dihydro-1H-indene; pyridyl substituted with C₁₋₆alkyl; phenyl; and phenyl substituted with one or two members each independently selected from the group consisting of: halo, C₁₋₆alkyl, C₁₋₆alkyl substituted with OH, C₁₋₆alkyl substituted with CO₂H, C₁₋₆haloalkyl, OC₁₋₆haloalkyl, C₃₋₆cycloalkyl, O-phenyl, and C₃₋₆cycloalkyl substituted with CH₃;

R^a and R^b are each independently selected from the group consisting of: H and halo; and

R^c is H or CH₃.

39. The use of embodiment 38, wherein the MGL receptor mediated disease, disorder, or condition is selected from the group consisting of: pain, psychiatric conditions, neurological conditions, cancers, and eye conditions.

40. The use of embodiment 39, wherein the MGL receptor mediated disease, disorder or condition is selected from the group consisting of major depressive disorder, treatment resistant depression, anxious depression, and bipolar disorder.

41. The use of embodiment 39, wherein the MGL receptor mediated disease, disorder or condition is inflammatory pain.